ZA200404919B - Effectors of innate immunity - Google Patents
Effectors of innate immunity Download PDFInfo
- Publication number
- ZA200404919B ZA200404919B ZA200404919A ZA200404919A ZA200404919B ZA 200404919 B ZA200404919 B ZA 200404919B ZA 200404919 A ZA200404919 A ZA 200404919A ZA 200404919 A ZA200404919 A ZA 200404919A ZA 200404919 B ZA200404919 B ZA 200404919B
- Authority
- ZA
- South Africa
- Prior art keywords
- peptide
- seq
- expression
- polynucleotide
- protein
- Prior art date
Links
- 230000015788 innate immune response Effects 0.000 title claims description 49
- 239000012636 effector Substances 0.000 title description 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 424
- 108091033319 polynucleotide Proteins 0.000 claims description 266
- 102000040430 polynucleotide Human genes 0.000 claims description 266
- 239000002157 polynucleotide Substances 0.000 claims description 260
- 210000004027 cell Anatomy 0.000 claims description 174
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 164
- 230000014509 gene expression Effects 0.000 claims description 155
- 125000002091 cationic group Chemical group 0.000 claims description 144
- 238000000034 method Methods 0.000 claims description 97
- 108090000623 proteins and genes Proteins 0.000 claims description 78
- 239000003795 chemical substances by application Substances 0.000 claims description 66
- 150000001875 compounds Chemical class 0.000 claims description 64
- 102100040247 Tumor necrosis factor Human genes 0.000 claims description 50
- 102000004169 proteins and genes Human genes 0.000 claims description 49
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 48
- 230000001105 regulatory effect Effects 0.000 claims description 48
- 150000001413 amino acids Chemical class 0.000 claims description 47
- 206010040047 Sepsis Diseases 0.000 claims description 45
- 102000005962 receptors Human genes 0.000 claims description 43
- 108020003175 receptors Proteins 0.000 claims description 42
- 230000004044 response Effects 0.000 claims description 39
- 230000000694 effects Effects 0.000 claims description 37
- 150000007523 nucleic acids Chemical class 0.000 claims description 35
- 102000039446 nucleic acids Human genes 0.000 claims description 34
- 108020004707 nucleic acids Proteins 0.000 claims description 34
- 230000001939 inductive effect Effects 0.000 claims description 33
- 230000002757 inflammatory effect Effects 0.000 claims description 28
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 27
- 108020004414 DNA Proteins 0.000 claims description 26
- 208000015181 infectious disease Diseases 0.000 claims description 26
- 102000019034 Chemokines Human genes 0.000 claims description 24
- 108010012236 Chemokines Proteins 0.000 claims description 24
- 230000001580 bacterial effect Effects 0.000 claims description 24
- 229920001184 polypeptide Polymers 0.000 claims description 22
- 230000000770 proinflammatory effect Effects 0.000 claims description 20
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 claims description 16
- 241000894006 Bacteria Species 0.000 claims description 15
- 102000004890 Interleukin-8 Human genes 0.000 claims description 15
- 108090001007 Interleukin-8 Proteins 0.000 claims description 15
- 230000005764 inhibitory process Effects 0.000 claims description 15
- 238000012360 testing method Methods 0.000 claims description 15
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 claims description 14
- 230000000638 stimulation Effects 0.000 claims description 14
- 229910052717 sulfur Inorganic materials 0.000 claims description 14
- 102000003298 tumor necrosis factor receptor Human genes 0.000 claims description 14
- 101710082513 C-X-C chemokine receptor type 4 Proteins 0.000 claims description 13
- 206010061218 Inflammation Diseases 0.000 claims description 13
- 230000004054 inflammatory process Effects 0.000 claims description 13
- -1 CCRS5 Proteins 0.000 claims description 12
- 239000005557 antagonist Substances 0.000 claims description 12
- 230000008859 change Effects 0.000 claims description 11
- 108091000080 Phosphotransferase Proteins 0.000 claims description 10
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 claims description 10
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 claims description 10
- 230000003260 anti-sepsis Effects 0.000 claims description 10
- 238000006243 chemical reaction Methods 0.000 claims description 10
- 102000020233 phosphotransferase Human genes 0.000 claims description 10
- 230000007423 decrease Effects 0.000 claims description 9
- 108010055166 Chemokine CCL5 Proteins 0.000 claims description 8
- 230000035605 chemotaxis Effects 0.000 claims description 8
- 229910052700 potassium Inorganic materials 0.000 claims description 8
- 102100021943 C-C motif chemokine 2 Human genes 0.000 claims description 7
- 101710155857 C-C motif chemokine 2 Proteins 0.000 claims description 7
- 102100032367 C-C motif chemokine 5 Human genes 0.000 claims description 7
- 102000015696 Interleukins Human genes 0.000 claims description 7
- 108010063738 Interleukins Proteins 0.000 claims description 7
- 239000000954 inflammatory inducer Substances 0.000 claims description 7
- 230000028709 inflammatory response Effects 0.000 claims description 7
- 102100032366 C-C motif chemokine 7 Human genes 0.000 claims description 6
- 101710155834 C-C motif chemokine 7 Proteins 0.000 claims description 6
- 102000009410 Chemokine receptor Human genes 0.000 claims description 6
- 108050000299 Chemokine receptor Proteins 0.000 claims description 6
- 102000003814 Interleukin-10 Human genes 0.000 claims description 6
- 108090000174 Interleukin-10 Proteins 0.000 claims description 6
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 6
- 229910052731 fluorine Inorganic materials 0.000 claims description 6
- 239000000816 peptidomimetic Substances 0.000 claims description 6
- 229910052727 yttrium Inorganic materials 0.000 claims description 6
- 102100025074 C-C chemokine receptor-like 2 Human genes 0.000 claims description 5
- 102100032710 E3 ubiquitin-protein ligase Jade-2 Human genes 0.000 claims description 5
- 101000716068 Homo sapiens C-C chemokine receptor type 6 Proteins 0.000 claims description 5
- 101000994468 Homo sapiens E3 ubiquitin-protein ligase Jade-2 Proteins 0.000 claims description 5
- 102000014150 Interferons Human genes 0.000 claims description 5
- 108010050904 Interferons Proteins 0.000 claims description 5
- 241000700605 Viruses Species 0.000 claims description 5
- 229910052698 phosphorus Inorganic materials 0.000 claims description 5
- 229910052721 tungsten Inorganic materials 0.000 claims description 5
- 101000665837 Homo sapiens Protein Red Proteins 0.000 claims description 4
- 102100035678 Interferon gamma receptor 1 Human genes 0.000 claims description 4
- 102100038276 Protein Red Human genes 0.000 claims description 4
- 108091023040 Transcription factor Proteins 0.000 claims description 4
- 102000040945 Transcription factor Human genes 0.000 claims description 4
- 230000036039 immunity Effects 0.000 claims description 4
- 102000006495 integrins Human genes 0.000 claims description 4
- 108010044426 integrins Proteins 0.000 claims description 4
- DAZSWUUAFHBCGE-KRWDZBQOSA-N n-[(2s)-3-methyl-1-oxo-1-pyrrolidin-1-ylbutan-2-yl]-3-phenylpropanamide Chemical compound N([C@@H](C(C)C)C(=O)N1CCCC1)C(=O)CCC1=CC=CC=C1 DAZSWUUAFHBCGE-KRWDZBQOSA-N 0.000 claims description 4
- 102100031151 C-C chemokine receptor type 2 Human genes 0.000 claims description 3
- 101710149815 C-C chemokine receptor type 2 Proteins 0.000 claims description 3
- 102100036301 C-C chemokine receptor type 7 Human genes 0.000 claims description 3
- 101710112613 C-C motif chemokine 13 Proteins 0.000 claims description 3
- 102100023702 C-C motif chemokine 13 Human genes 0.000 claims description 3
- 101710155833 C-C motif chemokine 8 Proteins 0.000 claims description 3
- 102100034871 C-C motif chemokine 8 Human genes 0.000 claims description 3
- 102100036166 C-X-C chemokine receptor type 1 Human genes 0.000 claims description 3
- 108010017009 CD11b Antigen Proteins 0.000 claims description 3
- 102000004354 CD11b Antigen Human genes 0.000 claims description 3
- 108090000613 Cathepsin S Proteins 0.000 claims description 3
- 102100035654 Cathepsin S Human genes 0.000 claims description 3
- 102000000844 Cell Surface Receptors Human genes 0.000 claims description 3
- 108010001857 Cell Surface Receptors Proteins 0.000 claims description 3
- 102100023309 Centrosomal protein of 152 kDa Human genes 0.000 claims description 3
- 102100038493 Cytokine receptor-like factor 1 Human genes 0.000 claims description 3
- 101710194728 Cytokine receptor-like factor 1 Proteins 0.000 claims description 3
- 241000233866 Fungi Species 0.000 claims description 3
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 claims description 3
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 claims description 3
- 101000716065 Homo sapiens C-C chemokine receptor type 7 Proteins 0.000 claims description 3
- 101000947174 Homo sapiens C-X-C chemokine receptor type 1 Proteins 0.000 claims description 3
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 claims description 3
- 101000908174 Homo sapiens Centrosomal protein of 152 kDa Proteins 0.000 claims description 3
- 101000701393 Homo sapiens Serine/threonine-protein kinase 26 Proteins 0.000 claims description 3
- 101000595531 Homo sapiens Serine/threonine-protein kinase pim-1 Proteins 0.000 claims description 3
- 101710174028 Interferon gamma receptor 1 Proteins 0.000 claims description 3
- 101710151805 Mitochondrial intermediate peptidase 1 Proteins 0.000 claims description 3
- 108010063954 Mucins Proteins 0.000 claims description 3
- 101000978374 Mus musculus C-C motif chemokine 12 Proteins 0.000 claims description 3
- 108010064527 OSM-LIF Receptors Proteins 0.000 claims description 3
- 101710094502 Proteasome subunit beta type-5 Proteins 0.000 claims description 3
- 102100036127 Proteasome subunit beta type-5 Human genes 0.000 claims description 3
- 102100030617 Serine/threonine-protein kinase 26 Human genes 0.000 claims description 3
- 102100036077 Serine/threonine-protein kinase pim-1 Human genes 0.000 claims description 3
- 102100033726 Tumor necrosis factor receptor superfamily member 17 Human genes 0.000 claims description 3
- 101710187885 Tumor necrosis factor receptor superfamily member 17 Proteins 0.000 claims description 3
- 102000003675 cytokine receptors Human genes 0.000 claims description 3
- 108010057085 cytokine receptors Proteins 0.000 claims description 3
- 230000002708 enhancing effect Effects 0.000 claims description 3
- 230000002209 hydrophobic effect Effects 0.000 claims description 3
- 229940079322 interferon Drugs 0.000 claims description 3
- 108010085650 interferon gamma receptor Proteins 0.000 claims description 3
- AEUKDPKXTPNBNY-XEYRWQBLSA-N mcp 2 Chemical compound C([C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CS)NC(=O)[C@H](C)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)C1=CC=CC=C1 AEUKDPKXTPNBNY-XEYRWQBLSA-N 0.000 claims description 3
- 210000002824 peroxisome Anatomy 0.000 claims description 3
- 230000002829 reductive effect Effects 0.000 claims description 3
- 108090000064 retinoic acid receptors Proteins 0.000 claims description 3
- 102000003702 retinoic acid receptors Human genes 0.000 claims description 3
- 108010041788 rho-Associated Kinases Proteins 0.000 claims description 3
- 102000000568 rho-Associated Kinases Human genes 0.000 claims description 3
- 238000012216 screening Methods 0.000 claims description 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims description 2
- 101710149863 C-C chemokine receptor type 4 Proteins 0.000 claims description 2
- 102100036850 C-C motif chemokine 23 Human genes 0.000 claims description 2
- 102100028989 C-X-C chemokine receptor type 2 Human genes 0.000 claims description 2
- 102100023272 Dual specificity mitogen-activated protein kinase kinase 5 Human genes 0.000 claims description 2
- 102100023401 Dual specificity mitogen-activated protein kinase kinase 6 Human genes 0.000 claims description 2
- 102100023227 E3 SUMO-protein ligase EGR2 Human genes 0.000 claims description 2
- 101000713081 Homo sapiens C-C motif chemokine 23 Proteins 0.000 claims description 2
- 101001049692 Homo sapiens E3 SUMO-protein ligase EGR2 Proteins 0.000 claims description 2
- 101001098557 Homo sapiens Proteinase-activated receptor 3 Proteins 0.000 claims description 2
- 101000959153 Homo sapiens RNA demethylase ALKBH5 Proteins 0.000 claims description 2
- 102100036157 Interferon gamma receptor 2 Human genes 0.000 claims description 2
- 102000004551 Interleukin-10 Receptors Human genes 0.000 claims description 2
- 108010017550 Interleukin-10 Receptors Proteins 0.000 claims description 2
- 108010018951 Interleukin-8B Receptors Proteins 0.000 claims description 2
- 108010068305 MAP Kinase Kinase 5 Proteins 0.000 claims description 2
- 108010068306 MAP Kinase Kinase 6 Proteins 0.000 claims description 2
- 102100028397 MAP kinase-activated protein kinase 3 Human genes 0.000 claims description 2
- 101710141393 MAP kinase-activated protein kinase 3 Proteins 0.000 claims description 2
- 108700027650 Mitogen-Activated Protein Kinase 7 Proteins 0.000 claims description 2
- 102100026932 Mitogen-activated protein kinase 12 Human genes 0.000 claims description 2
- 108700015929 Mitogen-activated protein kinase 12 Proteins 0.000 claims description 2
- 102100037805 Mitogen-activated protein kinase 7 Human genes 0.000 claims description 2
- 102000006746 NADH Dehydrogenase Human genes 0.000 claims description 2
- 108010086428 NADH Dehydrogenase Proteins 0.000 claims description 2
- 102100037133 Proteinase-activated receptor 3 Human genes 0.000 claims description 2
- 102100033605 RING finger protein 10 Human genes 0.000 claims description 2
- 101710119956 RING finger protein 10 Proteins 0.000 claims description 2
- 102100039083 RNA demethylase ALKBH5 Human genes 0.000 claims description 2
- 229910052799 carbon Inorganic materials 0.000 claims description 2
- 102000033650 death receptor binding proteins Human genes 0.000 claims description 2
- 108091009627 death receptor binding proteins Proteins 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- 229940047122 interleukins Drugs 0.000 claims description 2
- 230000003071 parasitic effect Effects 0.000 claims description 2
- 102000015278 OSM-LIF Receptors Human genes 0.000 claims 2
- 102000004357 Transferases Human genes 0.000 claims 2
- 108090000992 Transferases Proteins 0.000 claims 2
- 101710185494 Zinc finger protein Proteins 0.000 claims 2
- 102100023597 Zinc finger protein 816 Human genes 0.000 claims 2
- 102100032976 CCR4-NOT transcription complex subunit 6 Human genes 0.000 claims 1
- 101100502609 Caenorhabditis elegans fem-1 gene Proteins 0.000 claims 1
- 102100025705 Centrosomal protein of 170 kDa protein B Human genes 0.000 claims 1
- 102000005636 Cyclic AMP Response Element-Binding Protein Human genes 0.000 claims 1
- 108010045171 Cyclic AMP Response Element-Binding Protein Proteins 0.000 claims 1
- 101710088194 Dehydrogenase Proteins 0.000 claims 1
- 101100334582 Drosophila melanogaster Fem-1 gene Proteins 0.000 claims 1
- 102100031480 Dual specificity mitogen-activated protein kinase kinase 1 Human genes 0.000 claims 1
- 102100023275 Dual specificity mitogen-activated protein kinase kinase 3 Human genes 0.000 claims 1
- 102100029782 Eukaryotic translation initiation factor 3 subunit I Human genes 0.000 claims 1
- 101710109054 Eukaryotic translation initiation factor 3 subunit I Proteins 0.000 claims 1
- 108010049003 Fibrinogen Proteins 0.000 claims 1
- 102000008946 Fibrinogen Human genes 0.000 claims 1
- 102000004315 Forkhead Transcription Factors Human genes 0.000 claims 1
- 108090000852 Forkhead Transcription Factors Proteins 0.000 claims 1
- 101710117710 GTPase activating protein 1 Proteins 0.000 claims 1
- 102000009331 Homeodomain Proteins Human genes 0.000 claims 1
- 108010048671 Homeodomain Proteins Proteins 0.000 claims 1
- 101000983874 Homo sapiens Centrosomal protein of 170 kDa protein B Proteins 0.000 claims 1
- 101001006895 Homo sapiens Krueppel-like factor 11 Proteins 0.000 claims 1
- 101001069810 Homo sapiens Psoriasis susceptibility 1 candidate gene 2 protein Proteins 0.000 claims 1
- 102100027797 Krueppel-like factor 11 Human genes 0.000 claims 1
- 108010068342 MAP Kinase Kinase 1 Proteins 0.000 claims 1
- 108010068355 MAP Kinase Kinase 3 Proteins 0.000 claims 1
- 102000005879 Mucin-5B Human genes 0.000 claims 1
- 108010030201 Mucin-5B Proteins 0.000 claims 1
- 102000015728 Mucins Human genes 0.000 claims 1
- 102100034249 Psoriasis susceptibility 1 candidate gene 2 protein Human genes 0.000 claims 1
- 101710146873 Receptor-binding protein Proteins 0.000 claims 1
- 102100021669 Stromal cell-derived factor 1 Human genes 0.000 claims 1
- 101710088580 Stromal cell-derived factor 1 Proteins 0.000 claims 1
- 108090000190 Thrombin Proteins 0.000 claims 1
- 230000000903 blocking effect Effects 0.000 claims 1
- 108700021031 cdc Genes Proteins 0.000 claims 1
- 230000024245 cell differentiation Effects 0.000 claims 1
- 230000004069 differentiation Effects 0.000 claims 1
- 239000003862 glucocorticoid Substances 0.000 claims 1
- 230000001629 suppression Effects 0.000 claims 1
- 229960004072 thrombin Drugs 0.000 claims 1
- 239000002158 endotoxin Substances 0.000 description 134
- 229920006008 lipopolysaccharide Polymers 0.000 description 122
- 241000282414 Homo sapiens Species 0.000 description 60
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 42
- 235000018102 proteins Nutrition 0.000 description 40
- 239000002299 complementary DNA Substances 0.000 description 34
- 235000001014 amino acid Nutrition 0.000 description 33
- 229940024606 amino acid Drugs 0.000 description 33
- 102000004127 Cytokines Human genes 0.000 description 30
- 108090000695 Cytokines Proteins 0.000 description 30
- 241000588724 Escherichia coli Species 0.000 description 29
- 210000002919 epithelial cell Anatomy 0.000 description 29
- 210000002540 macrophage Anatomy 0.000 description 28
- 238000004519 manufacturing process Methods 0.000 description 27
- 238000003491 array Methods 0.000 description 26
- 238000002474 experimental method Methods 0.000 description 22
- 241000699670 Mus sp. Species 0.000 description 19
- 102000002727 Protein Tyrosine Phosphatase Human genes 0.000 description 18
- 108020000494 protein-tyrosine phosphatase Proteins 0.000 description 17
- 238000011282 treatment Methods 0.000 description 17
- 244000052769 pathogen Species 0.000 description 15
- 238000002965 ELISA Methods 0.000 description 14
- 238000003556 assay Methods 0.000 description 14
- 239000000047 product Substances 0.000 description 14
- 239000000523 sample Substances 0.000 description 14
- 241000699666 Mus <mouse, genus> Species 0.000 description 13
- 230000006870 function Effects 0.000 description 13
- 210000004369 blood Anatomy 0.000 description 11
- 239000008280 blood Substances 0.000 description 11
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 11
- 239000002953 phosphate buffered saline Substances 0.000 description 11
- 239000011669 selenium Substances 0.000 description 10
- 238000011725 BALB/c mouse Methods 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 9
- 230000001965 increasing effect Effects 0.000 description 9
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 9
- 230000009467 reduction Effects 0.000 description 9
- 239000006228 supernatant Substances 0.000 description 9
- 108091006112 ATPases Proteins 0.000 description 8
- 102000057290 Adenosine Triphosphatases Human genes 0.000 description 8
- 239000002253 acid Substances 0.000 description 8
- 239000003242 anti bacterial agent Substances 0.000 description 8
- 239000000427 antigen Substances 0.000 description 8
- 108091007433 antigens Proteins 0.000 description 8
- 102000036639 antigens Human genes 0.000 description 8
- 230000034994 death Effects 0.000 description 8
- 231100000517 death Toxicity 0.000 description 8
- 239000007928 intraperitoneal injection Substances 0.000 description 8
- 231100000518 lethal Toxicity 0.000 description 8
- 230000001665 lethal effect Effects 0.000 description 8
- 210000000265 leukocyte Anatomy 0.000 description 8
- 230000004083 survival effect Effects 0.000 description 8
- 238000003786 synthesis reaction Methods 0.000 description 8
- 231100000419 toxicity Toxicity 0.000 description 8
- 230000001988 toxicity Effects 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 7
- 241001433703 Escherichia coli O111:B4 Species 0.000 description 7
- 239000004743 Polypropylene Substances 0.000 description 7
- 102000002689 Toll-like receptor Human genes 0.000 description 7
- 108020000411 Toll-like receptor Proteins 0.000 description 7
- 229940088710 antibiotic agent Drugs 0.000 description 7
- 239000012228 culture supernatant Substances 0.000 description 7
- 239000013604 expression vector Substances 0.000 description 7
- 230000012010 growth Effects 0.000 description 7
- 239000012678 infectious agent Substances 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 230000011664 signaling Effects 0.000 description 7
- MSWZFWKMSRAUBD-GASJEMHNSA-N 2-amino-2-deoxy-D-galactopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O MSWZFWKMSRAUBD-GASJEMHNSA-N 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 101800001224 Disintegrin Proteins 0.000 description 6
- 108091028043 Nucleic acid sequence Proteins 0.000 description 6
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 6
- 230000006907 apoptotic process Effects 0.000 description 6
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 6
- 230000003115 biocidal effect Effects 0.000 description 6
- POIUWJQBRNEFGX-XAMSXPGMSA-N cathelicidin Chemical compound C([C@@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC(C)C)C1=CC=CC=C1 POIUWJQBRNEFGX-XAMSXPGMSA-N 0.000 description 6
- 210000002865 immune cell Anatomy 0.000 description 6
- 238000007912 intraperitoneal administration Methods 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- 230000002103 transcriptional effect Effects 0.000 description 6
- 208000035143 Bacterial infection Diseases 0.000 description 5
- 208000037487 Endotoxemia Diseases 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 108091006027 G proteins Proteins 0.000 description 5
- 108090000744 Mitogen-Activated Protein Kinase Kinases Proteins 0.000 description 5
- 102000004232 Mitogen-Activated Protein Kinase Kinases Human genes 0.000 description 5
- 108010093965 Polymyxin B Proteins 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 230000000845 anti-microbial effect Effects 0.000 description 5
- 208000022362 bacterial infectious disease Diseases 0.000 description 5
- 108060001132 cathelicidin Proteins 0.000 description 5
- 102000014509 cathelicidin Human genes 0.000 description 5
- 230000001413 cellular effect Effects 0.000 description 5
- 230000003399 chemotactic effect Effects 0.000 description 5
- 238000011109 contamination Methods 0.000 description 5
- 229940088598 enzyme Drugs 0.000 description 5
- 230000002068 genetic effect Effects 0.000 description 5
- 230000028993 immune response Effects 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 230000003993 interaction Effects 0.000 description 5
- 230000000813 microbial effect Effects 0.000 description 5
- 229920000642 polymer Polymers 0.000 description 5
- 229920000024 polymyxin B Polymers 0.000 description 5
- 229960005266 polymyxin b Drugs 0.000 description 5
- 230000007112 pro inflammatory response Effects 0.000 description 5
- 230000010076 replication Effects 0.000 description 5
- 238000003757 reverse transcription PCR Methods 0.000 description 5
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 4
- 241000589513 Burkholderia cepacia Species 0.000 description 4
- 102000000905 Cadherin Human genes 0.000 description 4
- 108050007957 Cadherin Proteins 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 208000035473 Communicable disease Diseases 0.000 description 4
- 102000053602 DNA Human genes 0.000 description 4
- 241000192125 Firmicutes Species 0.000 description 4
- 102000030782 GTP binding Human genes 0.000 description 4
- 108091000058 GTP-Binding Proteins 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 102000043136 MAP kinase family Human genes 0.000 description 4
- 108091054455 MAP kinase family Proteins 0.000 description 4
- 102000005741 Metalloproteases Human genes 0.000 description 4
- 108010006035 Metalloproteases Proteins 0.000 description 4
- 241001529936 Murinae Species 0.000 description 4
- 239000004698 Polyethylene Substances 0.000 description 4
- 206010040070 Septic Shock Diseases 0.000 description 4
- 230000003321 amplification Effects 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000033228 biological regulation Effects 0.000 description 4
- 235000018417 cysteine Nutrition 0.000 description 4
- 230000016396 cytokine production Effects 0.000 description 4
- 230000001086 cytosolic effect Effects 0.000 description 4
- 230000007123 defense Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000004520 electroporation Methods 0.000 description 4
- 239000003623 enhancer Substances 0.000 description 4
- 238000009396 hybridization Methods 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- 238000002493 microarray Methods 0.000 description 4
- 244000005700 microbiome Species 0.000 description 4
- 230000031990 negative regulation of inflammatory response Effects 0.000 description 4
- 238000003199 nucleic acid amplification method Methods 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 4
- 230000004853 protein function Effects 0.000 description 4
- 230000007115 recruitment Effects 0.000 description 4
- 239000003161 ribonuclease inhibitor Substances 0.000 description 4
- JUJBNYBVVQSIOU-UHFFFAOYSA-M sodium;4-[2-(4-iodophenyl)-3-(4-nitrophenyl)tetrazol-2-ium-5-yl]benzene-1,3-disulfonate Chemical compound [Na+].C1=CC([N+](=O)[O-])=CC=C1N1[N+](C=2C=CC(I)=CC=2)=NC(C=2C(=CC(=CC=2)S([O-])(=O)=O)S([O-])(=O)=O)=N1 JUJBNYBVVQSIOU-UHFFFAOYSA-M 0.000 description 4
- 239000007790 solid phase Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 230000003827 upregulation Effects 0.000 description 4
- 240000005020 Acaciella glauca Species 0.000 description 3
- 102100028728 Bone morphogenetic protein 1 Human genes 0.000 description 3
- 108090000654 Bone morphogenetic protein 1 Proteins 0.000 description 3
- 108020004635 Complementary DNA Proteins 0.000 description 3
- OABOXRPGTFRBFZ-IMJSIDKUSA-N Cys-Cys Chemical compound SC[C@H](N)C(=O)N[C@@H](CS)C(O)=O OABOXRPGTFRBFZ-IMJSIDKUSA-N 0.000 description 3
- 108010002069 Defensins Proteins 0.000 description 3
- 102000000541 Defensins Human genes 0.000 description 3
- AHCYMLUZIRLXAA-SHYZEUOFSA-N Deoxyuridine 5'-triphosphate Chemical compound O1[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(=O)NC(=O)C=C1 AHCYMLUZIRLXAA-SHYZEUOFSA-N 0.000 description 3
- 206010014824 Endotoxic shock Diseases 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 108010007457 Extracellular Signal-Regulated MAP Kinases Proteins 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
- 102000001291 MAP Kinase Kinase Kinase Human genes 0.000 description 3
- 108060006687 MAP kinase kinase kinase Proteins 0.000 description 3
- 102100024193 Mitogen-activated protein kinase 1 Human genes 0.000 description 3
- 241000186359 Mycobacterium Species 0.000 description 3
- 102000015223 NK Cell Lectin-Like Receptors Human genes 0.000 description 3
- 108010039435 NK Cell Lectin-Like Receptors Proteins 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 108091034117 Oligonucleotide Proteins 0.000 description 3
- 102000035195 Peptidases Human genes 0.000 description 3
- 108091005804 Peptidases Proteins 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 230000004721 adaptive immunity Effects 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 210000001185 bone marrow Anatomy 0.000 description 3
- 210000004979 bone marrow derived macrophage Anatomy 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 230000021164 cell adhesion Effects 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 230000012292 cell migration Effects 0.000 description 3
- 210000002421 cell wall Anatomy 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 108010004073 cysteinylcysteine Proteins 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 239000008121 dextrose Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 230000002538 fungal effect Effects 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 210000003714 granulocyte Anatomy 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- USSYUMHVHQSYNA-SLDJZXPVSA-N indolicidin Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(N)=O)CC1=CNC2=CC=CC=C12 USSYUMHVHQSYNA-SLDJZXPVSA-N 0.000 description 3
- 210000005007 innate immune system Anatomy 0.000 description 3
- 230000021995 interleukin-8 production Effects 0.000 description 3
- 208000032839 leukemia Diseases 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 235000003499 redwood Nutrition 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 230000005730 ADP ribosylation Effects 0.000 description 2
- 102000014133 Antimicrobial Cationic Peptides Human genes 0.000 description 2
- 108010050820 Antimicrobial Cationic Peptides Proteins 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
- 108010049931 Bone Morphogenetic Protein 2 Proteins 0.000 description 2
- 102100024506 Bone morphogenetic protein 2 Human genes 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 102100035875 C-C chemokine receptor type 5 Human genes 0.000 description 2
- 102000014914 Carrier Proteins Human genes 0.000 description 2
- 108010078791 Carrier Proteins Proteins 0.000 description 2
- 102100035904 Caspase-1 Human genes 0.000 description 2
- 108050004290 Cecropin Proteins 0.000 description 2
- 108091006146 Channels Proteins 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 108010048623 Collagen Receptors Proteins 0.000 description 2
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 2
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 2
- 101800000620 Disintegrin-like Proteins 0.000 description 2
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 2
- 101000968267 Drosophila melanogaster Protein dachsous Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 102100039622 Granulocyte colony-stimulating factor receptor Human genes 0.000 description 2
- 108010066705 H-cadherin Proteins 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- 101001078133 Homo sapiens Integrin alpha-2 Proteins 0.000 description 2
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 2
- 102000004157 Hydrolases Human genes 0.000 description 2
- 108090000604 Hydrolases Proteins 0.000 description 2
- 102100025305 Integrin alpha-2 Human genes 0.000 description 2
- 102000000507 Integrin alpha2 Human genes 0.000 description 2
- 108010017642 Integrin alpha2beta1 Proteins 0.000 description 2
- 102000000589 Interleukin-1 Human genes 0.000 description 2
- 108010002352 Interleukin-1 Proteins 0.000 description 2
- 102000013462 Interleukin-12 Human genes 0.000 description 2
- 108010065805 Interleukin-12 Proteins 0.000 description 2
- 102000013691 Interleukin-17 Human genes 0.000 description 2
- 108050003558 Interleukin-17 Proteins 0.000 description 2
- 102000004889 Interleukin-6 Human genes 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- 102100021747 Leukemia inhibitory factor receptor Human genes 0.000 description 2
- 241000239218 Limulus Species 0.000 description 2
- 102000052508 Lipopolysaccharide-binding protein Human genes 0.000 description 2
- 108010053632 Lipopolysaccharide-binding protein Proteins 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 2
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 108060003100 Magainin Proteins 0.000 description 2
- MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 description 2
- 108010002998 NADPH Oxidases Proteins 0.000 description 2
- 102000004722 NADPH Oxidases Human genes 0.000 description 2
- 102100038815 Nocturnin Human genes 0.000 description 2
- 108010029741 Notch4 Receptor Proteins 0.000 description 2
- 108010013639 Peptidoglycan Proteins 0.000 description 2
- 102100022239 Peroxiredoxin-6 Human genes 0.000 description 2
- 101710185569 Peroxiredoxin-6 Proteins 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 102100035842 Prostaglandin E2 receptor EP1 subtype Human genes 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 101710172204 Proteasome subunit alpha Proteins 0.000 description 2
- 239000013614 RNA sample Substances 0.000 description 2
- 108091006207 SLC-Transporter Proteins 0.000 description 2
- 102000037054 SLC-Transporter Human genes 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 108010033711 Telomeric Repeat Binding Protein 1 Proteins 0.000 description 2
- 102100036497 Telomeric repeat-binding factor 1 Human genes 0.000 description 2
- 102000009618 Transforming Growth Factors Human genes 0.000 description 2
- 108010009583 Transforming Growth Factors Proteins 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- 239000013504 Triton X-100 Substances 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- ZSLZBFCDCINBPY-ZSJPKINUSA-N acetyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZSLZBFCDCINBPY-ZSJPKINUSA-N 0.000 description 2
- 239000008186 active pharmaceutical agent Substances 0.000 description 2
- 239000011543 agarose gel Substances 0.000 description 2
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 2
- RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 235000009582 asparagine Nutrition 0.000 description 2
- 229960001230 asparagine Drugs 0.000 description 2
- 108091008324 binding proteins Proteins 0.000 description 2
- 210000000424 bronchial epithelial cell Anatomy 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 229910002091 carbon monoxide Inorganic materials 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 239000002975 chemoattractant Substances 0.000 description 2
- 238000007398 colorimetric assay Methods 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 239000003636 conditioned culture medium Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
- 150000001945 cysteines Chemical group 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000008260 defense mechanism Effects 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- FFYPMLJYZAEMQB-UHFFFAOYSA-N diethyl pyrocarbonate Chemical compound CCOC(=O)OC(=O)OCC FFYPMLJYZAEMQB-UHFFFAOYSA-N 0.000 description 2
- 230000003828 downregulation Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 231100000284 endotoxic Toxicity 0.000 description 2
- 230000002346 endotoxic effect Effects 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 2
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 230000005745 host immune response Effects 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- 210000003963 intermediate filament Anatomy 0.000 description 2
- PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 235000005772 leucine Nutrition 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 244000000010 microbial pathogen Species 0.000 description 2
- 238000000329 molecular dynamics simulation Methods 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- 238000010606 normalization Methods 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 102000007863 pattern recognition receptors Human genes 0.000 description 2
- 108010089193 pattern recognition receptors Proteins 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 239000004300 potassium benzoate Substances 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 235000019419 proteases Nutrition 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 229930002330 retinoic acid Natural products 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- FGDZQCVHDSGLHJ-UHFFFAOYSA-M rubidium chloride Chemical compound [Cl-].[Rb+] FGDZQCVHDSGLHJ-UHFFFAOYSA-M 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- ATHGHQPFGPMSJY-UHFFFAOYSA-N spermidine Chemical compound NCCCCNCCCN ATHGHQPFGPMSJY-UHFFFAOYSA-N 0.000 description 2
- PFNFFQXMRSDOHW-UHFFFAOYSA-N spermine Chemical compound NCCCNCCCCNCCCN PFNFFQXMRSDOHW-UHFFFAOYSA-N 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 210000001550 testis Anatomy 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 108700012359 toxins Proteins 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 229960001727 tretinoin Drugs 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 239000004474 valine Substances 0.000 description 2
- 235000014393 valine Nutrition 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- MEANFMOQMXYMCT-OLZOCXBDSA-M (6R)-5,10-methenyltetrahydrofolate Chemical compound C([C@H]1CNC=2N=C(NC(=O)C=2[N+]1=C1)N)N1C1=CC=C(C(=O)N[C@@H](CCC([O-])=O)C([O-])=O)C=C1 MEANFMOQMXYMCT-OLZOCXBDSA-M 0.000 description 1
- MZAGXDHQGXUDDX-JSRXJHBZSA-N (e,2z)-4-ethyl-2-hydroxyimino-5-nitrohex-3-enamide Chemical compound [O-][N+](=O)C(C)C(/CC)=C/C(=N/O)/C(N)=O MZAGXDHQGXUDDX-JSRXJHBZSA-N 0.000 description 1
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- 102100034487 28S ribosomal protein S18b, mitochondrial Human genes 0.000 description 1
- 102100031928 40S ribosomal protein S29 Human genes 0.000 description 1
- QYNUQALWYRSVHF-ABLWVSNPSA-N 5,10-methylenetetrahydrofolic acid Chemical compound C1N2C=3C(=O)NC(N)=NC=3NCC2CN1C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 QYNUQALWYRSVHF-ABLWVSNPSA-N 0.000 description 1
- 102100028505 6-pyruvoyl tetrahydrobiopterin synthase Human genes 0.000 description 1
- 108010045523 6-pyruvoyltetrahydropterin synthase Proteins 0.000 description 1
- PCFGFYKGPMQDBX-FEKONODYSA-N 78355-50-7 Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)NCC(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 PCFGFYKGPMQDBX-FEKONODYSA-N 0.000 description 1
- 108091022885 ADAM Proteins 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 102100022712 Alpha-1-antitrypsin Human genes 0.000 description 1
- 108091093088 Amplicon Proteins 0.000 description 1
- 108010031677 Anaphase-Promoting Complex-Cyclosome Proteins 0.000 description 1
- 102000005446 Anaphase-Promoting Complex-Cyclosome Human genes 0.000 description 1
- 108010049777 Ankyrins Proteins 0.000 description 1
- 102000008102 Ankyrins Human genes 0.000 description 1
- 108010005853 Anti-Mullerian Hormone Proteins 0.000 description 1
- 101710120040 Antifungal peptide Proteins 0.000 description 1
- 101710145634 Antigen 1 Proteins 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 108020000946 Bacterial DNA Proteins 0.000 description 1
- 102100021971 Bcl-2-interacting killer Human genes 0.000 description 1
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 description 1
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 description 1
- 102100027052 Bone morphogenetic protein receptor type-1B Human genes 0.000 description 1
- 108030001720 Bontoxilysin Proteins 0.000 description 1
- 102100026435 Breast carcinoma-amplified sequence 4 Human genes 0.000 description 1
- 101710149870 C-C chemokine receptor type 5 Proteins 0.000 description 1
- 108050009406 C-type lectin-like Proteins 0.000 description 1
- 102000002086 C-type lectin-like Human genes 0.000 description 1
- 108010039171 CC cytokine receptor-4 Proteins 0.000 description 1
- 101150019010 CCR3 gene Proteins 0.000 description 1
- 108010029697 CD40 Ligand Proteins 0.000 description 1
- 102100032937 CD40 ligand Human genes 0.000 description 1
- 102100035680 Cadherin EGF LAG seven-pass G-type receptor 2 Human genes 0.000 description 1
- 102100024155 Cadherin-11 Human genes 0.000 description 1
- 102000014818 Cadherin-13 Human genes 0.000 description 1
- 102100024154 Cadherin-13 Human genes 0.000 description 1
- 101100005789 Caenorhabditis elegans cdk-4 gene Proteins 0.000 description 1
- 101100042630 Caenorhabditis elegans sin-3 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000003643 Callosities Diseases 0.000 description 1
- 102000004041 Caspase 7 Human genes 0.000 description 1
- 108090000567 Caspase 7 Proteins 0.000 description 1
- 108090000426 Caspase-1 Proteins 0.000 description 1
- 108010076667 Caspases Proteins 0.000 description 1
- 102000011727 Caspases Human genes 0.000 description 1
- 102000016362 Catenins Human genes 0.000 description 1
- 108010067316 Catenins Proteins 0.000 description 1
- 102400001330 Cathepsin H Human genes 0.000 description 1
- 108090000619 Cathepsin H Proteins 0.000 description 1
- 108010072135 Cell Adhesion Molecule-1 Proteins 0.000 description 1
- 102100024649 Cell adhesion molecule 1 Human genes 0.000 description 1
- 102100031203 Centrosomal protein 43 Human genes 0.000 description 1
- 108010062745 Chloride Channels Proteins 0.000 description 1
- 102000011045 Chloride Channels Human genes 0.000 description 1
- UDMBCSSLTHHNCD-UHFFFAOYSA-N Coenzym Q(11) Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(O)=O)C(O)C1O UDMBCSSLTHHNCD-UHFFFAOYSA-N 0.000 description 1
- 108050001774 Cold shock domains Proteins 0.000 description 1
- 102000010091 Cold shock domains Human genes 0.000 description 1
- 102100031506 Complement C5 Human genes 0.000 description 1
- 108010028773 Complement C5 Proteins 0.000 description 1
- 102400000739 Corticotropin Human genes 0.000 description 1
- 101800000414 Corticotropin Proteins 0.000 description 1
- 102000008130 Cyclic AMP-Dependent Protein Kinases Human genes 0.000 description 1
- 108010049894 Cyclic AMP-Dependent Protein Kinases Proteins 0.000 description 1
- 102100027309 Cyclic AMP-responsive element-binding protein 5 Human genes 0.000 description 1
- 102000016736 Cyclin Human genes 0.000 description 1
- 108050006400 Cyclin Proteins 0.000 description 1
- 108010016777 Cyclin-Dependent Kinase Inhibitor p27 Proteins 0.000 description 1
- 102000000577 Cyclin-Dependent Kinase Inhibitor p27 Human genes 0.000 description 1
- 102100023419 Cystic fibrosis transmembrane conductance regulator Human genes 0.000 description 1
- 102100028202 Cytochrome c oxidase subunit 6C Human genes 0.000 description 1
- 102100035861 Cytosolic 5'-nucleotidase 1A Human genes 0.000 description 1
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 1
- 102100029905 DNA polymerase epsilon subunit 3 Human genes 0.000 description 1
- 230000033616 DNA repair Effects 0.000 description 1
- 102000009058 Death Domain Receptors Human genes 0.000 description 1
- 108010049207 Death Domain Receptors Proteins 0.000 description 1
- 108020005199 Dehydrogenases Proteins 0.000 description 1
- 102100039104 Dolichyl-diphosphooligosaccharide-protein glycosyltransferase subunit DAD1 Human genes 0.000 description 1
- 101710178850 Dolichyl-diphosphooligosaccharide-protein glycosyltransferase subunit DAD1 Proteins 0.000 description 1
- 101100042883 Drosophila melanogaster sna gene Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 102000012737 Electron-Transferring Flavoproteins Human genes 0.000 description 1
- 108010079426 Electron-Transferring Flavoproteins Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102100030011 Endoribonuclease Human genes 0.000 description 1
- 101710199605 Endoribonuclease Proteins 0.000 description 1
- 102000013128 Endothelin B Receptor Human genes 0.000 description 1
- 108010090557 Endothelin B Receptor Proteins 0.000 description 1
- 241000194033 Enterococcus Species 0.000 description 1
- 108010062466 Enzyme Precursors Proteins 0.000 description 1
- 102000010911 Enzyme Precursors Human genes 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 102000034286 G proteins Human genes 0.000 description 1
- 102000054184 GADD45 Human genes 0.000 description 1
- 102000002464 Galactosidases Human genes 0.000 description 1
- 108010093031 Galactosidases Proteins 0.000 description 1
- 108010010038 Gamma-protocadherins Proteins 0.000 description 1
- 102100033053 Glutathione peroxidase 3 Human genes 0.000 description 1
- 101710119049 Glutathione peroxidase 3 Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000010956 Glypican Human genes 0.000 description 1
- 108050001154 Glypican Proteins 0.000 description 1
- 108050007238 Glypican-1 Proteins 0.000 description 1
- 102000006771 Gonadotropins Human genes 0.000 description 1
- 108010086677 Gonadotropins Proteins 0.000 description 1
- 108060003393 Granulin Proteins 0.000 description 1
- 108010054017 Granulocyte Colony-Stimulating Factor Receptors Proteins 0.000 description 1
- 102000008651 Growth factor receptor-bound protein 14 Human genes 0.000 description 1
- 108050000445 Growth factor receptor-bound protein 14 Proteins 0.000 description 1
- 102100033067 Growth factor receptor-bound protein 2 Human genes 0.000 description 1
- 108091009389 Growth factor receptor-bound protein 2 Proteins 0.000 description 1
- UYTPUPDQBNUYGX-UHFFFAOYSA-N Guanine Natural products O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 1
- 102100028967 HLA class I histocompatibility antigen, alpha chain G Human genes 0.000 description 1
- 108010024164 HLA-G Antigens Proteins 0.000 description 1
- 102000009824 Hepatocyte Nuclear Factor 1-alpha Human genes 0.000 description 1
- 108010020382 Hepatocyte Nuclear Factor 1-alpha Proteins 0.000 description 1
- 241000709721 Hepatovirus A Species 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101000639839 Homo sapiens 28S ribosomal protein S18b, mitochondrial Proteins 0.000 description 1
- 101000970576 Homo sapiens Bcl-2-interacting killer Proteins 0.000 description 1
- 101000766275 Homo sapiens Breast carcinoma-amplified sequence 4 Proteins 0.000 description 1
- 101000777564 Homo sapiens C-C chemokine receptor type 1 Proteins 0.000 description 1
- 101000946926 Homo sapiens C-C chemokine receptor type 5 Proteins 0.000 description 1
- 101000715674 Homo sapiens Cadherin EGF LAG seven-pass G-type receptor 2 Proteins 0.000 description 1
- 101000715398 Homo sapiens Caspase-1 Proteins 0.000 description 1
- 101000776477 Homo sapiens Centrosomal protein 43 Proteins 0.000 description 1
- 101000737958 Homo sapiens Chromatin target of PRMT1 protein Proteins 0.000 description 1
- 101000726193 Homo sapiens Cyclic AMP-responsive element-binding protein 5 Proteins 0.000 description 1
- 101000907783 Homo sapiens Cystic fibrosis transmembrane conductance regulator Proteins 0.000 description 1
- 101000861049 Homo sapiens Cytochrome c oxidase subunit 6C Proteins 0.000 description 1
- 101000802744 Homo sapiens Cytosolic 5'-nucleotidase 1A Proteins 0.000 description 1
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 description 1
- 101000864175 Homo sapiens DNA polymerase epsilon subunit 3 Proteins 0.000 description 1
- 101000746364 Homo sapiens Granulocyte colony-stimulating factor receptor Proteins 0.000 description 1
- 101001066158 Homo sapiens Growth arrest and DNA damage-inducible protein GADD45 alpha Proteins 0.000 description 1
- 101001081552 Homo sapiens Inhibitor of Bruton tyrosine kinase Proteins 0.000 description 1
- 101001001420 Homo sapiens Interferon gamma receptor 1 Proteins 0.000 description 1
- 101001033249 Homo sapiens Interleukin-1 beta Proteins 0.000 description 1
- 101000998020 Homo sapiens Keratin, type I cytoskeletal 18 Proteins 0.000 description 1
- 101000998011 Homo sapiens Keratin, type I cytoskeletal 19 Proteins 0.000 description 1
- 101001139136 Homo sapiens Krueppel-like factor 3 Proteins 0.000 description 1
- 101100020598 Homo sapiens LAPTM4A gene Proteins 0.000 description 1
- 101001020548 Homo sapiens LIM/homeobox protein Lhx1 Proteins 0.000 description 1
- 101000984190 Homo sapiens Leukocyte immunoglobulin-like receptor subfamily B member 1 Proteins 0.000 description 1
- 101000984192 Homo sapiens Leukocyte immunoglobulin-like receptor subfamily B member 3 Proteins 0.000 description 1
- 101000984186 Homo sapiens Leukocyte immunoglobulin-like receptor subfamily B member 4 Proteins 0.000 description 1
- 101001044093 Homo sapiens Lipopolysaccharide-induced tumor necrosis factor-alpha factor Proteins 0.000 description 1
- 101000942701 Homo sapiens Liprin-alpha-3 Proteins 0.000 description 1
- 101000950648 Homo sapiens Malectin Proteins 0.000 description 1
- 101000645296 Homo sapiens Metalloproteinase inhibitor 2 Proteins 0.000 description 1
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 1
- 101000884270 Homo sapiens Natural killer cell receptor 2B4 Proteins 0.000 description 1
- 101000918983 Homo sapiens Neutrophil defensin 1 Proteins 0.000 description 1
- 101001117517 Homo sapiens Prostaglandin E2 receptor EP3 subtype Proteins 0.000 description 1
- 101001076724 Homo sapiens RNA-binding protein 28 Proteins 0.000 description 1
- 101000999079 Homo sapiens Radiation-inducible immediate-early gene IEX-1 Proteins 0.000 description 1
- 101001104108 Homo sapiens Rap1 GTPase-activating protein 1 Proteins 0.000 description 1
- 101000763579 Homo sapiens Toll-like receptor 1 Proteins 0.000 description 1
- 101000831567 Homo sapiens Toll-like receptor 2 Proteins 0.000 description 1
- 101000669460 Homo sapiens Toll-like receptor 5 Proteins 0.000 description 1
- 101000866336 Homo sapiens Transcription factor E2F5 Proteins 0.000 description 1
- 101000845269 Homo sapiens Transcription termination factor 1 Proteins 0.000 description 1
- 101000713585 Homo sapiens Tubulin beta-4A chain Proteins 0.000 description 1
- 101000830565 Homo sapiens Tumor necrosis factor ligand superfamily member 10 Proteins 0.000 description 1
- 101000801232 Homo sapiens Tumor necrosis factor receptor superfamily member 1B Proteins 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- 206010020649 Hyperkeratosis Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 1
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 1
- 102100027638 Inhibitor of Bruton tyrosine kinase Human genes 0.000 description 1
- 102100025323 Integrin alpha-1 Human genes 0.000 description 1
- 102100022339 Integrin alpha-L Human genes 0.000 description 1
- 108010041341 Integrin alpha1 Proteins 0.000 description 1
- 102000012334 Integrin beta4 Human genes 0.000 description 1
- 108010022238 Integrin beta4 Proteins 0.000 description 1
- 102100020944 Integrin-linked protein kinase Human genes 0.000 description 1
- 108010064600 Intercellular Adhesion Molecule-3 Proteins 0.000 description 1
- 102100037871 Intercellular adhesion molecule 3 Human genes 0.000 description 1
- 102000004344 Interferon regulatory factor 2 Human genes 0.000 description 1
- 108090000908 Interferon regulatory factor 2 Proteins 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102100039065 Interleukin-1 beta Human genes 0.000 description 1
- 102100026017 Interleukin-1 receptor type 2 Human genes 0.000 description 1
- 101710149731 Interleukin-1 receptor type 2 Proteins 0.000 description 1
- 102000003815 Interleukin-11 Human genes 0.000 description 1
- 108090000177 Interleukin-11 Proteins 0.000 description 1
- 102100020792 Interleukin-12 receptor subunit beta-2 Human genes 0.000 description 1
- 101710103840 Interleukin-12 receptor subunit beta-2 Proteins 0.000 description 1
- 102000003810 Interleukin-18 Human genes 0.000 description 1
- 108090000171 Interleukin-18 Proteins 0.000 description 1
- 102000004557 Interleukin-18 Receptors Human genes 0.000 description 1
- 108010017537 Interleukin-18 Receptors Proteins 0.000 description 1
- 102000006541 Ionotropic Glutamate Receptors Human genes 0.000 description 1
- 108010008812 Ionotropic Glutamate Receptors Proteins 0.000 description 1
- 241000726306 Irus Species 0.000 description 1
- 101150021395 JUND gene Proteins 0.000 description 1
- 102100033421 Keratin, type I cytoskeletal 18 Human genes 0.000 description 1
- 102100033420 Keratin, type I cytoskeletal 19 Human genes 0.000 description 1
- 102100020678 Krueppel-like factor 3 Human genes 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 1
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 1
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- 102100031764 LINE-1 retrotransposable element ORF1 protein Human genes 0.000 description 1
- 101710157664 LINE-1 retrotransposable element ORF1 protein Proteins 0.000 description 1
- 108090000581 Leukemia inhibitory factor Proteins 0.000 description 1
- 102100032352 Leukemia inhibitory factor Human genes 0.000 description 1
- 101710142062 Leukemia inhibitory factor receptor Proteins 0.000 description 1
- 102100025584 Leukocyte immunoglobulin-like receptor subfamily B member 1 Human genes 0.000 description 1
- 102100025582 Leukocyte immunoglobulin-like receptor subfamily B member 3 Human genes 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 102100021607 Lipopolysaccharide-induced tumor necrosis factor-alpha factor Human genes 0.000 description 1
- 102100032892 Liprin-alpha-3 Human genes 0.000 description 1
- 108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 description 1
- 102100035304 Lymphotactin Human genes 0.000 description 1
- 102100034728 Lysosomal-associated transmembrane protein 4A Human genes 0.000 description 1
- 108010064171 Lysosome-Associated Membrane Glycoproteins Proteins 0.000 description 1
- 102000014944 Lysosome-Associated Membrane Glycoproteins Human genes 0.000 description 1
- 102000025498 MAP Kinase Kinase Kinase 2 Human genes 0.000 description 1
- 108010075656 MAP Kinase Kinase Kinase 2 Proteins 0.000 description 1
- 102100034069 MAP kinase-activated protein kinase 2 Human genes 0.000 description 1
- 108010041955 MAP-kinase-activated kinase 2 Proteins 0.000 description 1
- 102100028123 Macrophage colony-stimulating factor 1 Human genes 0.000 description 1
- 101710127797 Macrophage colony-stimulating factor 1 Proteins 0.000 description 1
- 102000004318 Matrilysin Human genes 0.000 description 1
- 108090000855 Matrilysin Proteins 0.000 description 1
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 1
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 1
- 108010036176 Melitten Proteins 0.000 description 1
- 102100026262 Metalloproteinase inhibitor 2 Human genes 0.000 description 1
- 102100026261 Metalloproteinase inhibitor 3 Human genes 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 1
- 108700027648 Mitogen-Activated Protein Kinase 8 Proteins 0.000 description 1
- 102100037808 Mitogen-activated protein kinase 8 Human genes 0.000 description 1
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 1
- 102100030173 Muellerian-inhibiting factor Human genes 0.000 description 1
- 101100421767 Mus musculus Snai1 gene Proteins 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 102000003505 Myosin Human genes 0.000 description 1
- 108060008487 Myosin Proteins 0.000 description 1
- 102000019148 NF-kappaB-inducing kinase activity proteins Human genes 0.000 description 1
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 description 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 1
- 102100038082 Natural killer cell receptor 2B4 Human genes 0.000 description 1
- 101800000287 Neutrophil defensin 2 Proteins 0.000 description 1
- 102400001060 Neutrophil defensin 2 Human genes 0.000 description 1
- 101001123254 Nicotiana tabacum Protoporphyrinogen oxidase, chloroplastic Proteins 0.000 description 1
- 102000001753 Notch4 Receptor Human genes 0.000 description 1
- 102100021858 Nuclear receptor-binding protein Human genes 0.000 description 1
- 101710127265 Nuclear receptor-binding protein Proteins 0.000 description 1
- 102000012547 Olfactory receptors Human genes 0.000 description 1
- 108050002069 Olfactory receptors Proteins 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 102000004140 Oncostatin M Human genes 0.000 description 1
- 108090000630 Oncostatin M Proteins 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 102000016978 Orphan receptors Human genes 0.000 description 1
- 108070000031 Orphan receptors Proteins 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 108091008606 PDGF receptors Proteins 0.000 description 1
- 101710190786 PI protein Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- 108010044843 Peptide Initiation Factors Proteins 0.000 description 1
- 102000005877 Peptide Initiation Factors Human genes 0.000 description 1
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 1
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 description 1
- 102000011653 Platelet-Derived Growth Factor Receptors Human genes 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 101710097690 Prostaglandin E2 receptor EP1 subtype Proteins 0.000 description 1
- 102100024447 Prostaglandin E2 receptor EP3 subtype Human genes 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 101710096541 Proteasome subunit beta Proteins 0.000 description 1
- 101710094499 Proteasome subunit beta type-4 Proteins 0.000 description 1
- 101710094473 Proteasome subunit beta type-7 Proteins 0.000 description 1
- 102100035763 Proteasome subunit beta type-7 Human genes 0.000 description 1
- 101710095664 Protein 6.3 Proteins 0.000 description 1
- 102000006010 Protein Disulfide-Isomerase Human genes 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 102100023087 Protein S100-A4 Human genes 0.000 description 1
- 108010001648 Proto-Oncogene Proteins c-ret Proteins 0.000 description 1
- 102000000813 Proto-Oncogene Proteins c-ret Human genes 0.000 description 1
- 240000004350 Prunus spinosa Species 0.000 description 1
- 235000010829 Prunus spinosa Nutrition 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 102100020834 RCC1 and BTB domain-containing protein 2 Human genes 0.000 description 1
- 101710186923 RCC1 and BTB domain-containing protein 2 Proteins 0.000 description 1
- 108020004518 RNA Probes Proteins 0.000 description 1
- 239000003391 RNA probe Substances 0.000 description 1
- 102100025872 RNA-binding protein 28 Human genes 0.000 description 1
- 102100036900 Radiation-inducible immediate-early gene IEX-1 Human genes 0.000 description 1
- 102100040088 Rap1 GTPase-activating protein 1 Human genes 0.000 description 1
- 101710141795 Ribonuclease inhibitor Proteins 0.000 description 1
- 229940122208 Ribonuclease inhibitor Drugs 0.000 description 1
- 102100037968 Ribonuclease inhibitor Human genes 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 102000002278 Ribosomal Proteins Human genes 0.000 description 1
- 108010000605 Ribosomal Proteins Proteins 0.000 description 1
- 108010085149 S100 Calcium-Binding Protein A4 Proteins 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 101710113029 Serine/threonine-protein kinase Proteins 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 108010052164 Sodium Channels Proteins 0.000 description 1
- 102000018674 Sodium Channels Human genes 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 108700017375 Specific Granule Deficiency Proteins 0.000 description 1
- 241000295644 Staphylococcaceae Species 0.000 description 1
- 206010041925 Staphylococcal infections Diseases 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 101100335596 Sulfolobus acidocaldarius (strain ATCC 33909 / DSM 639 / JCM 8929 / NBRC 15157 / NCIMB 11770) ftsY gene Proteins 0.000 description 1
- 102000006467 TATA-Box Binding Protein Human genes 0.000 description 1
- 108010044281 TATA-Box Binding Protein Proteins 0.000 description 1
- 101710159236 TGFB1-induced anti-apoptotic factor 1 Proteins 0.000 description 1
- 102100033077 TNF receptor-associated factor 2 Human genes 0.000 description 1
- 108090000925 TNF receptor-associated factor 2 Proteins 0.000 description 1
- 102100033082 TNF receptor-associated factor 3 Human genes 0.000 description 1
- 108090000922 TNF receptor-associated factor 3 Proteins 0.000 description 1
- 102100036494 Testisin Human genes 0.000 description 1
- 108050003829 Testisin Proteins 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 102000006601 Thymidine Kinase Human genes 0.000 description 1
- 108020004440 Thymidine kinase Proteins 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- 108010031429 Tissue Inhibitor of Metalloproteinase-3 Proteins 0.000 description 1
- 102100027010 Toll-like receptor 1 Human genes 0.000 description 1
- 102100024333 Toll-like receptor 2 Human genes 0.000 description 1
- 102100039357 Toll-like receptor 5 Human genes 0.000 description 1
- 102000011409 Transcobalamins Human genes 0.000 description 1
- 108010023603 Transcobalamins Proteins 0.000 description 1
- 102100031632 Transcription factor E2F5 Human genes 0.000 description 1
- 241000984695 Troglodytinae Species 0.000 description 1
- 102100036788 Tubulin beta-4A chain Human genes 0.000 description 1
- 102100024598 Tumor necrosis factor ligand superfamily member 10 Human genes 0.000 description 1
- 102100033733 Tumor necrosis factor receptor superfamily member 1B Human genes 0.000 description 1
- 206010054094 Tumour necrosis Diseases 0.000 description 1
- 102000014384 Type C Phospholipases Human genes 0.000 description 1
- 108010079194 Type C Phospholipases Proteins 0.000 description 1
- 108010051765 Type I Bone Morphogenetic Protein Receptors Proteins 0.000 description 1
- 108091000117 Tyrosine 3-Monooxygenase Proteins 0.000 description 1
- 102000048218 Tyrosine 3-monooxygenases Human genes 0.000 description 1
- LFTYTUAZOPRMMI-NESSUJCYSA-N UDP-N-acetyl-alpha-D-galactosamine Chemical compound O1[C@H](CO)[C@H](O)[C@H](O)[C@@H](NC(=O)C)[C@H]1O[P@](O)(=O)O[P@](O)(=O)OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](N2C(NC(=O)C=C2)=O)O1 LFTYTUAZOPRMMI-NESSUJCYSA-N 0.000 description 1
- LFTYTUAZOPRMMI-UHFFFAOYSA-N UNPD164450 Natural products O1C(CO)C(O)C(O)C(NC(=O)C)C1OP(O)(=O)OP(O)(=O)OCC1C(O)C(O)C(N2C(NC(=O)C=C2)=O)O1 LFTYTUAZOPRMMI-UHFFFAOYSA-N 0.000 description 1
- 108090000848 Ubiquitin Proteins 0.000 description 1
- 102400000757 Ubiquitin Human genes 0.000 description 1
- 102000003431 Ubiquitin-Conjugating Enzyme Human genes 0.000 description 1
- 108060008747 Ubiquitin-Conjugating Enzyme Proteins 0.000 description 1
- 102100038932 Unconventional myosin-XVIIIa Human genes 0.000 description 1
- 108010059993 Vancomycin Proteins 0.000 description 1
- 108010003205 Vasoactive Intestinal Peptide Proteins 0.000 description 1
- 102400000015 Vasoactive intestinal peptide Human genes 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 101100421768 Xenopus laevis snai1 gene Proteins 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 238000004847 absorption spectroscopy Methods 0.000 description 1
- 229940100228 acetyl coenzyme a Drugs 0.000 description 1
- 102000005421 acetyltransferase Human genes 0.000 description 1
- 108020002494 acetyltransferase Proteins 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 210000005006 adaptive immune system Anatomy 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 1
- LNQVTSROQXJCDD-UHFFFAOYSA-N adenosine monophosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(CO)C(OP(O)(O)=O)C1O LNQVTSROQXJCDD-UHFFFAOYSA-N 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000000868 anti-mullerian hormone Substances 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 238000011203 antimicrobial therapy Methods 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 150000001483 arginine derivatives Chemical class 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- RHISNKCGUDDGEG-UHFFFAOYSA-N bactenecin Chemical compound CCC(C)C1NC(=O)C(C(C)C)NC(=O)C(C(C)C)NC(=O)C(C(C)CC)NC(=O)C(CCCN=C(N)N)NC(=O)C(NC(=O)C(CC(C)C)NC(=O)C(N)CCCN=C(N)N)CSSCC(C(=O)NC(CCCN=C(N)N)C(O)=O)NC(=O)C(C(C)C)NC(=O)C(CCCN=C(N)N)NC1=O RHISNKCGUDDGEG-UHFFFAOYSA-N 0.000 description 1
- 108010016341 bactenecin Proteins 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 229940112869 bone morphogenetic protein Drugs 0.000 description 1
- 229940053031 botulinum toxin Drugs 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 108010007004 cathelin Proteins 0.000 description 1
- 101150059448 cdk7 gene Proteins 0.000 description 1
- 230000008568 cell cell communication Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- KNHUKKLJHYUCFP-UHFFFAOYSA-N clofibrate Chemical compound CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 KNHUKKLJHYUCFP-UHFFFAOYSA-N 0.000 description 1
- 230000004186 co-expression Effects 0.000 description 1
- RGJOEKWQDUBAIZ-UHFFFAOYSA-N coenzime A Natural products OC1C(OP(O)(O)=O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-UHFFFAOYSA-N 0.000 description 1
- 239000005516 coenzyme A Substances 0.000 description 1
- 229940093530 coenzyme a Drugs 0.000 description 1
- 230000002281 colonystimulating effect Effects 0.000 description 1
- 229920001577 copolymer Chemical compound 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 1
- 229960000258 corticotropin Drugs 0.000 description 1
- 239000013058 crude material Substances 0.000 description 1
- 210000004292 cytoskeleton Anatomy 0.000 description 1
- 210000000172 cytosol Anatomy 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 238000000326 densiometry Methods 0.000 description 1
- 238000010217 densitometric analysis Methods 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- KDTSHFARGAKYJN-UHFFFAOYSA-N dephosphocoenzyme A Natural products OC1C(O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 KDTSHFARGAKYJN-UHFFFAOYSA-N 0.000 description 1
- 238000000586 desensitisation Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 229910003460 diamond Inorganic materials 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- 230000002222 downregulating effect Effects 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 230000009762 endothelial cell differentiation Effects 0.000 description 1
- 108010072542 endotoxin binding proteins Proteins 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 239000002622 gonadotropin Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 102000017941 granulin Human genes 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 229940029575 guanosine Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- XGFJCRNRWOXGQM-UHFFFAOYSA-N hot-2 Chemical compound CCSC1=CC(OC)=C(CCNO)C=C1OC XGFJCRNRWOXGQM-UHFFFAOYSA-N 0.000 description 1
- 102000018474 human neutrophil peptide 1 Human genes 0.000 description 1
- 125000001165 hydrophobic group Chemical group 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 229940088592 immunologic factor Drugs 0.000 description 1
- 239000000367 immunologic factor Substances 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 230000003960 inflammatory cascade Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 108091006086 inhibitor proteins Proteins 0.000 description 1
- 238000013383 initial experiment Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000002608 insulinlike Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 108010059517 integrin-linked kinase Proteins 0.000 description 1
- 230000005732 intercellular adhesion Effects 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 229940100601 interleukin-6 Drugs 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- VBUWHHLIZKOSMS-RIWXPGAOSA-N invicorp Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)C(C)C)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 VBUWHHLIZKOSMS-RIWXPGAOSA-N 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 235000014705 isoleucine Nutrition 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 108010019677 lymphotactin Proteins 0.000 description 1
- 108091005446 macrophage receptors Proteins 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- VDXZNPDIRNWWCW-JFTDCZMZSA-N melittin Chemical compound NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(N)=O)CC1=CNC2=CC=CC=C12 VDXZNPDIRNWWCW-JFTDCZMZSA-N 0.000 description 1
- 210000003071 memory t lymphocyte Anatomy 0.000 description 1
- 239000001369 metatartaric acid Substances 0.000 description 1
- 208000015688 methicillin-resistant staphylococcus aureus infectious disease Diseases 0.000 description 1
- UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 1
- 150000004702 methyl esters Chemical group 0.000 description 1
- 229960003085 meticillin Drugs 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- YIEDSISPYKQADU-UHFFFAOYSA-N n-acetyl-n-[2-methyl-4-[(2-methylphenyl)diazenyl]phenyl]acetamide Chemical compound C1=C(C)C(N(C(C)=O)C(=O)C)=CC=C1N=NC1=CC=CC=C1C YIEDSISPYKQADU-UHFFFAOYSA-N 0.000 description 1
- 201000011216 nasopharynx carcinoma Diseases 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- GRZXCHIIZXMEPJ-HTLKCAKFSA-N neutrophil peptide-2 Chemical compound C([C@H]1C(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@H](C(N[C@@H](C)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=4C=CC(O)=CC=4)NC(=O)[C@@H](N)CSSC[C@H](NC2=O)C(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](C)C(=O)N3)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](C)C(=O)N1)[C@@H](C)CC)[C@@H](C)O)=O)[C@@H](C)CC)C1=CC=CC=C1 GRZXCHIIZXMEPJ-HTLKCAKFSA-N 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 239000000346 nonvolatile oil Substances 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 150000002895 organic esters Chemical class 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 108010000953 osteoblast cadherin Proteins 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 108010069653 peptide E (adrenal medulla) Proteins 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 1
- 231100000683 possible toxicity Toxicity 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 230000007126 proinflammatory cytokine response Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 108020003519 protein disulfide isomerase Proteins 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 108010008366 protein phosphatase 6 Proteins 0.000 description 1
- 230000004844 protein turnover Effects 0.000 description 1
- 210000001938 protoplast Anatomy 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 229910052761 rare earth metal Inorganic materials 0.000 description 1
- 108700042226 ras Genes Proteins 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000027425 release of sequestered calcium ion into cytosol Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 108010093173 ribosomal protein S29 Proteins 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000007423 screening assay Methods 0.000 description 1
- 101150015999 sec24 gene Proteins 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 208000013223 septicemia Diseases 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 208000000162 specific granule deficiency Diseases 0.000 description 1
- 229940063673 spermidine Drugs 0.000 description 1
- 229940063675 spermine Drugs 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 210000003371 toe Anatomy 0.000 description 1
- 230000002463 transducing effect Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 1
- 229960003165 vancomycin Drugs 0.000 description 1
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000005167 vascular cell Anatomy 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 210000004340 zona pellucida Anatomy 0.000 description 1
- KRJOFJHOZZPBKI-KSWODRSDSA-N α-defensin-1 Chemical compound C([C@H]1C(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@H](C(N[C@@H](C)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=4C=CC(O)=CC=4)NC(=O)[C@H](CSSC[C@H](NC2=O)C(O)=O)NC(=O)[C@H](C)N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](C)C(=O)N3)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](C)C(=O)N1)[C@@H](C)CC)[C@@H](C)O)=O)[C@@H](C)CC)C1=CC=CC=C1 KRJOFJHOZZPBKI-KSWODRSDSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4723—Cationic antimicrobial peptides, e.g. defensins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/521—Chemokines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7158—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for chemokines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/505—Cells of the immune system involving T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Veterinary Medicine (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pathology (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- General Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Tropical Medicine & Parasitology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
Description
EFFECTORS OF INNATE IMMUNITY
. RELATED APPLICATION DATA
This application claims priority under 35 USC 119(e) to US Patent Application Serial
No. 60/336,632, filed December 3, 2001, herein incorporated by reference in its entirety.
[0001] The present invention relates generally to peptides and specifically to peptides effective as therapeutics and for drug discovery related to pathologies resulting from microbial infections and for modulating innate immunity or anti-inflammatory activity.
[0002] Infectious diseases are the leading cause of death worldwide. According to a 1999 World Health Organization study, over 13 million people die from infectious diseases each year. Infectious diseases are the third leading cause of death in North
America, accounting for 20% of deaths annually and increasing by 50% since 1980.
The success of many medical and surgical treatments also hinges on the control of infectious diseases. The discovery and use of antibiotics has been one of the great achievements of modern medicine. Without antibiotics, physicians would be unable to perform complex surgery, chemotherapy or most medical interventions such as catheterization.
[0003] Current sales of antibiotics are US$26 billion worldwide. However, the overuse and sometimes unwarranted use of antibiotics have resulted in the evolution ' of new antibiotic-resistant strains of bacteria. Antibiotic resistance has become part of the medical landscape. Bacteria such as vancomycin-resistant Enterococcus, VRE, and methicillin-resistant Staphylococcus aureus and MRSA, strains cannot be treated with antibiotics and often, patients suffering from infections with such bacteria die.
Antibiotic discovery has proven to be onc of the most difficult areas for new drug development and many large pharmaceutical companies have cut back or completely halted their antibiotic development programs. However, with the dramatic rise of antibiotic resistance, including the emergence of untreatable infections, there is a clear unmet medical need for novel types of anti-microbial therapies, and agents that } impact on innate immunity would be one such class of agents.
[0004] The innate immune system is a highly effective and evolved general defense system. Elements of innate immunity are always present at low levels and are : activated very rapidly when stimulated. Stimulation can include interaction of bacterial signaling molecules with pattern recognition receptors on the surface of the body’s cells or other mechanisms of disease. Every day, humans are exposed to tens of thousands of potential pathogenic microorganisms through the food and water we ingest, the air we breathe and the surfaces, pets and people that we touch. The innate immune system acts to prevent these pathogens from causing disease. The innate immune system differs from so-called adaptive immunity (which includes antibodies and antigen-specific B- and T-lymphocytes) because it is always present, effective . immediately, and relatively non-specific for any given pathogen. The adaptive immune system requires amplification of specific recognition elements and thus takes days to weeks to respond. Even when adaptive immunity is pre-stimulated by vaccination, it may take three days or more to respond to a pathogen whereas innate immunity is immediately or rapidly (hours) available. Innate immunity involves a + variety of effector functions including phagocytic cells, complement, etc, but is generally incompletely understood. Generally speaking many innate immune responses are “triggered” by the binding of microbial signaling molecules with pattern recognition receptors termed Toll-like receptors on the surface of host cells. Many of these effector functions are grouped together in the inflammatory response. However too severe an inflammatory response can result in responses that are harmful to the body, and in an extreme case sepsis and potentially death can occur. .
[0005] The release of structural components from infectious agents during infection causes an inflammatory response, which when unchecked can lead to the potentially ++ + lethal condition, sepsis. Sepsis occurs in approximately 780,000 patients in North
America annually. Sepsis may develop as a result of infections acquired in the community such as pneumonia, or it may be a complication of the treatment of trauma, cancer or major surgery. Severe sepsis occurs when the body is overwhelmed by the inflammatory response and body organs begin to fail. Up to 120,000 deaths ] occur annually in the United Stated due to sepsis. Sepsis may also involve pathogenic microorganisms or toxins in the blood (e.g., septicemia), which is a leading cause of death among humans. Gram-negative bacteria are the organisms most commonly associated with such diseases. However, gram-positive bacteria are an increasing cause of infections. Gram-negative and Gram-positive bacteria and their components can all cause sepsis.
[0006] The presence of microbial components induce the release of pro- inflammatory cytokines of which tumor necrosis factor-a (TNF-a) is of extreme importance. TNF-a and other pro-inflammatory cytokines can then cause the release of other pro-inflammatory mediators and lead to an inflammatory cascade. Gram- negative sepsis is usually caused by the release of the bacterial outer membrane component, lipopolysaccharide (LPS; also referred to as endotoxin). Endotoxin in the blood, called endotoxemia comes primarily from a bacterial infection, and may be released during treatment with antibiotics. Gram-positive sepsis can be caused by the release of bacterial cell wall components such as lipoteichoic acid (LTA), peptidoglycan (PG), rhamnose-glucose polymers made by Streptococci, or capsular polysaccharides made by Staphylococci. Bacterial or other non-mammalian DNA that, unlike mammalian DNA, frequently contains unmethylated cytosine-guanosine
E dimers (CpG DNA) has also been shown to induce septic conditions including the production of TNF-a. Mammalian DNA contains CpG dinucleotides at a much lower frequency, often in a methylated form. In addition to their natural release during bacterial infections, antibiotic treatment can also cause release of the bacterial cell wall components LPS and LTA and probably also bacterial DNA. This can then . hinder recovery from infection or even cause sepsis.
[0007] Cationic peptides are being increasingly recognized as a form of defense against infection, although the major effects recognized in the scientific and patent literature are the antimicrobial effects (Hancock, R.E.W., and R. Lehrer. 1998.
. Cationic peptides: a new source of antibiotics. Trends in Biotechnology 16: 82-88.).
Cationic peptides having antimicrobial activity have been isolated from a wide variety of organisms. In nature, such peptides provide a defense mechanism against microorganisms such as bacteria and yeast. Generally, these cationic peptides are thought to exert their antimicrobial activity on bacteria by interacting with the . cytoplasmic membrane, and in most cases, forming channels or lesions. In gram- negative bacteria, they interact with LPS to permeabilize the outer membrane, leading to self promoted uptake across the outer membrane and access to the cytoplasmic membrane. Examples of cationic antimicrobial peptides include indolicidin, defensins, cecropins, and magainins.
[0008] Recently it has been increasingly recognized that such peptides are effectors in other aspects of innate immunity (Hancock, R.E.W. and G. Diamond. 2000. The role of cationic peptides in innate host defenses. Trends in Microbiology 8:402-410.;
Hancock, R.E.W. 2001. Cationic peptides: effectors in innate immunity and novel antimicrobials. Lancet Infectious Diseases 1:156-164) although it was not known if the antimicrobial and effector functions are independent.
[0009] Some cationic peptides have an affinity for binding bacterial products such as
LPS and LTA. Such cationic peptides can suppress cytokine production in response to LPS, and to varying extents can prevent lethal shock. However it has not been proven as to whether such effects are due to binding of the peptides to LPS and LTA, or due to a direct interaction of the peptides with host cells. Cationic peptides are induced, in response to challenge by microbes or microbial signaling molecules like
LPS, by a regulatory pathway similar to that used by the mammalian immune system (involving Toll like receptors and the transcription factor; NFkB). Cationic peptides therefore appear to have a key role in innate immunity. Mutations that affect the induction of antibacterial peptides can reduce survival in response to bacterial challenge. As well, mutations of the Toll pathway of Drosophila that lead to decreased antifungal peptide expression result in increased susceptibility to lethal fungal infections. In humans, patients with specific granule deficiency syndrome, completely lacking in a-defensins, suffer from frequent and severe bacterial : infections. Other evidence includes the inducibility of some peptides by infectious agents, and the very high concentrations that have been recorded at sites of inflammation. Cationic peptides may also regulate cell migration, to promote the ability of leukocytes to combat bacterial infections. For example, two human a- defensin peptides, HNP-1 and HNP-2, have been indicated to have direct chemotactic ) activity for murine and human T cells and monocytes, and human -defensins appear to act as chemoattractants for immature dendritic cells and memory T cells through interaction with CCR6. Similarly, the porcine cationic peptide, PR-39 was found to be chemotactic for neutrophils. It is unclear however as to whether peptides of different structures and compositions share these properties.
[00010] The single known cathelicidin from humans, LL-37, is produced by myeloid precursors, testis, human keratinocytes during inflammatory disorders and airway epithelium. The characteristic feature of cathelicidin peptides is a high level of sequence identity at the N-terminus prepro regions termed the cathelin domain.
Cathelicidin peptides are stored as inactive propeptide precursors that, upon stimulation, are processed into active peptides.
[00011] The present invention is based on the seminal discovery that based on patterns of polynucleotide expression regulated by endotoxic lipopolysaccharide, lipoteichoic acid, CpG DNA, or other cellular components (e.g., microbes or their cellular components), and affected by cationic peptides, one can screen for novel compounds that block or reduce sepsis and/or inflammation in a subject. Further, based on the use of cationic peptides as a tool, one can identify selective enhancers of innate immunity that do not trigger the sepsis reaction and that can block/dampen inflammatory and/or septic responses.
[00012] Thus, in one embodiment, a method of identifying a polynucleotide or pattern of polynucleotides regulated by one or more sepsis or inflammatory inducing agents and inhibited by a cationic peptide is provided. The method of the invention includes contacting the polynucleotide or polynucleotides with one or more sepsis or inflammatory inducing agents and contacting the polynucleotide or polynucleotides with a cationic peptide either simultaneously or immediately thereafter. Differences in expression are detected in the presence and absence of the cationic peptide, and a change in expression, either up- or down-regulation, is indicative of a polynucleotide or pattern of polynucleotides that is regulated by a sepsis or inflammatory inducing ’ agent and inhibited by a cationic peptide. In another aspect the invention provides a polynucleotide or polynucleotides identified by the above method. Examples of sepsis or inflammatory regulatory agents include LPS, LTA or CpG DNA or microbial components (or any combination thereof), or related agents.
[0010] In another embodiment, the invention provides a method of identifying an agent that blocks sepsis or inflammation including combining a polynucleotide identified by the method set forth above with an agent wherein expression of the polynucleotide in the presence of the agent is modulated as compared with expression in the absence of the agent and wherein the modulation in expression affects an inflammatory or septic response.
[0011] In another embodiment, the invention provides a method of identifying a pattern of polynucleotide expression for inhibition of an inflammatory or septic response by 1) contacting cells with LPS, LTA and/or CpG DNA in the presence or absence of a cationic peptide and 2) detecting a pattern of polynucleotide expression for the cells in the presence and absence of the peptide. The pattern obtained in the presence of the peptide represents inhibition of an inflammatory or septic response.
In another aspect the pattern obtained in the presence of the peptide is compared to the pattern of a test compound to identify a compound that provides a similar pattern.
In another aspect the invention provides a compound identified by the foregoing method.
[0012] In another embodiment, the invention provides a method of identifying an agent that enhances innate immunity by contacting a polynucleotide or polynucleotides that encode a polypeptide involved in innate immunity, with an agent of interest, wherein expression of the polynucleotide in the presence of the agent is modulated as compared with expression of the polynucleotide in the absence of the : agent and wherein the modulated expression results in enhancement of innate immunity. Preferably, the agent does not stimulate a sepsis reaction in a subject. In one aspect, the agent increases the expression of an anti-inflammatory polynucleotide.
Exemplary, but non-limiting anti-inflammatory polynucleotides encode proteins such as IL-1 R antagonist homolog 1 (A1167887), IL-10 R beta (AA486393), IL-10 R + alpha (U00672) TNF Receptor member 1B (AA150416), TNF receptor member 5 (H98636), TNF receptor member 11b (AA194983), IK cytokine down-regulator of
HLA II (R39227), TGF-B inducible early growth response 2 (A1473938), CD2 (AA927710), IL-19 (NM_013371) or IL-10 (M57627). In one aspect, the agent decreases the expression of polynucleotides encoding proteasome subunits involved in NF-xB activation such as proteasome subunit 26S (NM _013371). In one aspect, the agent may act as an antagonist of protein kinases. In one aspect, the agent is a peptide selected from SEQ ID NO:4-54.
[0013] In another embodiment, the invention provides a method of identifying a pattern of polynucleotide expression for identification of a compound that selectively enhances innate immunity. The invention includes detecting a pattern of polynucleotide expression for cells contacted in the presence and absence of a cationic peptide, wherein the pattern in the presence of the peptide represents stimulation of innate immunity; detecting a pattern of polynucleotide expression for cells contacted in the presence of a test compound, wherein a pattern with the test compound that is similar to the pattern observed in the presence of the cationic peptide, is indicative of a compound that enhances innate immunity. It is preferred that the compound does not stimulate a septic reaction in a subject.
[0014] In another embodiment, the invention provides a method for inferring a state of infection in a mammalian subject from a nucleic acid sample of the subject by identifying in the nucleic acid sample a polynucleotide expression pattern exemplified by an increase in polynucleotide expression of at least 2 polynucleotides in Table 50, 51 and or 52, as compared to a non-infected subject. Also included is a polynucleotide expression pattern obtained by any of the methods described above.
[00013] In another aspect a cationic peptide that is an antagonist of CXCR-4 is provided. In still another aspect, a method of identifying a cationic peptide that is an antagonist of CXCR-4 by contacting T cells with SDF-1 in the presence of absence of a test peptide and measuring chemotaxis is provided. A decrease in chemotaxis in the presence of the test peptide is indicative of a peptide that is an antagonist of CXCR-4.
Cationic peptide also acts to reduce the expression of the SDF-1 receptor polynucleotide (NM_013371).
[0015] In all of the above described methods, the compounds or agents of the invention include but are not limited to peptides, cationic peptides, peptidomimetics, chemical compounds, polypeptides, nucleic acid molecules and the like.
[0016] In still another aspect the invention provides an isolated cationic peptide. An isolated cationic peptide of the invention is represented by one of the following general formulas and the single letter amino acid code:
XX XEIX4PX4IPXsX, X, (SEQ ID NO: 4), where X, is one or two of R, L or
K, X;isone of C, Sor A, X; is one of Ror P, X; is one of A or V and Xs is one of V or W;
X LX2X3K Xa XoXsX PX 3X (SEQ ID NO: 11), where X, is one or two of D,
E,S, TorN,X2isoneortwoof P, Gor DD, Xzisoneof G, A,V,L,lorY, X,is one of R, KorHand Xsisoneof S, TT, C, MorR;
Xi Xo X3XaWX4, WX XsK (SEQ ID NO: 18), where X is one to four chosen from A, P or R, X; is one or two aromatic amino acids (F, Y and W), X3 is one of P or
K, X4 is one, two or none chosen from A, P, Y or W and Xs is one to three chosen from R or P;
Xi Xo X3XaX; VX3X4RGX 4X 3X X1 X3X, (SEQ ID NO: 25) where X; is one or two of R or K, X; is a polar or charged amino acid (S, T, M, N, Q, D, E, K, R and H),
X3isC,S,M,DorAand XsisF, I, V,MorR;
X1XoX3X eX VXsX4RGX XXX 1 X3X; (SEQ ID NO: 32), where X| is one or two of R or K, X; is a polar or charged amino acid (S, T, M, N, Q, D, E, K, R and H),
Xsisoneof C,S,M,D or A, Xsisoneof F, I, V,MorR and Xs isone of A, I, S, M,
D or R; and
KX, KX;FX;KMLMX,ALKK X; (SEQ ID NO: 39), where X; is a polar amino : acid (C, S, T.M, Nand Q); X; isone of A, L, S or K and Xj is 1-17 amino acids chosen from G, A, V,L,I, PF, S, T, K and H;
KWKX,X Xi X2X2X1 XXX: XX, X,IFHTALKPISS (SEQ ID NO: 46), where
X is a hydrophobic amino acid and X; is a hydrophilic amino acid.
[0017] Additionally, in another aspect the invention provides isolated cationic peptides KWKSFLRTFKSPVRTVFHTALKPISS (SEQ ID NO: 53) and
KWKSYAHTIMSPVRLVFHTALKPISS (SEQ ID NO: 54).
[0018] Also provided are nucleic acid sequences encoding the cationic peptides of the invention, vectors including such polynucleotides and host cells containing the vectors.
10019] The present invention provides novel cationic peptides, characterized by a group of generic formulas, which have ability to modulate (e.g., up- and/or down regulate) polynucleotide expression, thereby regulating sepsis and inflammatory responses and/or innate immunity.
[0020] “Innate immunity” as used herein refers to the natural ability of an organism to defend itself against invasions by pathogens. Pathogens or microbes as used herein may include, but are not limited to bacteria, fungi, parasites and viruses. Innate : immunity is contrasted with acquired/adaptive immunity in which the organism develops a defensive mechanism based substantially on antibodies and/or immune lymphocytes that is characterized by specificity, amplifiability and self vs. non-self dsicrimination. With innate immunity, broad, nonspecific immunity is provided and there is no immunologic memory of prior exposure. The hallmarks of innate immunity are effectiveness against a broad variety of potential pathogens, independence of prior exposure to a pathogen, and immediate effectiveness (in contrast to the specific immune response which takes days to weeks to be elicited). In addition, innate immunity includes immune responses that affect other diseases, such as cancer, inflammatory diseases, multiple sclerosis, various viral infections, and the : like.
[0021] As uscd herein, the term “cationic peptide” refers to a sequence of amino acids from about 5 to about 50 amino acids in length. In one aspect, the cationic peptide of the invention is from about 10 to about 35 amino acids in length. A peptide is “cationic” if it possesses sufficient positively charged amino acids to have a pKa greater than 9.0. Typically, at least two of the amino acid residues of the cationic peptide will be positively charged, for example, lysine or arginine. “Positively charged” refers to the side chains of the amino acid residues which havc a net positive charge at pH 7.0. Examples of naturally occurring cationic antimicrobial peptides which can be recombinantly produced according to the invention include defensins, cathelicidins, magainins, melittin, and cecropins, bactenecins, indolicidins, polyphemusins, tachyplesins, and analogs thereof. A variety of organisms make cationic peptides, molecules used as part of a non-specific defense mechanism against microorganisms. When isolated, these peptides are toxic to a wide variety of microorganisms, including bacteria, fungi, and certain enveloped viruses. While cationic peptides act against many pathogens, notable exceptions and varying degrees of toxicity exist. However this patent reveals additional cationic peptides with no toxicity towards microorganisms but an ability to protect against infections through stimulation of innate immunity, and this invention is not limited to cationic peptides with antimicrobial activity. In fact, many peptides useful in the present invention do not have antimicrobial activity. 10022] Cationic peptides known in the art include for example, the human cathelicidin
LL-37, and the bovine neutrophil peptide indolicidin and the bovine variant of bactenecin, BacZ2A.
LL-37 LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES (SEQ
ID NO: 1)
Indolicidin ILPWKWPWWPWRR-NH, (SEQ ID NO: 2)
Bac2A RLARIVVIRVAR-NH; (SEQ ID NO: 3)
[0023] In innate immunity, the immune response is not dependent upon antigens. The innate immunity process may include the production of secretory molecules and cellular components as set forth above. In innate immunity, the pathogens are : recognized by receptors encoded in the germline. These Toll-like receptors have broad specificity and are capable of recognizing many pathogens. When cationic peptides are present in the immune response, they aid in the host response to pathogens. This change in the immune response induces the release of chemokines, which promote the recruitment of immune cells to the site of infection. ‘ [0024] Chemokines, or chemoattractant cytokines, are a subgroup of immune factors that mediate chemotactic and other pro-inflammatory phenomena (See, Schall, 1991,
Cytokine 3:165-183). Chemokines are small molecules of approximately 70-80 residues in length and can generally be divided into two subgroups, a which have two
N-terminal cysteines separated by a single amino acid (CxC) and p which have two adjacent cysteines at the N terminus (CC). RANTES, MIP-1a and MIP-18 are members of the B subgroup (reviewed by Horuk, R., 1994, Trends Pharmacol. Sci, 15:159-165; Murphy, P. M., 1994, Annu. Rev. Immunol., 12:593-633). The amino terminus of the B chemokines RANTES, MCP-1, and MCP-3 have been implicated in the mediation of cell migration and inflammation induced by these chemokines. This involvement is suggested by the observation that the deletion of the amino terminal 8 residues of MCP-1, amino terminal 9 residues of MCP-3, and amino terminal 8 residues of RANTES and the addition of a methionine to the amino terminus of
RANTES, antagonize the chemotaxis, calcium mobilization and/or enzyme release stimulated by their native counterparts (Gong et al., 1996 J. Biol. Chem. 271:10521- 10527; Proudfoot et al., 1996 J. Biol. Chem. 271:2599-2603). Additionally, a chemokine-like chemotactic activity has been introduced into MCP-1 via a double mutation of Tyr 28 and Arg 30 to leucine and valine, respectively, indicating that internal regions of this protein also play a role in regulating chemotactic activity (Beall et al., 1992, J. Biol. Chem. 267:3455-3459).
[0025] The monomeric forms of all chemokines characterized thus far share significant structural homology, although the quaternary structures of a and B groups are distinct. While the monomeric structures of the and a chemokines are very similar, the dimeric structures of the two groups are completely different. An additional chemokine, lymphotactin, which has only one N terminal cysteine has also been identified and may represent an additional subgroup (v) of chemokines (Yoshida
RY!
et al, 1995, FEBS Lett. 360:155-159; and Kelner et al., 1954, Science 266:1395-
[0026] Receptors for chemokines belong to the large family of G-protein coupled, 7 transmembrane domain receptors (GCR’s) (See, reviews by Horuk, R., 1994, Trends : Pharmacol. Sci. 15:159-165; and Murphy, P. M., 1994, Annu. Rev. Immunol. 12:593- 633). Competition binding and cross-desensitization studies have shown that chemokine receptors exhibit considerable promiscuity in ligand binding. Examples demonstrating the promiscuity among B chemokine receptors include: CC CKR-1 , which binds RANTES and MIP-1a (Neote et al., 1993, Cell 72: 415-425), CC CKR-4, which binds RANTES, MIP-1a, and MCP-1 (Power et al., 1995, J. Biol. Chem. 270:19495-19500), and CC CKR-5, which binds RANTES, MIP-1q, and MIP-13 (Alkhatib et al., 1996, Science, in press and Dragic et al., 1996, Nature 381:667-674).
Erythrocytes possess a receptor (known as the Duffy antigen) which binds both a and p chemokines (Horuk et al., 1994, J. Biol. Chem. 269:17730-17733; Neote et al., 1994, Blood 84:44-52; and Neote et al., 1993, J. Biol. Chem. 268:12247-12249). Thus the sequence and structural homologies evident among chemokines and their receptors allows some overlap in receptor-ligand interactions.
[0027] In one aspect, the present invention provides the use of compounds including cationic peptides of the invention to reduce sepsis and inflammatory responses by acting directly on host cells. In this aspect, a method of identification of a polynucleotide or polynucleotides that are regulated by one or more sepsis or inflammatory inducing agents is provided, where the regulation is altered by a cationic peptide. Such sepsis or inflammatory inducing agents include, but are not limited to endotoxic lipopolysaccharide (LPS), lipoteichoic acid (LTA) and/or CpG
DNA or intact bacteria or other bacterial components. The identification is performed by contacting the polynucleotide or polynucleotides with the sepsis or inflammatory inducing agents and further contacting with a cationic peptide either simultaneously or immediately after. The expression of the polynucleotide in the presence and absence of the cationic peptide is observed and a change in expression is indicative of a polynucleotide or pattern of polynucleotides that is regulated by a sepsis or inflammatory inducing agent and inhibited by a cationic peptide. In another aspect, the invention provides a polynucleotide identified by the method. : [0028] Once identified, such polynucleotides will be useful in methods of screening for compounds that can block sepsis or inflammation by affecting the expression of the polynucleotide. Such an effect on expression may be either up regulation or down regulation of expression. By identifying compounds that do not trigger the sepsis reaction and that can block or dampen inflammatory or septic responses, the present invention also presents a method of identifying enhancers of innate immunity.
Additionally, the present invention provides compounds that are used or identified in the above methods.
[0029] Candidate compounds are obtained from a wide variety of sources including libraries of synthetic or natural compounds. For example, numerous means are available for random and directed synthesis of a wide variety of organic compounds and biomolecules, including expression of randomized oligonucleotides and oligopeptides. Alternatively, libraries of natural compounds in the form of bacterial, fungal, plant and animal extracts are available or readily produced. Additionally, natural or synthetically produced libraries and compounds are readily modified through conventional chemical, physical and biochemical means, and may be used to produce combinatorial libraries. Known pharmacological agents may be subjected to directed or random chemical modifications, such as acylation, alkylation, esterification, amidification, and the like to produce structural analogs. Candidate agents are also found among biomolecules including, but not limited to: peptides, peptidiomimetics, saccharides, fatty acids, steroids, purines, pyrimidines, polypeptides, polynucleotides, chemical compounds, derivatives, structural analogs or combinations thereof.
[0030] incubating components of a screening assay includes conditions which allow contact between the test compound and the polynucleotides of interest. Contacting includes in solution and in solid phase, or in a cell. The test compound may optionally be a combinatorial library for screening a plurality of compounds.
Compounds identified in the method of the invention can be further evaluated,
detected, cloned, sequenced, and the like, either in solution or after pinding to a solid support, by any method usually applied to the detection of a compound.
[0031] Generally, in the methods of the invention, a cationic peptide is utilized to : detect and locate a polynucleotide that is essential in the process of sepsis or inflammation. Once identified, a pattern of polynucleotide expression may be obtained by observing the expression in the presence and absence of the cationic peptide. The pattern obtained in the presence of the cationic peptide is then useful in identifying additional compounds that can inhibit expression of the polynucleotide . and therefore block sepsis or inflammation. It is well known to one of skill in the art that non-peptidic chemicals and peptidomimetics can mimic the ability of peptides to bind to receptors and enzyme binding sites and thus can be used to block or stimulate biological reactions. Where an additional compound of interest provides a pattern of polynucleotide expression similar to that of the expression in the presence of a cationic peptide, that compound is also useful in the modulation of sepsis or an innate immune response. In this manner, the cationic peptides of the invention, which are known inhibitors of sepsis and inflammation and enhancers of innate immunity are useful as tools in the identification of additional compounds that inhibit sepsis and inflammation and enhance innate immunity.
[0032] As can be seen in the Examples below, peptides of the invention have a widespread ability to reduce the expression of polynucleotides regulated by LPS.
High levels of endotoxin in the blood are responsible for many of the symptoms seen during a serious infection or inflammation such as fever and an elevated white blood cell count. Endotoxin is a component of the cell wall of Gram-negative bacteria and is a potent trigger of the pathophysiology of sepsis. The basic mechanisms of inflammation and sepsis are related. In Example 1, polynucleotide arrays were utilized to determine the effect of cationic peptides on the transcriptional response of - epithehal cells. Specifically, the effects on over 14,000 different specific polynucleotide probes induced by LPS were observed. The tables show the changes seen with cells treated with peptide compared to control cells. The resulting data indicated that the peptides have the ability to reduce the expression of polynucleotides : induced by LPS.
[0033] Example 2, similarly, shows that peptides of the invention are capable of neutralizing the stimulation of immune cells by Gram positive and Gram negative bacterial products. Additionally, it is noted that certain pro-inflammatory polynucleotides are down-regulated by cationic peptides, as set forth in table 24 such : as TLR1 (AI339155), TLR2 (T57791), TLR5 (N41021), TNF receptor-associated factor 2 (T55353), TNF receptor-associated factor 3 (AA504259), TNF receptor superfamily, member 12 (W71984), TNF receptor superfamily, member 17 (AA987627), small inducible cytokine subfamily B, member 6 (AI889554), IL-12R beta 2 (AA977194), IL-18 receptor 1 (AA482489), while anti-inflammatory polynucleotides are up-regulated by cationic peptides, as seen in table 25 such as IL-1
R antagonist homolog 1 (A1167887), IL-10 R beta (AA486393), TNF Receptor member 1B (AA150416), TNF receptor member 5 (H98636), TNF receptor member 11b (AA194983), IK cytokine down-regulator of HLA II (R39227), TGF-B inducible early growth response 2 (A1473938), or CD2 (AA927710). The relevance and application of these results are confirmed by an in vivo application to mice. Example 3 demonstrates that such peptides do not generally demponstrate toxicity towards the host cells they contact.
[0034] In Example 4 it can be seen that the cationic peptides of the invention alter polynucleotide expression in macrophage and epithelial cells. The results of this example show that pro-inflammatory polynucleotides are down-regulated by cationic peptides (Table 24) whereas anti-inflammatory polynucleotides are up-regulated by cationic peptides (Table 25).
[0035] In another aspect, the invention provides a method of identifying an agent that enhances innate immunity. In the method, a host cell polynucleotide or : polynucleotides that encode a polypeptide involved in innate immunity is contacted with an agent of interest. Expression of the polynucleotide is determined, both in the presence and absence of the agent. The expression is compared and of the specific modulation of expression was indicative of an enhancement of innate immunity. In another aspect, the agent does not stimulate a septic reaction as revealed by the lack of upregulation of the pro-inflammatory cytokine TNF-a. In still another aspect the agent reduces or blocks the inflammatory or septic response. In yet another aspect,
WO $3/0-18383 PCT/CA02/01830 the agent reduces the expression of TNI-a and/or interleukins including, but not limited to, IL-18, IL-6, IL-12 p40, IL-12 p70, and IL-8.
[0036] In another aspect, the invention provides methods of direct polynucleotide regulation by cationic peptides and the use of compounds including cationic peptides to stimulate elements of innate immunity. In this aspect, the invention provides a method of identification of a pattern of polynucleotide expression for identification of a compound that enhances innate immunity. In the method of the invention, an initial detection of a pattern of polynucleotide expression for cells contacted in the presence and absence of a cationic peptide is made. The pattern resulting from polynucleotide expression in the presence of the peptide represents stimulation of innate immunity.
A pattern of polynucleotide expression is then detected in the presence of a test compound, where a resulting pattern with the test compound that is similar to the pattern observed in the presence of the cationic peptide is indicative of a compound that enhances innate immunity. In another aspect, the invention provides compounds that are identified in the above methods. In another aspect, the compound of the invention stimulates chemokine or chemokine receptor expression. Chemokine or chemokine receptors may include, but are not limited to CXCR4, CXCR1, CXCR2,
CCR2, CCR4, CCR5, CCR6, MIP-1 alpha, MDC, MIP-3 alpha, MCP-1, MCP-2, : MCP-3, MCP-4, MCP-5, and RANTES. In still another aspect, the compound is a peptide, peptidomimetic, chemical compound, or a nucleic acid molecule.
[0037] In still another aspect the polynucleotide expression pattern includes expression of pro-inflammatory polynucleotides. Such pro-inflammatory polynucleotides may include, but are not limited to, ring finger protein 10 (D87451), serine/threonine protein kinase MASK (AB040057), KIAA0912 protein (AB020719),
KIAA0239 protein (D87076), RAP1, GTPase activating protein 1 (M64788), FEM-1- like death receptor binding protein (AB007856), cathepsin S (M90696), hypothetical protein FLJ20308 (AK000315), pim-1 oncogene (M54915), proteasome subunit beta type 5 (D29011), KIAA0239 protein (D87076), mucin 5 subtype B tracheobronchial (AJ001403), cAMP response element-binding protein CREBPa, integrin alpha M (J03925), Rho-associated kinase 2 (NM_004850), PTD017 protein (AL050361) - unknown genes (AK001143, AK034348, AL049250, AL16199, AL031983) and any combination thereof. In still another aspect the polynucleotide expression pattern includes expression of cell surface receptors that may include but is not limited (0 retinoic acid receptor (X06614), G protein-coupled receptors (294155, X81892,
U52219, U22491, AF015257, U66579) chemokine (C-C motif) receptor 7 (L31584), tumor necrosis factor receptor superfamily member 17 (Z29575), interferon gamma receptor 2 (U05875), cytokine receptor-like factor 1 (AF059293), class I cytokine receptor (AF053004), coagulation factor II (thrombin) receptor-like 2 (U92971), leukemia inhibitory factor receptor (NM_002310), interferon gamma receptor 1 (AL050337).
[0038] It is shown below, for example, in tables 1-15, that cationic peptides can neutralize the host response to the signaling molecules of infectious agents as well as modify the transcriptional responses of host cells, mainly by down-regulating the pro- inflammatory response and/or up-regulating the anti-inflammatory response.
Example 5 shows that the cationic peptides can aid in the host response to pathogens by inducing the release of chemokines, which promote the recruitment of immune cells to the site of infection. The results are confirmed by an in vivo application to mice.
[0039] It is seen from the examples below that cationic peptides have a substantial influence on the host response to pathogens in that they assist in regulation of the host immune response by inducing selective pro-inflammatory responses that for example promote the recruitment of immune cells to the site of infection but not inducing potentially harmful pro-inflammatory cytokines. Sepsis appears to be caused in part by an overwhelming pro-inflammatory response to infectious agents. Cationic peptides aid the host in a “balanced” response to pathogens by inducing an anti- inflammatory response and suppressing certain potentially harmful pro-inflammatory responses.
[0040] In Example 7, the activation of selected MAP kinases was examined, to study the basic mechanisms behind the effects of interaction of cationic peptides with cells.
Macrophages activate MEK/ERK kinases in response to bacterial infection. MEK is a
MAP kinase kinase that when activated, phosphorylates the downstream kinase ERK
(extracellular regulated kinase), which then dimerizes and transiocaics to the nucieus where it activates transcription factors such as Elk-1 to modify polynucleotide expression. MEK/ERK kinases have been shown to impair replication of Salmonella within macrophages. Signal transduction by MEK kinase and NADPH oxidase may play an important role in innate host defense against intracellular pathogens. By affecting the MAP kinases as shown below the cationic peptides have an effect on bacterial infection. The cationic peptides can directly affect kinascs. Table 21 demonstrates but is not limited to MAP kinase polynucleotide expression changes in response to peptide. The kinases include MAP kinase kinase 6 (H070920), MAP kinase kinase 5 (W69649), MAP kinase 7 (H39192), MAP kinase 12 (AI1936909) and
MAP kinase-activated protein kinase 3 (W68281).
[0041] In another method, the methods of the invention may be used in combination, to identify an agent with multiple characteristics, i.e. a peptide with anti- inflammatory/anti-sepsis activity, and the ability to enhance innate immunity, in part by inducing chemokines in vivo. :
[0042] In another aspect, the invention provides a method for inferring a state of infection in a mammalian subject from a nucleic acid sample of the subject by identifying in the nucleic acid sample a polynucleotide expression pattern exemplified by an increase in polynucleotide expression of at least 2 polynucleotides in Table 55 as compared to a non-infected subject. In another aspect the invention provides a method for inferring a state of infection in a mammalian subject from a nucleic acid sample of the subject by identifying in the nucleic acid sample a polynucleotide expression pattern exemplified by a polynucleotide expression of at least 2 polynucleotides in Table 56 or Table 57 as compared to a non-infected subject. In one aspect of the invention, the state of infection is due to infectious agents or signaling molecules derived therefrom, such as, but not limited to, Gram negative bacteria and Gram positive bacteria, viral, fungal or parasitic agents. In still another aspect the invention provides a polynucleotide expression pattern of a subject having a state of infection identified by the above method. Once identified, such polynucleotides will be useful in methods of diagnosis of a condition associated with x the activity or presence of such infectious agents or signaling molecules.
[0043] Example 10 below demonstrates this aspect of the invention. Specifically, table 61 demonstrates that both MEK and the NADPH oxidase inhibitors can limit bacterial replication (infection of IFN-y-primed macrophages by S. typhimurium triggers a MEK kinase). This is an example of how bacterial survival can be impacted by changing host cell signaling molecules.
[0044] In still another aspect of the invention, compounds are presented that inhibit stromal derived factor-1 (SDF-1) induced chemotaxis of T cells. . Compounds are also presented which decrease expression of SDF-1 receptor. Such compounds also may act as an antagonist or inhibitor of CXCR-4. In one aspect the invention provides a cationic peptide that is an antagonist of CXCR-4. In another aspect the invention provides a method of identifying a cationic peptide that is an antagonist of
CXCR-4. The method includes contacting T cells with SDF-1 in the presence of absence of a test peptide and measuring chemotaxis. A decrease in chemotaxis in the presence of the test peptide is then indicative of a peptide that is an antagonist of
CXCR-4. Such compounds and methods are useful in therapeutic applications in HIV patients. These types of compounds and the utility thereof is demonstrated, for example, in Example 11 (sce also Tables 62, 63). In that example, cationic peptides are shown to inhibit cell migration and therefore antiviral activity.
[0045] In one embodiment, the invention provides an isolated cationic peptides having an amino acid sequence of the general formula (Formula A):
Xi Xo XGIXPX4IPX5X,X, (SEQ ID NO: 4), wherein X, isone or two of R, L or K, X; isone of C, Sor A, Xsisone of R or P, X4 is one of A or V and Xsis one of V or W.
Examples of the peptides of the invention include, but are not limited to:
LLCRIVPVIPWCK (SEQ ID NO: 5), LRCPIAPVIPVCKK (SEQ ID NO: 6),
KSRIVPAIPVSLL (SEQ ID NO: 7), KKSPIAPAIPWSR (SEQ ID NO: 8),
RRARIVPAIPVARR (SEQ ID NO: 9) and LSRIAPAIPWAKL (SEQ ID NO: 10).
[0046] In another embodiment, the invention provides an isolated linear cationic peptide having an amino acid sequence of the general formula (Formula B):
XiLX:X3K Xe X2XsX3PX3X, (SEQ ID NO: 11), wherein X; isoneortwo of D,E,S, T orN, X2isoneortwoof P, Gor D, Xsisoneof G, A, V,L,lorY, Xsisoneof R, K or Hand Xsisoncof 5, T, C, M or R. Examples of the peptides of the invention include, but are not limited to: DLPAKRGSAPGST (SEQ ID NO: 12),
SELPGLKHPCVPGS (SEQ ID NO: 13), TTLGPVKRDSIPGE (SEQ ID NO: 14),
SLPIKHDRLPATS (SEQ ID NO: 15), ELPLKRGRVPVE (SEQ ID NO: 16) and
NLPDLKKPRVPATS (SEQ ID NO: 17).
[0047] In another embodiment, the invention provides an isolated linear cationic peptide having an amino acid sequence of the general formula (Formula C):
Xi Xo X3XaWX4WX XK (SEQ ID NO: 18) (this formula includes CP12a and CP12d) , wherein X; is one to four chosen from A, P or R, X; is one or two aromatic amino acids (F, Y and W), Xj is one of P or K, X4 is one, two or none chosen from A, P, Y or W and Xs is one to three chosen from R or P. Examples of the peptides of the invention include, but are not limited to: RPRYPWWPWWPYRPRK (SEQ ID NO: 19), RRAWWKAWWARRK (SEQ ID NO: 20), RAPYWPWAWARPRK (SEQ ID
NO: 21), RPAWKYWWPWPWPRRK (SEQ ID NO: 22), RAAFKWAWAWWRRK (SEQ ID NO: 23) and RRRWKWAWPRRK (SEQ ID NO: 24).
[0048] In another embodiment, the invention provides an isolated hexadecameric cationic peptide having an amino acid sequence of the general formula (Formula D):
X1X2X3X 4X1 VX;3X4RG XX 3X X1 X3X, (SEQ ID NO: 25) wherein X; is one'or two of
R or K, X; is a polar or charged amino acid (S, T,M, N, Q, D, E, K, R and H). Xj; is
C,S,M,DorAand X4isF, I, V, Mor R. Examples of the peptides of the invention include, but are not limited to: RRMCIKVCVRGVCRRKCRK (SEQ ID NO: 26),
KRSCFKVSMRGVSRRRCK (SEQ ID NO: 27), KKDAIKKVDIRGMDMRRAR (SEQ ID NO: 28), RKMVKVDVRGIMIRKDRR (SEQ ID NO: 29),
KQCVKVAMRGMALRRCK (SEQ ID NO: 30) and
RREAIRRVAMRGRDMKRMRR (SEQ ID NO: 31).
[0049] In still another embodiment, the invention provides an isolated hexadecameric cationic peptide having an amino acid sequence of the general formula (Formula E):
XX X3XaX; VXsXsRGXsX5 Xa X1X3X; (SEQ ID NO: 32), wherein X; 1s one or two of Ror K, X; is a polar or charged amino acid (S, T, M, N, Q, D, E, K, Rand H), X; : isoneof C,S,M,Dor A, Xsisoneof F,I, V, MorR and Xsisone of A,I, S,M, D or R. Examples of the peptides of the invention include, but are not limited to:
RTCVKRVAMRGIIRKRCR (SEQ ID NO: 33), KKQMMKRVDVRGISVKRKR (SEQ ID NO: 34), KESIKVIIRGMMVRMKK (SEQ ID NO: 35),
RRDCRRVMVRGIDIKAK (SEQ ID NO: 36), KRTAIKKVSRRGMSVKARR (SEQ
ID NO: 37) and RHCIRRVSMRGIIMRRCK (SEQ ID NO: 38).
[0050] In another embodiment, the invention provides an isolated longer cationic peptide having an amino acid sequence of the general formula (Formula F):
KX KX FX, KMLMX,;ALKKX; (SEQ ID NO: 39), wherein X, is a polar amino acid (C,S, T,M,Nand Q); X; isone of A, L, S or K and X;3 is 1-17 amino acids chosen fromG, A, V,L,I,P,F, S, T,K and H. Examples of the peptides of the invention include, but are not limited to: KCKLFKKMLMLALKKVLTTGLPALKLTK (SEQ
ID NO: 40), KSKSFLKMLMKALKKVLTTGLPALIS (SEQ ID NO: 41),
KTKKFAKMLMMALKKVVSTAKPLAILS (SEQ ID NO: 42),
KMKSFAKMLMLALKKVLKVLTTALTLKAGLPS (SEQ ID NO: 43),
KNKAFAKMLMKALKKVTTAAKPLTG (SEQ ID NO: 44) and
KQKLFAKMLMSALKKKTLVTTPLAGK (SEQ ID NO: 45).
[0051] In yet another embodiment, the invention provides an isolated longer cationic peptide having an amino acid sequence of the general formula (Formula G):
KWKX, XX XX Xi XXX 1 Xi XX, IFHTALKPISS (SEQ ID NO: 46), wherein X; is a hydrophobic amino acid and X; is a hydrophilic amino acid. Examples of the peptides of the invention include, but are not limited to:
KWKSFLRTFKSPVRTIFHTALKPISS (SEQ ID NO: 47),
KWKSYAHTIMSPVRLIFHTALKPISS (SEQ ID NO: 48),
KWKRGAHRFMKFLSTIFHTALKPISS (SEQ ID NO: 49),
KWKKWAHSPRKVLTRIFHTALKPISS (SEQ ID NO: 50),
KWKSLVMMFKKPARRIFHTALKPISS (SEQ ID NO: 51) and
KWKHALMKAHMLWHMIFHTALKPISS (SEQ ID NO: 52).
[0052] In still another embodiment, the invention provides an isolated cationic peptide having an amino acid sequence of the formula:
KWKSFLRTFKSPVRTVFHTALKPISS (SEQ ID NO: 53) or
KWKSYAHTIMSPVRLVFHTALKPISS (SEQ ID NO: 54).
[0053] The term “isolated” as used herein refers to a peptide that is substantially free of other proteins, lipids, and nucleic acids (e.g., cellular components with which an in vivo-produced peptide would naturally be associated). Preferably, the peptide is at least 70%, 80%, or most preferably 90% pure by weight.
[0054] The invention also includes analogs, derivatives, conservative variations, and cationic peptide variants of the enumerated polypeptides, provided that the analog, derivative, conservative variation, or variant has a detectable activity in which it enhances innate immunity or has anti-inflammatory activity. It is not necessary that the analog, derivative, variation, or variant have activity identical to the activity of the peptide from which the analog, derivative, conservative variation, or variant is derived.
[0055] A cationic peptide “variant” is an peptide that is an altered form of a referenced cationic peptide. For example, the term “variant” includes a cationic peptide in which at least one amino acid. of a reference peptide is substituted in an expression library. The term “reference” peptide means any of the cationic peptides of the invention (e.g., as defined in the above formulas), from which a variant, derivative, analog, or conservative variation is derived. Included within the term “derivative” is a hybrid peptide that includes at least a portion of each of two cationic peptides (e.g., 30-80% of each of two cationic peptides). Also included are peptides in which one or more amino acids are deleted from the sequence of a peptide enumerated herein, provided that the derivative has activity in which it enhances innate immunity or has anti-inflammatory activity. This can lead to the development of a smaller active molecule which would also have utility. For example, amino or carboxy terminal amino acids which may not be required for enhancing innate immunity or anti-inflammatory activity of a peptide can be removed. Likewise, : additional derivatives can be produced by adding one or a few (e.g., less than 5) amino acids to a cationic peptide without completely inhibiting the activity of the : peptide. In addition, C-terminal derivatives, e.g., C-terminal methyl esters, and N-
terminal derivatives can be produced and are encompassed by the invention. Peptides of the invention include any analog, homolog, mutant, isomer or derivative of the peptides disclosed in the present invention, so long as the bioactivity as described herein remains. Also included is the reverse sequence of a peptide encompassed by the general formulas set forth above. Additionally, an amino acid of “D” configuration may be substituted with an amino acid of “L” configuration and vice versa. Alternatively the peptide may be cyclized chemically or by the addition of two or more cysteine residues within the sequence and oxidation to form disulphide bonds.
[0056] The invention also includes peptides that are conservative variations of those peptides exemplified herein. The term “conservative variation” as used herein denotes a polypeptide in which at least one amino acid is replaced by another, biologically similar residue. Examples of conservative variations include the substitution of one hydrophobic residue, such as isoleucine, valine, leucine, alanine, cysteine, glycine, phenylalanine, proline, tryptophan, tyrosine, norleucine or methionine for another, or the substitution of one polar residue for another, such as the substitution of arginine for lysine, glutamic for aspartic acid, or glutamine for asparagine, and the like. Neutral hydrophilic amino acids that can be substituted for one another include asparagine, glutamine, serine and threonine. The term “conservative variation” also encompasses a peptide having a substituted amino acid in place of an unsubstituted parent amino acid. Such substituted amino acids may include amino acids that have been methylated or amidated. Other substitutions will be known to those of skill in the art. In one aspect, antibodies raised to a substituted polypeptide will also specifically bind the unsubstituted polypeptide.
[0057] Peptides of the invention can be synthesized by commonly used methods such as those that include t-BOC or FMOC protection of alpha-amino groups. Both methods involve stepwise synthesis in which a single amino acid is added at each step ) starting from the C-terminus of the peptide (See, Coligan, et al., Current Protocols in
Immunology, Wiley Interscience, 1991, Unit 9). Peptides of the invention can also be synthesized by the well known solid phase peptide synthesis methods such as those described by Merrifield, J. Am. Chem. Soc., 85:2149, 1962) and Stewart and Young,
Solid Phase Peptides Synthesis, Freeman, San Francisco, 1969, pp.27 62) using a copoly (styrene-divinylbenzene) containing 0.1-1.0 mMol amines/g polymer. On completion of chemical synthesis, the peptides can be deprotected and cleaved from the polymer by treatment with liquid HF-10% anisole for about 1/4-1 hours at 0°C.
After evaporation of the reagents, the peptides are extracted from the polymer with a 1% acetic acid solution, which is then lyophilized to yield the crude material. The peptides can be purified by such techniques as gel filtration on Sephadex G-15 using 5% acetic acid as a solvent. Lyophilization of appropriate fractions of the column eluate yield homogeneous peptide, which can then be characterized by standard techniques such as amino acid analysis, thin layer chromatography, high performance liquid chromatography, ultraviolet absorption spectroscopy, molar rotation, or measuring solubility. If desired, the peptides can be quantitated by the solid phase
Edman degradation.
[0058] The invention also includes isolated nucleic acids (e.g., DNA, cDNA, or
RNA) encoding the peptides of the invention. Included are nucleic acids that encode analogs, mutants, conservative variations, and variants of the peptides described herein. The term “isolated” as used herein refers to a nucleic acid that is substantially free of proteins, lipids, and other nucleic acids with which an in vivo-produced nucleic acids naturally associated. Preferably, the nucleic acid is at least 70%, 80%, or preferably 90% pure by weight, and conventional methods for synthesizing nucleic acids in vitro can be used in lieu of in vivo methods. As used herein, “nucleic acid” refers to a polymer of deoxyribo-nucleotides or ribonucleotides, in the form of a separate fragment or as a component of a larger genetic construct (e.g., by operably linking a promoter to a nucleic acid encoding a peptide of the invention). Numerous genetic constructs (e.g., plasmids and other expression vectors) are known in the art and can be used to produce the peptides of the invention in celi-free systems or prokaryotic or eukaryotic (e.g., yeast, insect, or mammalian) cells. By taking into account the degeneracy of the genetic code, one of ordinary skill in the art can readily synthesize nucleic acids encoding the polypeptides of the invention. The nucleic acids of the invention can readily be used in conventional molecular biology methods } to produce the peptides of the invention.
[0059] DNA encoding the cationic peptides of the invention can be inserted into an “expression vector.” The term “expression vector” refers to a genetic construct such as a plasmid, virus or other vehicle known in the art that can be engineered to contain a nucleic acid encoding a polypeptide of the invention. Such expression vectors are i preferably plasmids that contain a promoter sequence that facilitates transcription of the inserted genetic sequence in a host cell. The expression vector typically contains an origin of replication, and a promoter, as well as polynucleotides that allow phenotypic selection of the transformed cells (e.g., an antibiotic resistance polynucleotide). Various promoters, including inducible and constitutive promoters, can be utilized in the invention. Typically, the expression vector contains a replicon site and control sequences that are derived from a species compatible with the host cell.
[0060] Transformation or transfection of a recipient with a nucleic acid of the invention can be carried out using conventional techniques well known to those skilled in the art. For example, where the host cell is E. coli, competent cells that are capable of DNA uptake can be prepared using the CaCl, MgCl, or RbCl methods known in the art. Alternatively, physical means, such as electroporation or microinjection can be used. Electroporation allows transfer of a nucleic acid into a cell by high voltage electric impulse. Additionally, nucleic acids can be introduced into host cells by protoplast fusion, using methods well known in the art. Suitable methods for transforming eukaryotic cells, such as electroporation and lipofection, also are known.
[0061] “Host cells” or “Recipient cells” encompassed by of the invention are any cells in which the nucleic acids of the invention can be used to express the polypeptides of the invention. The term also includes any progeny of a recipient or host cell. Preferred recipient or host cells of the invention include E. coli, S. aureus and P. aeruginosa, although other Gram-negative and Gram-positive bacterial, fungal and mammalian cells and organisms known in the art can be utilized as long as the expression vectors contain an origin of replication to permit expression in the host. :
[0062] The cationic peptide polynucleotide sequence used according to the meinod of the invention can be isolated from an organism or synthesized in the laboratory.
Specific DNA sequences encoding the cationic peptide of interest can be obtained by: 1) isolation of a double-stranded DNA sequence from the genomic DNA; 2) chemical manufacture of a DNA sequence to provide the necessary codons for the cationic peptide of interest; and 3) in vitro synthesis of a double-stranded DNA sequence by reverse transcription of mRNA isolated from a donor cell. In the latter case, a doublc- stranded DNA complement of mRNA is eventually formed which is generally referred to as cDNA.
[0063] The synthesis of DNA sequences is frequently the method of choice when the entire sequence of amino acid residues of the desired peptide product is known. In the present invention, the synthesis of a DNA sequence has the advantage of allowing the incorporation of codons which are more likely to be recognized by a bacterial host, thereby permitting high level expression without difficulties in translation. In addition, virtually any peptide can be synthesized, including those encoding natural cationic peptides, variants of the same, or synthetic peptides.
[0064] When the entire sequence of the desired peptide is not known, the direct synthesis of DNA sequences is not possible and the method of choice is the formation of cDNA sequences. Among the standard procedures for’isolating cDNA sequences of interest is the formation of plasmid or phage containing cDNA libraries which are derived from reverse transcription of mRNA which is abundant in donor cells that have a high level of genetic expression. When used in combination with polymerase chain reaction technology, even rare expression products can be cloned. In those cases where significant portions of the amino acid sequence of the cationic peptide are known, the production of labeled single or double-stranded DNA or RNA probe sequences duplicating a sequence putatively present in the target cDNA may be employed in DNA/DNA hybridization procedures which are carried out on cloned copies of the cDNA which have been denatured into a single stranded form (Jay, et al., Nuc. Acid Res., 11:2325, 1983).
[0065] The peptide of the invention can be administered parenterally by injection or by gradual infusion over time. The peptide can be administered intravenously, intraperitoneally, intramuscularly, subcutaneously, intracavity, or transdermally.
Preferred methods for delivery of the peptide include orally, by encapsulation in microspheres or proteinoids, by aerosol delivery to the lungs, or transdermally by iontophoresis or transdermal electroporation. Other methods of administration will be known to those skilled in the art.
[0066] Preparations for parenteral administration of a peptide of the invention include sterile aqueous or non-aqueous solutions, suspensions, and emulsions. Examples of non-aqueous solvents are propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable organic esters such as ethyl oleate. Aqueous carriers include water, alcoholic/aqueous solutions, emulsions or suspensions, including saline and buffered media Parenteral vehicles include sodium chloride solution, Ringer’s dextrose, dextrose and sodium chloride, sodium acetate, sodium citrate, lactated
Ringer's, or fixed oils. Intravenous vehicles include fluid and nutrient replenishers, electrolyte replenishers (such as those based on Ringer's dextrose), and the like.
Preservatives and other additives may also be present such as, for example, antimicrobials, anti-oxidants, chelating agents, and inert gases and the like.
[0067] The invention will now be described in greater detail by reference to the following non-limiting examples. While the invention has been described in detail with reference to certain preferred embodiments thereof, it will be understood that modifications and variations are within the spirit and scope of that which is described and claimed. :
EXAMPLE 1
ANTI-SEPSIS/ANTI- INFLAMMATORY ACTIVITY
[0068] Polynucleotide arrays were utilized to determine the effect of cationic peptides on the transcriptional response of epithelial cells. The A549 human epithelial cell line was maintained in DMEM (Gibco) supplemented with 10 % fetal bovine serum (FBS, . Medicorp). The A549 cells were plated in 100 mm tissue culture dishes at 2.5 x 10° cells/dish, cultured overnight and then incubated with 100 ng/ml £. coli O111:B4 LPS
(Sigma), without (control) or with 50 pg/mi peptide or medium aione for 4 h. After stimulation, the cells were washed once with diethyl pyrocarbonate-treated phosphate buffered saline (PBS), and detached from the dish using a cell scraper. Total RNA was isolated using RNAqueous (Ambion, Austin, TX). The RNA pellet was resuspended in RNase-free water containing Superase-In (RNase inhibitor; Ambion).
DNA contamination was removed with DNA-free kit, Ambion). The quality of the
RNA was assessed by gel electrophoresis on a 1% agarose gel.
[0069] The polynucleotide arrays used were the Human Operon arrays (identification number for the genome is PRHUO04-S1), which consist of about 14,000 human oligos spotted in duplicate. Probes were prepared from 10 pg of total RNA and labeled with
Cy3 or Cy5 labeled dUTP. The probes were purified and hybridized to printed glass slides overnight at 42°C and washed. After washing, the image was captured using a
Perkin Elmer array scanner. The image processing software (Imapolynucleotide 5.0,
Marina Del Rey, CA) determines the spot mean intensity, median intensities, and background intensities. A “homemade” program was used to remove background.
The program calculates the bottom 10 % intensity for each subgrid and subtracts this for each grid. Analysis was performed with Genespring software (Redwood City,
CA). The intensities for each spot were normalized by taking the median spot intensity value from the population of spot values within a slide and comparing this value to the values of all slides in the experiment. The relative changes seen with cells treated with peptide compared to control cells can be found in Tables 1 and 2.
These tables 2 reflect only those polynucleotides that demonstrated significani changes in expression of the 14,000 polynucleotides that were tested for altered expression. The data indicate that the peptides have a widespread ability to reduce the expression of polynucleotides that were induced by LPS.
[0070] In Table 1, the peptide, SEQ ID NO: 27 is shown to potently reduce the expression of many of the polynucleotides up-regulated by E. coli O111:B4 LPS as studied by polynucleotide microarrays. Peptide (50 pg/ml) and LPS (0.1 ug/ml) or
LPS alone was incubated with the A549 cells for 4 h and the RNA was isolated. Five ug total RNA was used to make Cy3/Cy5 labeled cDNA probes and hybridized onto
Co Human Operon arrays (PRHU04). The intensity of unstimulated cells is shown in the third column of Table 1. The “Ratio: LPS/control” column refers to the intensity of polynucleotide expression in LPS simulated cells divided by in the intensity of unstimulated cells. The “Ratio: LPS+ ID 27/control” column refers to the intensity of polynucleotide expression in cells stimulated with LPS and peptide divided by unstimulated cells.
Table 1: Reduction, by peptide SEQ ID 27, of A549 human epithelial cell polynucleotide expression up-regulated by E.coli O111:B4 LPS
Accession Polynucleotide Control: Ratio: Ratio: LPS+
Number? Gene Function | Mediaonly | LPS/control | ID 27/control
Intensity
ADP- ribosylation
L04510 factor 0.655 213.6 1.4 ring finger hypothetical ee |e | we
Ric -like expressed in
U78166 neurons 0.051 91.7 0.2 mucin 5 subtype
B
AJ001403 | tracheobronchial 0.203 53.4 15.9 serine/threonine protein kinase
AB040057 MASK 0.95 44.3 15.8
Accession | Polynucleotide Control: Ratio: Ratio: LPS+
Number® Gene Function Media only | LPS/control | ID 27/control
Intensity [we
RNA lariat debranching
NM 016216 enzyme 6.151 22.3 | 10.9 hypothetical a I NLC LJ
FEM-1-like death receptor ee Ze growth arrest- cytosolic ovarian carcinoma
AK000353 antigen 1 0.453 13.5 1.0 myeloid/lymphoi d or mixed- lineage leukemia
D14539 | translocated to 1 2033 11.6 3.1 integration site for Epstein-Barr
X76785 virus 0.728 11.6
I LL NL caspase recruitment :
NM_006092 domain 4 0.369 11.0 0.5 integrin_alpha ars | er |e
Accession Polynucleotide Control: Ratio: Ratio: LPS+
Number? Gene Function Media only LPS/control | ID 27/control
Intensity
ADP- ribosylation
NM_001663 factor 6 0.439 9.7 1.7
RAS p21 protein thymidine kinase [am | | a transmembrane 9 superfamily
U94831 member 1 3.265 7.1 1.5 zinc finger
Cn |e Low [0 hypothetical
PE el I I guanine nucleotide
U43083 binding protein 0.841
DKFZp434J181
Pl I IP
ATP-binding cassette sub- family C (CFTR/MRP)
AF085692 member 3 3.175 6.5 2.4 hypothetical protein
AKO001239 FLJ10377 2.204 6.4 1.3
ATPase Na+/K+
RN Fcc PS
Accession | Polynuclestide Control: Ratio: Ratio: LPS+
Number? Gene Function Media only LPS/control | 1D 27/control re ee ewes unactive =
L24804 receptor 3.403 1.1 dual specificity ligase | DNA _ ar [om] on colony stimulating spermidine/ spermine N1-
AL050290 | acetyltransferase 2.724 5.6 1.4
Re ec I WLI retinoic acid ve [So oe | | on putative L-type neutral amino
ABO007896 | acid transporter 0.94 5.3 1.8
DKFZP564B116
Pe Ep hypothetical os] Cn | un | sa
NM_016406 protein 1.314 5.2 1.2 }
Accession Polynucleotide Control: Ratio: Ratio: LPS+
Number® Gene Function | Mediaonly | LPS/control | ID 27/control
Rd = a leukemia trans-
I EE zona pellucida replication initiation region leukemia dentatorubral- pallidoluysian ne
NM_001940 atrophy 2.034 4.7 1.2 cytosolic acyl coenzyme A thioester
U91316 hydrolase 2.043 4.7 1.4 death-associated
KIAAOQ0095 gene monocyte to macrophage differentiation-
X85750 associated 1.01 4.3 1.1
Accession | Polynucleotide Control: Ratio: Ratio: LPS+
Number® Gene Function Media only LPS/control | ID 27/control ee
CD164 antigen_ fibroblast melanoma- associated
U19796 antigen 4.0 hypothetical
PP lO PO hypothetical sterol-C4-methyl
EY I hypothetical ms] hypothetical
RAN member
RAS oncogene :
NM_006325 family 1.242 3.5 1.4 aldehyde
FH1/FH2 domain- .
NM_013241 containing 1.264 3.3 0.6
Accession Polynucleotide Control: Ratio: Ratio: LPS+
Number* Gene Function Media only LPS/control | ID 27/control
Intensity
IE Hc I esterase
D/formylglutathi
AF112219 one hydrolase 1.839 3.3 anaphase- promoting complex subunit
NM _016237 5 2.71 3.2
KIAAQ669 gene hypothetical protein phosphatase 6 proteasome 26S subunit ATPase
AF035309 5 5.628 3.1 1.3
I cc IL NL electron- transfer- flavoprotein alpha
J04058 polypeptide 3.265 3.1 1.2 interleukin 6 galactosidase _ :
Accession Polynuclestide Control: Ratio: Ratio: LPS+
Number® Gene Function Media only | LPS/control | ID 27/control
Intensity
EC 5. 2 mitogen- : activated protein
X80692 Kinase 6 2.463 29 1.3 tumor necrosis factor receptor superfamily
M32315 member 1B 0.639 2.4 0.4
LPS-induced
TNF-alpha
NM_004862 factor 6.077 2.3 1.1 interferon gamma receptor
AL050337 1 2.064 2.1 1.0
All Accession Numbers in Table 1 through Table 64 refer to GenBank Accession
Numbers.
[0071] In Table 2, the cationic peptides at a concentration of 50 ug/ml were shown to potently reduce the expression of many of the polynucleotides up-regulated by 100 ng/ml E. coli O111:B4 LPS as studied by polynucleotide microarrays. Peptide and
LPS or LPS alone was incubated with the A549 cells for 4 h and the RNA was isolated. 5 pg total RNA was used to make Cy3/Cy5 labeled cDNA probes and hybridized onto Human Operon arrays (PRHU04). The intensity of unstimulated cells is shown in the third column of Table 2. The “Ratio: LPS/control” column refers to the intensity of polynucleotide expression in LPS-simulated cells divided by in the intensity of unstimulated cells. The other columns refer to the intensity of polynucleotide expression in cells stimulated with LPS and peptide divided by unstimulated cells.
[0072] Table 2: Human A549 Epithelial Cell Polynucleotide Expression up-regulated by E.coli O111:B4 LPS and reduced by Cationic Peptides
Number Media LPS/ LPS+ | LPS+ID | LPS+ID only control | ID 27/ 16/ 22/
Intensity control | control | control oe ribosylation
L04510 factor 213.6 1.4 2.44 3.79 ring finger hypothetical
MHC class Il ve [ae [son [0 [on corns | “en | on | on | ow | ow | on
AK001904 protein 0.03 32.8 593 0.37 0.37 hypothetical thioredoxin- dependent peroxide
L19185 reductase 1 0.06 16.3 0.18 2.15 0.18
Transcobalamin ee | on [on [on [on [en
FEM-1-like death ee] 0 [
Number Media LPS/ LPS+ | LPS+ID | LPS+ID only control | ID 27/ 16/ 22/
Intensity control | control peer] I cytosolic ovarian E ’ smooth muscle
EP pei Pp PY hypothetical
PE RP PN phospholipase C hypothetical retinoic acid putative L-type neutral amino
ABO007896 | acid transporter 0.94 5.3 1.82 2.15 2.41
BAl1-associated ome Tu Ta To Tw oo hypothetical 2 [me] [To To [on on ankyrin 2_ were] | en | [on [on [oe inter-alpha brain and nasopharyngeal carcinoma . susceptibility
Co AF095687 protéin 0.39 21 0.48 0.03 0.98
Number Media LPS/ LPS+ | LPS+ID | LPS+ID only control | ID 27/ 16/ 22/
Intensity control | control | control
NK cell activation inducing ligand
BEREAN
KIAA0981 wi | | an Ta Leo Lon Lor
EXAMPLE 2
NEUTRALIZATION OF THE STIMULATION OF IMMUNE CELLS
[0073] The ability of compounds to neutralize the stimulation of immune cells by both Gram-negative and Gram-positive bacterial products was tested. Bacterial products stimulate cells of the immune system to produce inflammatory cytokines and when unchecked this can lead to sepsis. Initial experiments utilized the murine macrophage cell line RAW 264.7, which was obtained from the American Type
Culture Collection, (Manassas, VA), the human epithelial cell line, A549, and primary macrophages derived from the bone marrow of BALB/c mice (Charles River
Laboratories, Wilmington, MA). The cells from mouse bone marrow were cultured in 150-mm plates in Dulbecco's modified Eagle medium (DMEM; Life Technologies,
Burlington, ON) supplemented with 20 % FBS (Sigma Chemical Co,St. Louis, MO) and 20 % L cell-conditioned medium as a source of M-CSF. Once macrophages were 60-80 % confluent, they were deprived of L cell-conditioned medium for 14-16 h to render the cells quiescent and then were subjected to treatments with 100 ng/ml LPS or 100 ng/ml LPS + 20 pg/ml peptide for 24 hours. The release of cytokines into the culture supernatant was determined by ELISA (R&D Systems, Minneapolis, MN).
The cell lines, RAW 264.7 and A549, were maintained in DMEM supplemented with % fetal calf serum. RAW 264.7 cells were seeded in 24 well plates at a density of 10° cells per well in DMEM and A549 cells were seeded in 24 well plates at a density of 10° cells per well in DMEM and both were incubated at 37°C in 5 % CO; overnight. DMEM was aspirated from cells grown overnight and replaced with fresh medium. In some experiments, blood from volunteer human donors was coliecied (according to procedures accepted by UBC Clinical Research Ethics Board, certificate
C00-0537) by venipuncture into tubes (Becton Dickinson, Franklin Lakes, NJ) containing 14.3 USP units heparin/ml blood. The blood was mixed with LPS with or without peptide in polypropylene tubes at 37°C for 6 h. The samples were centrifuged for 5 min at 2000 x g, the plasma was collected and then stored at —20°C until being analyzed for IL-8 by ELISA (R&D Systems). In the experiments with cells, LPS of other bacterial products were incubated with the cells for 6-24 hr at 37°C in 5 % CO.
S. typhimurium LPS and E. coli 0111:B4 LPS were purchased from Sigma.
Lipoteichoic acid (LTA) from S. aureus (Sigma) was resuspended in endotoxin free water (Sigma). The Limulus amoebocyte lysate assay (Sigma) was performed on
LTA preparations to confirm that lots were not significantly contaminated by endotoxin. Endotoxin contamination was less than 1 ng/ml, a concentration that did not cause significant cytokine production in the RAW 264.7 cells. Non-capped lipoarabinomannan (AraLAM ) was a gift from Dr. John T. Belisle of Colorado State
University. The AraLAM from Mycobacterium was filter sterilized and the endotoxin contamination was found to be 3.75 ng per 1.0 mg of LAM as determined by Limulus
Amebocyte assay. At the same time as LPS addition (or later where specifically described), cationic peptides were added at a range of concentrations. The supernatants were removed and tested for cytokine production by ELISA (R&D
Systems). All assays were performed at least three times with similar results. To confirm the anti-sepsis activity in vivo, sepsis was induced by intraperitoneal injection of 2 or 3 ug of E. coli O111:B4 LPS in phosphate-buffered saline (PBS; pH 7.2) into galactosamine-sensitized 8- to 10- week-old female CD-1 or BALB/c mice. In experiments involving peptides, 200 pg in 100ul of sterile water was injected at separate intraperitoneal sites within 10 min of LPS injection. In other experiments,
CD-1 mice were injected with 400 ug E. coli O111:B4 LPS and 10 min later peptide (200 pg) was introduced by intraperitoneal injection. Survival was monitored for 48 hours post injection. ’
[0074] Hyperproduction of TNF-a has been classically linked to development of ’ sepsis. The three types of LPS, LTA or AralLAM used in this example represented products released by both Gram-negative and Gram-positive bacteria. Peptide, SEQ
ID NO: 1, was able to significantly reduce TNF-a production stimulated by S. typhimurium, B. cepacia, and E. coli O111:B4 LPS, with the former being affected to a somewhat lesser extent (Table 3). At concentrations as low as 1 pg/ml of peptide : (0.25 nM) substantial reduction of TNF-a production was observed in the latter two cases. A different peptide, SEQ ID NO: 3 did not reduce LPS-induced production of
TNF-a in RAW macrophage cells, demonstrating that this is not a uniform and predictable property of cationic peptides. Representative peptides from each Formula were also tested for their ability to affect TNF-a production stimulated by E. coli
O111:B4 LPS (Table 4). The peptides had a varied ability to reduce TNF-a production although many of them lowered TNF-a by at least 60%.
[0075] At certain concentrations peptides SEQ ID NO: 1 and SEQ ID NO: 2, could also reduce the ability of bacterial products to stimulate the production of IL-8 by an epithelial cell line. LPS is a known potent stimulus of IL-8 production by epithelial cells. Peptides, at low concentrations (1-20 pg/ml), neutralized the IL-8 induction responses of epithelial cells to LPS (Table 5-7). Peptide SEQ ID 2 also inhibited
LPS-induced production of IL-8 in whole human blood (Table 4). Conversely, high concentrations of peptide SEQ ID NO: 1 (50 to 100 pg/ml) actually resulted in increased levels of IL-8 (Table 5). This suggests that the peptides have different effects at different concentrations.
[0076] The effect of peptides on inflammatory stimuli was also demonstrated in primary murine cells, in that peptide SEQ ID NO: 1 significantly reduced TNF-a production (>90 %) by bone marrow-derived macrophages from BALB/c mice that had been stimulated with 100 ng/ml E. coli 0111:B4 LPS (Table 8). These experiments were performed in the presence of serum, which contains LPS-binding protein (LBP), a protein that can mediate the rapid binding of LPS to CD14. Delayed addition of SEQ ID NO: 1 to the supernatants of macrophages one hour after stimulation with 100 ng/ml E. coli LPS still resulted in substantial reduction (70 %) of
TNF-a production (Table 9).
18077] Consistent with the ability of SEQ ID NO: 1 to prevent LPS-induced production of TNF-a in vitro, certain peptides also protected mice against lethal shock induced by high concentrations of LPS. In some experiments, CD-1 mice were sensitized to LPS with a prior injection of galactosamine. Galactosamine-sensitized mice that were injected with 3 pug of E. coli 0111:B4 LPS were all killed within 4-6 hours. When 200 pg of SEQ ID NO: 1 was injected 15 min after the LPS, 50 % of the mice survived (Table 10). In other experiments when a higher concentration of
LPS was injected into BALB/c mice with no D-galactosamine, peptide protected 100 % compared to the control group in which there was no survival (Table 13). Selected other peptides were also found to be protective in these models (Tables 11,12).
[0078] Cationic peptides were also able to lower the stimulation of macrophages by
Gram-positive bacterial products such as Mycobacterium non-capped lipoarabinomannan (AraLAM) and S. aureus LTA. For example, SEQ ID NO: 1 inhibited induction of TNF-a in RAW 264.7 cells by the Gram-positive bacterial products, LTA (Table 14) and to a lesser extent AralLAM (Table 15). Another peptide, SEQ ID NO: 2, was also found to reduce LTA-induced TNF-a production by
RAW 264.7 cells. Ata concentration of 1 ug/ml SEQ ID NO: 1 was able to substantially reduce (>75 %) the induction of TNF-a production by 1 pg/ml S. aureus
LTA. At 20 ug/ml SEQ ID NO: 1, there was >60 % inhibition of AraLAM induced
TNF-a. Polymyxin B (PMB) was included as a control to demonstrate that contaminating endotoxin was not a significant factor in the inhibition by SEQ ID NO: 1 of AraLAM induced TNF-a. These results demonstrate that cationic peptides can reduce the pro-inflammatory cytokine response of the immune system to bacterial products.
[0079] Table 3: Reduction by SEQ ID 1 of LPS induced TNF-a production in
RAW 264.7 cells. RAW 264.7 mouse macrophage cells were stimulated with 100 ng/ml S. typhimurium LPS, 100 ng/ml B. cepacia LPS and 100 ng/ml E. coli 0111:B4 :
LPS in the presence of the indicated concentrations of SEQ ID 1 for 6 hr. The concentrations of TNF-a released into the culture supernatants were determined by
ELISA. 100 % represents the amount of TNF-a resulting from RAW 264.7 cells incubated with LPS alone for 6 hours (S. typhimurium LPS = 34.5 t+ 3.2 ng/ml, B. cepacia LPS = 11.6 + 2.9 ng/ml, and E. coli 0111:B4 LPS = 30.8 + 2.4 ng/ml).
Background levels of TNF-a production by the RAW 264.7 cells cultured with no stimuli for 6 hours resulted in TNF-a levels ranging from 0.037 — 0.192 ng/ml. The data is from duplicate samples and presented as the mean of three experiments + standard error.
Amount of Inhibition of TNF-a (%)*
SEQ ID 1 (ug/mD) | B. cepacia LPS | E. coli LPS S. typhimurium LPS 23.0 + 11.4 36.6 + 7.5 9.8 + 6.6 55.41 8 65.0 + 3.6 311+ 7.0 63.1+8 75.0 + 3.4 374 +75 71.7+5.8 81.0 + 3.5 58.5+10.5 86.7 + 4.3 92.6 +25 73.1+9.1
[0080] Table 4: Reduction by Cationic Peptides of E. coli LPS induced TNF-a production in RAW 264.7 cells. RAW 264.7 mouse macrophage cells were stimulated with 100 ng/ml E. coli 0111:B4 LPS in the presence of the indicated concentrations of cationic peptides for 6 h. The concentrations of TNF-a. released into the culture supernatants were determined by ELISA. Background levels of TNF-a production by the RAW 264.7 cells cultured with no stimuli for 6 hours resulted in
TNF-a levels ranging from 0.037 — 0.192 ng/ml. The data is from duplicate samples and presented as the mean of three experiments + standard deviation.
Peptide (20 ug/ml) | Inhibition of TNF-a (%)
SEQID 5 65.6% 1.6
SEQID 6 59.8+1.2
SEQID 7 50.6 + 0.6
SEQID 8 39.3+1.9
50.8 + 1.67 73.3+0.36
[0081] Table 5: Reduction by SEQ ID 1 of LPS induced IL-8 production in A549 cells. A549 cells were stimulated with increasing concentrations of SEQ ID 1 in the presence of LPS (100 ng/ml E. coli O111:B4) for 24 hours. The concentration of IL-8 in the culture supernatants was determined by ELISA. The background levels of IL-8 from cells alone was 0.172 + 0.029 ng/ml. The data is presented as the mean of three experiments + standard error.
IL EU
I EL
[0082] Table 6: Reduction by SEQ ID 2 of E. coli LPS induced IL-8 production in A549 cells. Human A549 epithelial cells were stimulated with increasing concentrations of SEQ ID 2 in the presence of LPS (100 ng/ml E. coli O111:B4) for 24 hours. The concentration of IL-8 in the culture supernatants was determined by : ELISA. The data is presented as the mean of three experiments + standard error.
Concentration of SEQ ID 2 {ug/inl) Inhibition of IL-8 (%)
I EES A
[0083] Table 7: Reduction by SEQ ID 2 of E. coli LPS induced IL-8 in human blood. Whole human blood was stimulated with increasing concentrations of peptide and E.coli O111:B4 LPS for 4 hr. The human blood samples were centrifuged and the serum was removed and tested for IL-8 by ELISA. The data is presented as the average of 2 donors.
SEQ ID 2 (ug/ml) IL-8 (pg/ml)
[0084] Table 8: Reduction by SEQ ID 1 of E. coli LPS induced TNF-a production in murine bone marrow macrophages. BALB/c Mouse bone marrow- derived macrophages were cultured for either 6 h or 24 h with 100 ng/ml E. coli 0111:B4 LPS in the presence or absence of 20 ug/ml of peptide. The supernatant was collected and tested for levels of TNF-a by ELISA. The data represents the amount of
TNF-a resulting from duplicate wells of bone marrow-derived macrophages incubated with LPS alone for 6 h (1.1 + 0.09 ng/ml) or 24 h (1.7 + 0.2 ng/ml).
Background levels of TNF-a were 0.038 + 0.008 ng/ml for 6 h and 0.06 + 0.012 ng/ml for 24h.
SEQ ID 1 (ug/ml) Production of TNF-a (ng/ml)
IE BL Bc
No LPS control 0.038 | 006
[0085] Table 9: Inhibition of E. coli LPS-induced TNF-a production by delayed addition of SEQ ID 1 to A549 cells. Peptide (20 pg/ml) was added at increasing time points to wells already containing A549 human epithelial cells and 100 ng/ml E. coli 0111:B4 LPS. The supernatant was collected after 6 hours and tested for levels of
TNF-a by ELISA. The data is presented as the mean of three experiments + standard error.
Time of addition of SEQ ID 1 Inhibition of TNF-a (%) after LPS (min)
I EE
IE ELS
[0086] Table 10: Protection against lethal endotoxaemia in galactosamine- ’ sensitized CD-1 mice by SEQ ID 1. CD-1 mice (9 weeks-old) were sensitized to endotoxin by three intraperitoneal injections of galactosamine (20 mg in 0.1 ml sterile
PBS). Then endotoxic shock was induced by intraperitoneal injection of E. coli 0111:B4 LPS (3 pg in 0.1 mi PBS). Peptide, SEQ ID 1, (200 pg/mouse = 8mg/kg)
was injected at a separate intraperitoneal siic 15 min after injection of LPS. The mice were monitored for 48 hours and the results were recorded.
D-Galactosamine E. coli Peptide or | Total Survival post : treatment 0111:B4 LPS buffer mice endotoxin shock
[0087] Table 11: Protection against lethal endotoxaemia in galactosamine- sensitized CD-1 mice by Cationic Peptides. CD-1 mice (9 weeks-old) were sensitized to endotoxin by intraperitoneal injection of galactosamine (20 mg in 0.1 ml sterile PBS). Then endotoxic shock was induced by intraperitoneal injection of E. coli 0111:B4 LPS (2 ug in 0.1 ml PBS). Peptide (200 pg/mouse = 8mg/kg) was injected at a separate intraperitoneal site 15 min after injection of LPS. The mice were monitored for 48 hours and the results were recorded.
Peptide Treatment | E. coli 0111:B4 [ Number | Survival (%)
LPS added of Mice
SE
Slide nT
[0088] Table 12: Protection against lethal endotoxaemia in galactosamine- sensitized BALB/c mice by Cationic Peptides. BALB/c mice (8 weeks-old) were sensitized to endotoxin by intraperitoneal injection of galactosamine (20 mg in 0.1 ml sterile PBS). Then endotoxic shock was induced by intraperitoneal injection of E. coli 0111:B4 LPS (2 ug in 0.1 ml PBS). Peptide (200 pg/mouse = 8mg/kg) was injected at a separate intraperitoneal site 15 min after injection of LPS. The mice were monitored for 48 hours and the results were recorded.
Peptide Treatment E. coli Number of Mice | Survival (%) i i a i NS LL NL
FE EC LN ELA
Fl I SS EO EL
Fl NS INC A i CS NN LA ia LN IR A
Fl ILS IS
Fl NS EL EL
Fl I NN ELA i I I won ew | ow | 0 il I EO A i HN I
Fl IN ICR SL
SEQ ID 29 ng
Ee
Fl I I
Fl IL NN
FC I aL ILS SC EL
[0089] Table 13: Protection against lethal endotoxaemia in BALB/c mice by SEQ
ID 1. BALB/c mice were injected intraperitoneal with 400 pug E. coli 0111:B4 LPS.
Peptide (200 pug/mouse = 8mg/kg) was injected at a separate intraperitoneal site and the mice were monitored for 48 hours and the results were recorded.
Peptide E. coli Number of Mice Survival (%) an ow | aw [5 [0
IC LT NO EL
[0090] Table 14: Peptide inhibition of TNF-a production induced by S. aureus
LTA. RAW 264.7 mouse macrophage cells were stimulated with 1 ug/ml S. aureus
LTA in the absence and presence of increasing concentrations of peptide. The supernatant was collected and tested for levels of TNF-a by ELISA. Background levels of TNF-a production by the RAW 264.7 cells cultured with no stimuli for 6 hours resulted in TNF-a levels ranging from 0.037 — 0.192 ng/ml. The data is presented as the mean of three or more experiments + standard error.
[0091] Table 15: Peptide inhibition of TNF-a production induced by
Mycobacterium non-capped lipoarabinomannan. RAW 264.7 mouse macrophage : cells were stimulated with 1 ug/ml AraLAM in the absence and presence of 20 ug/ml peptide or Polymyxin B. The supernatant was collected and tested for levels of TNF- - o by ELISA. Background levels of TNF-a production by the RAW 264.7 cells cultured with no stimuli for 6 hours resulted in TNF-a levels ranging from 0.037 — 0.192 ng/ml. The data is presented as the mean inhibition of three or more experiments + standard error. ewe [oT
EXAMPLE 3
ASSESSMENT OF TOXICITY OF THE CATIONIC PEPTIDES
[0092] The potential toxicity of the peptides was measured in two ways. First, the
Cytotoxicity Detection Kit (Roche) (Lactate dehydrogenase -LDH) Assay was used.
It is a colorimetric assay for the quantification of cell death and cell lysis, based on the measurement of LDH activity released from the cytosol of damaged cells into the supernatant. LDH is a stable cytoplasmic enzyme present in all cells and it is released into the cell culture supernatant upon damage of the plasma membrane. An increase in the amount of dead or plasma membrane-damaged cells results in an increase of the
LDH enzyme activity in the culture supernatant as measured with an ELISA plate reader, ODg9onm (the amount of color formed in the assay is proportional to the number of lysed cells). In this assay, human bronchial epithelial cells (16HBEo14,
HBE) cells were incubated with 100 pg of peptide for 24 hours, the supernatant removed and tested for LDH. The other assay used to measure toxicity of the cationic peptides was the WST-1 assay (Roche). This assay is a colorimetric assay for the quantification of cell proliferation and cell viability, based on the cleavage of the tetrazolium salt WST-1 by mitochondrial dehydrogenases in viable cells (a non- radioactive alternative to the [*H]-thymidine incorporation assay). In this assay, HBE cells were incubated with 100 ug of peptide for 24 hours, and then 10 ul/well Cell
Proliferation Reagent WST-1 was added. The cells are incubated with the reagent and the plate is then measured with an ELISA plate reader, OD gonm.
18093] The results shown below in Tables 16 and 17 demonstrate thai mosi of the peptides are not toxic to the cells tested. However, four of the peptides from Formula
F (SEQ ID NOS: 40, 41, 42 and 43) did induce membrane damage as measured by both assays.
[0094] Table 16: Toxicity of the Cationic Peptides as Measured by the LDH }
Release Assay. Human HBE bronchial epithelial cells were incubated with 100 pg/ml peptide or Polymyxin B for 24 hours. LDH activity was assayed in the supernatant of the cell cultures. As a control for 100% LDH release, Triton X-100 was added. The data is presented as the mean * standard deviation. Only peptides SEQ ID 40.41,42 and 43 showed any significant toxicity.
[0095] Table 17: Toxicity of the Cationic Peptides as Measured by the WST-1
Assay. HBE cells were incubated with 100 pg/ml peptide or Polymyxin B for 24 hours and cell viability was tested. The data is presented as the mean standard deviation. As a control for 100% LDH release, Triton X-100 was added. Only peptides SEQ ID 40,41,42 and 43 showed any significant toxicity.
EXAMPLE 4
POLYNUCLEOTIDE REGULATION BY CATIONIC PEPTIDES
[0096] Polynucleotide arrays were utilized to determine the effect of cationic peptides by themselves on the transcriptional response of macrophages and epithelial cells.
Mouse macrophage RAW 264.7, Human Bronchial cells (HBE), or A549 human epithelial cells were plated in 150 mm tissue culture dishes at 5.6 x 10° cells/dish, cultured overnight and then incubated with 50 pg/ml peptide or medium alone for 4 h.
After stimulation, the cells were washed once with diethyl pyrocarbonate-treated PBS, and detached from the dish using a cell scraper. Total RNA was isolated using Trizol (Gibco Life Technologies). The RNA pellet was resuspended in RNase-free water containing RNase inhibitor (Ambion, Austin, TX). The RNA was treated with DNasel (Clontech, Palo Alto, CA) for 1 h at 37°C. After adding termination mix (0.1 M
EDTA [pH 8.0], I mg/ml glycogen), the samples were extracted once with phenol: chloroform: isoamyl alcohol (25:24:1), and once with chloroform. The RNA was then precipitated by adding 2.5 volumes of 100% ethanol and 1/10" volume sodium ) acetate, pH 5.2. The RNA was resuspended in RNase-free water with RNase inhibitor (Ambion) and stored at -70°C. The quality of the RNA was assessed by gel electrophoresis on a 1% agarose gel. Lack of genomic DNA contamination was assessed by using the isolated RNA as a template for PCR amplification with B-actin-
specific primers (5'-GTCCCTGTATGCCTCTGGTC-3’ (SEQ iD NO: 55) and 5'-
GATGTCACGCACGATTTCC-3’ (SEQ ID NO: 56)). Agarose gel electrophoresis and ethidium bromide staining confirmed the absence of an amplicon after 35 cycles.
[0097] Atlas cDNA Expression Arrays (Clontech, Palo Alto, CA), which consist of 588 selected mouse cDNAs spotted in duplicate on positively charged membranes were used for early polynucleotide array studies (Tables 18,19). **P-radiolabeled cDNA probes prepared from 5 pg total RNA were incubated with the arrays overnight at 71°C. The filters were washed extensively and then exposed to a phosphoimager screen (Molecular Dynamics, Sunnyvale, CA) for 3 days at 4°C. The image was captured using a Molecular Dynamics PSI phosphoimager. The hybridization signals were analyzed using AtlasImage 1.0 Image Analysis software (Clontech) and Excel (Microsoft, Redmond, WA). The intensities for each spot were corrected for background levels and normalized for differences in probe labeling using the average values for 5 polynucleotides observed to vary little between the stimulation conditions: B-actin, ubiquitin, ribosomal protein S29, glyceraldehyde-3-phosphate dehydrogenase (GAPDH), and Ca®* binding protein. When the normalized : hybridization intensity for a given cDNA was less than 20, it was assigned a value of to calculate the ratios and relative expression.
[0098] The next polynucleotide arrays used (Tables 21-26) were the Resgen Human cDNA arrays (identification number for the genome is PRHUO03-S3), which consist of 7,458 human cDNAs spotted in duplicate. Probes were prepared from 15-20 pg of total RNA and labeled with Cy3 labeled dUTP. The probes were purified and hybridized to printed glass slides overnight at 42°C and washed. After washing, the image was captured using a Virtek slide reader. The image processing software (Imagene 4.1, Marina Del Rey, CA) determines the spot mean intensity, median intensities, and background intensities. Normalization and analysis was performed with Genespring software (Redwood City, CA). Intensity values were calculated by subtracting the mean background intensity from the mean intensity value determined by Imagene. The intensities for each spot were normalized by taking the median spot intensity value from the population of spot values within a slide and comparing this value to the values of all slides in the experiment. The relative changes seen with cells treated with peptide compared to control cells can be found in the Tables below.
[0099] The other polynucleotide arrays used (Tables 27-35) were the Human Operon arrays (identification number for the genome is PRHU04-S1), which consist of about 14,000 human oligos spotted in duplicate. Probes were prepared from 10 pg of total
RNA and labeled with Cy3 or Cy5 labeled dUTP. In these experiments, A549 epithelial cells were plated in 100 mm tissue culture dishes at 2.5 x 10° cells/dish.
Total RNA was isolated using RNAqueous (Ambion). DNA contamination was removed with DNA-free kit (Ambion). The probes prepared from total RNA were purified and hybridized to printed glass slides overnight at 42°C and washed. After washing, the image was captured using a Perkin Elmer array scanner. The image processing software (Imagene 5.0, Marina Del Rey, CA) determines the spot mean intensity, median intensities, and background intensities. An “in house” program was used to remove background. The program calculates the bottom 10% intensity for each subgrid and subtracts this for each grid. Analysis was performed with
Genespring software (Redwood City, CA). The intensities for cach spot were normalized by taking the median spot intensity value from the population of spot values within a slide and comparing this value to the values of all slides in the experiment. The relative changes seen with cells trcated with peptide compared to control cells can be found in the Tables below.
[00100] Semi-quantitative RT-PCR was performed to confirm polynucleotide array results. 1 ug RNA samples were incubated with 1 pl oligodT (500 pg/ml) and 1 pl mixed dNTP stock at 1 mM, in a 12 pl volume with DEPC treated water at 65°C for 5 min in a thermocycler. 4 pl 5X First Strand buffer, 2 ul 0.1M DTT, and 1 pl
RNaseOUT recombinant ribonuclease inhibitor (40 units/ul) were added and incubated at 42 °C for 2 min, followed by the addition of 1 pl (200 units) of
Superscript 11 (Invitrogen, Burlington, ON). Negative controls for each RNA source were generated using parallel reactions in the absence of Superscript Il. cDNAs were . amplified in the presence of 5’ and 3’ primers (1.0 uM), 0.2 mM dNTP mixture, 1.5 mM MgCl, 1 U of Tag DNA polymerase (New England Biolabs, Missisauga, ON), and 1X PCR buffer. Each PCR was performed with a thermal cycler by using 30-40 cycles consisting of 30s of denaturation at 94°C, 30s of anneaiing ai either 52°C or 55 °C and 40s of extension at 72 °C. The number of cycles of PCR was optimized to lie in the linear phase of the reaction for each primer and set of RNA samples. A housekeeping polynucleotide B-actin was amplified in each experiment to evaluate extraction procedure and to estimate the amount of RNA. The reaction product was ) visualized by electrophoresis and analyzed by densitometry, with relative starting
RNA concentrations calculated with reference to B-actin amplification.
[00101] Table 18 demonstrates that SEQ ID NO: 1 treatment of RAW 264.7 cells up-regulated the expression of more than 30 different polynucleotides on small Atlas microarrays with selected known polynucleotides. The polynucleotides up-regulated by peptide, SEQ ID NO: 1, were mainly from two categories: one that includes receptors (growth, chemokine, interleukin, interferon, hormone, neurotransmitter), cell surface antigens and cell adhesion and another one that includes cell-cell communication (growth factors, cytokines, chemokines, interleukin, interferons, hormones), cytoskeleton, motility, and protein turnover. The specific polynucleotides up-regulated included those encoding chemokine MCP-3, the anti-inflammatory cytokine IL-10, macrophage colony stimulating factor, and receptors such as IL-1R-2 (a putative antagonist of productive IL-1 binding to IL-1R1), PDGF receptor B,
NOTCH4, LIF receptor, LFA-1, TGF receptor 1, G-CSF receptor, and IFNy receptor. The peptide also up-regulated polynucleotides encoding several metalloproteinases, and inhibitors thereof, including the bone morphogenetic proteins
BMP-1, BMP-2, BMP-8a, TIMP2 and TIMP3. As well, the peptide up-regulated specific transcription factors, including JunD, and the YY and LIM-1 transcription factors, and kinases such as Etk1 and Csk demonstrating its widespread effects. It was also discovered from the polynucleotide array studies that SEQ ID NO: 1 down- regulated at least 20 polynucleotides in RAW 264.7 macrophage cells (Table 19). The polynucleotides down-regulated by peptide included DNA repair proteins and several inflammatory mediators such as MIP-1a, oncostatin M and 1L-12. A number of the effects of peptide on polynucleotide expression were confirmed by RT-PCR (Table 20). The peptides, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 19, and SEQ ID NO: ‘ 1, and representative peptides from each of the formulas also altered the transcriptional responses in a human epithelial cell line using mid-sized microarrays (7835 polynucleotides). The effect of SEQ ID NO: 1 on polynucleotide expression was compared in 2 human epithelial cell lines, A549 and HBE. Polynucleotides related to the host immune response that were up-regulated by 2 peptides or more by a ratio of 2-fold more than unstimulated cells are described in Table 21.
Polynucleotides that were down-regulated by 2 peptides or more by a ratio of 2-fold more than unstimulated cells are described in Table 22. In Table 23 and Table 24, the human epithelial pro-inflammatory polynucleotides that are up- and down-regulated respectively are shown. In Table 25 and Table 26 the anti-inflammatory polynucleotides affected by cationic peptides are shown. The trend becomes clear that the cationic peptides up-regulate the anti-inflammatory response and down-regulate the pro-inflammatory response. It was very difficult to find a polynucleotide related to the anti-inflammatory response that was down-regulated (Table 26). The pro- inflammatory polynucleotides upregulated by cationic peptides were mainly polynucleotides related to migration and adhesion. Of the down-regulated pro- inflammatory polynucleotides, it should be noted that all the cationic peptides affected several toll-like receptor (TLR) polynucleotides, which are very important in signaling the host response to infectious agents. An important anti-inflammatory polynucleotide that was up-regulated by all the peptides is the IL-10 receptor. IL-10 is an important cytokine involved in regulating the pro-inflammatory cytokines. These polynucleotide expression effects were also observed using primary human macrophages as observed for peptide SEQ ID NO: 6 in Tables 27 and 28. The effect of representative peptides from each of the formulas on human epithelial cell expression of selected polynucleotides (out of 14,000 examined) is shown in Tables 31-37 below. At least 6 peptides from each formula were tested for their ability to alter human epithelial polynucleotide expression and indeed they had a wide range of stimulatory effects. In each of the formulas there were at least 50 polynucleotides commonly up-regulated by each of the peptides in the group.
[00102] Table 18: Polynucleotides up-regulated by peptide, SEQ ID NO: 1, i treatment of RAW macrophage cells”. The cationic peptides at a concentration of 50 pg/ml were shown to potently induce the expression of several polynucleotides.
Peptide was incubated with the RAW cells for 4 h and the RNA was isolated,
converied into labeled cDNA probes and hybridized to Atlas arrays. The intensity of unstimulated cells is shown in the third column. The “Ratio Peptide: Unstimulated” column refers to the intensity of polynucleotide expression in peptide-simulated cells divided by the intensity of unstimulated cells.
[00103] The changes in the normalized intensities of the housekeeping polynucleotides ranged from 0.8-1.2 fold, validating the use of these polynucleotides for normalization. When the normalized hybridization intensity for a given cDNA was less than 20, it was assigned a value of 20 to calculate the ratios and relative
Co expression. The array experiments were repeated 3 times with different RNA preparations and the average fold change is shown above. Polynucleotides with a two fold or greater change in relative expression levels arc presented.
Polynucleotide Polynucleotide Unstimulated Ratio Accession / Protein Function Intensity peptide: Number ! Unstimulated”
Etkl Tyrosine-protein 20 43 M68513
I = Hd
Corticotropin releasing 20 23 X72305
Ih a a ed
NOTCH4 proto- 48 18 MB0456
I Pl ll hed
BMP-1 Bone morpho- 20 i4 L24755 polynucleotidetic protein
Endothelin b Receptor 20 14 U32329 ll Mell c-ret Oncopolynucleotide 20 13 X67812 }
Nc I a
Polynucleotide Polynucleotide Unstimulated Ratio Accession / Protein Function Intensity peptide: Number me
BMP-8a Bone morpho- 20 12 M97017 polynucleotidetic protein
CC cc NO WL LC
MCSF Macrophage colony 85 11 X05010 =r a I
GCSFR Granulocyte colony- 20 M58288 stimulating factor receptor a cc LC IL ILL a I Mi
Cas Crk-associated 31 U48853 re
IL-1B Interleukin precursor 5 M15131 =
SPi2-2 Serine protease 62 5 M64086
NA = I I hd
RE cc WL EO i NC IL Lc pI0inka cdk4 and cdk6 147 2 U19597 i i I I ed
Polynucleotide Polynucleotide Unsiimulated Ratio Accession / Protein Function Intensity peptide: Number
Unstimulated”
GADD45 DNA -damage- 88 3 128177
Re LL LI 8
POLDI1 DNA polymerase 649 2 221848
Vav proto- 613 2 X64361
Te
Cdk7 Cyclin-dependent 475 2 U11822
I rl A hd
MLCiA Myosin light subunit 453 2 M19436 i a al I hd
IFNGR Interferon gamma 308 2 M2R?733 pl =o el I i
Polynucleotide Polynucleotide Unstimulated Ratio Accession / Protein Function Intensity peptide: Number
Unstimulated”
IGF-1Ra Insulin-like growth 218 2 Uo00182
Ne el A fyn Tyrosine-protein 191 2 U70324
Te
BMP-2 Bone morpho- 2 1.25602 polynucleotidetic =
RS Tc I cl
BKLF CACCC Box- binding 138 2 U36340
I dE
Mas Proto- 131 2 X67735
I I I al
[00104] Table 19: Polynucleotides down-regulated by SEQ ID NO: 1 treatment of RAW macrophage cells’. The cationic peptides at a concentration of 50 pg/ml were shown to reduce the expression of several polynucleotides. Peptide was incubated with the RAW cells for 4 h and the RNA was isolated, converted into labeled cDNA probes and hybridized to Atlas arrays. The intensity of unstimulated cells is shown in the third column. The “Ratio Peptide: Unstimulated” column refers to the intensity of polynucleotide expression in peptide-simulated cells divided by the intensity of unstimulated cells. The array experiments were repeated 3 times with different cells and the average fold change is shown below. Poiynucieotides with an approximately two fold or greater change in relative expression levels are presented.
Unstimulated Ratio Accession
Polynucleotide Polynucleotide Intensity peptide: Number mm sodium channel Voltage-gated ion 257 0.08 L36179 dl a Ml id
CT cc NLA LI a cc CL Nc
KRT18 Intermediate filament 318 0.28 M11686
NE ll al
RE cc NC NA Rail
Oc IC HO ic
Unstimulated Ratio Accession
Polynucleotide Polynucleotide Intensity peptide: Number e
KRT19 Intermediate filament 622 0.52 M28698 ee
CTLA4 immunoglobin 468 0.57 X05719 =m
MTRP Lysosome-assaciated 498 0.58 U34259
Rl i el Ml hd
[00105] Table 20: Polynucleotide Expression changes in response to peptide,
SEQ ID NO: 1, could be confirmed by RT-PCR. RAW 264.7 macrophage cells were incubated with 50 pg/ml of peptide or media only for 4 hours and total RNA isolated and subjected to semi-quantitative RT-PCR. Specific primer pairs for each polynucleotide were used for amplification of RNA. Amplification of $-actin was used as a positive control and for standardization. Densitometric analysis of RT-PCR products was used. The results refer to the relative fold change in polynucleotide expression of peptide treated cells compared to cells incubated with media alone. The data is presented as the mean + standard error of three experiments.
[00106] Table 21: Polynucleotides up-regulated by peptide treatment of A549 epithelial cells’. The cationic peptides at concentrations of 50 ug/ml were shown to increase the expression of several polynucleotides. Peptide was incubated with the human A549 epithelial cells for 4 h and the RNA was isolated, converted into labeled cDNA probes and hybridized to Human cDNA arrays ID#PRHUO03-S3. The intensity of polynucleotides in unstimulated cells is shown in the second column. The “Ratio
Peptide: Unstimulated” columns refers to the intensity of polynucleotide expression in peptide-simulated cells divided by the intensity of unstimulated cells.
Accession
Polynucleotide/Protein Intensity (D2 IDI TID [
A I ec I ed
FS 0 I NL iad
SE I cH
NF R superfamily, member
NF R superfamily, member 5 wo Lufoe] | ome
NF R superfamily, member o Joo] interleukin enhancer binding sd PPR oy po oy ps
ON Nl Nh Bl Rial
Accession
Em
Polynucleotide/Protein Intensity (D2 [D3 [IDI IDT al cytokine inducible SH2- AN A AN NN vl RP PE py
K cytokine, down-regulator ytokine inducible SH2-
K cytokine, down-regulator mall inducible cytokine ubfamily A (Cys-Cys), member 21 3.9 2.4 Al922341
GFB inducible early growth rises IP PY PY PY
EN a Ri RA Rc 0% | 0 [39 | 39 | ST | Roan integrin, alpha 2 (CD49B, a alpha 2 subunit of VLA-2. receptor 1.00 2.4 3.6 AA463257 integrin, alpha 3 (antigen
ICD49C, alpha 3 subunit of
LA-3 receptor) 0.94 2.5 1.9 1.1 | AA424695
FE NC cl Wl LI al
Ech NC I lB id
EE NC ll CN id
EN cc IL a Il WE cid ach WO I Wl Wh NA Rid
: Accession
Polynucleotide/Protein Intensity calcium and integrin binding Ea oT disintegrin and : disintegrin and nc IP PY PY PP disintegrin and
Scie PO [PO PP disintegrin and cadherin 1, type 1, E-cadherin seen IPR PP og py adherin 12, type 2 (N-
Ei IVE PP
FC ll Wl Rad protocadherin gamma evil I A catenin (cadherin-associated srvwrigl IPOR P P P aminin R 1 (67kD, ribosomal killer cell lectin-like receptor
Er or ee killer cell lectin-like receptor rived IP PY PR py pe killer cell lectin-like receptor
Finer JPW OY Py poe
FT NO 1 I Ml id I
SL NC I I A dad
Accession
Unstimulated| Ratio Peptide: Unstimulated | Number
IPolynucleotide/Protein Intensity [102 [ID3TIDI] IDL uman proteinase activated
R-2 0.54 1.9 2.2 AA454652 prostaglandin E receptor 3 (subtype EP3) 0.25 4.1 3.8 AA406362 7 Cr growth factor receptor-bound protein 2 0.51 2.2 2.0 2.4 0.3 | AA449831
Mouse Mammary Turmor irus Receptor homolog W93891 prostaglandin E receptor 1 (subtype EP1) 0.65 7.2 1.5 | AA972293 growth factor receptor-bound protein 14 0.34 3.0 6.3 29 R24266 [Epstein-Barr virus induced polynucleotide 2 0.61 1.6 2.4 8.3 | AA037376 omplement component receptor 2 0.22 26 4.5 2.6 18.1 | AA521362 yrosine kinase, non-receptor, 1 0.12 7.8 8.5 10 8.7 Al936324 eceptor tyrosine kinase-like orphan receptor 2 0.40 7.3 5.0 2.5 N94921
Accession me
Polynucleotide/Protein Intensity protein tyrosine phosphatase, ha Rid A
Severna IE PY I PY protein tyrosine phosphatase, : protein tyrosine phosphatase, protein tyrosine phosphatase, sso IPPON PN YY protein tyrosine phosphatase, protein tyrosine phosphatase,
Free [oo en protein tyrosine phosphatase,
Sor EV PP protein tyrosine phosphatase, wri IP AP PI protein tyrosine phosphatase, protein tyrosine phosphatase, protein tyrosine phosphatase, eceptor type, C-associated
Sean ERE
AP kinase-activated protein oe] oo Lor fo
I RL I a NL
Accession
Wg —
Polynucleotide/Protein Intensity
A RM ci
Cc NL FE NL NO Bal regulator of G-protein Ril
EE 4 I egulator of G-protein mr | oo ore
BCL2-interacting killer [ol Lo] Jo aspase 6, apoptosis-related apoplosis-related protein aspase 8, apoptosis-related mp aL Lo
[00107] Table 22: Polynucleotides down-regulated by peptide treatment of
A549 epithelial cells”. The cationic peptides at concentrations of 50 pg/ml were shown to decrease the expression of several polynucleotides. Peptide was incubated with the human A549 epithelial cells for 4 h and the RNA was isolated, converted into labeled cDNA probes and hybridized to Human cDNA arrays ID#PRHUOQ3-S3. The intensity of polynucleotides in unstimulated cells is shown in the second column. The “Ratio Peptide: Unstimulated” columns refers to the intensity of polynucleotide expression in peptide-simulated cells divided by the intensity of unstimulated cells.
Accession
Polynucleotide/Protein Intensity | 102 [1D3 [ID 19) ID 1
AS SC i i NO NO Rl
NF receptor-associated a
NF receplor-associated rial J
NF receptor superfamily, weil I PE PY
NF R superfamily, member i I I
RAF and TNF receptor-
L-2 receptor, gamma (severe on
Garou J 8 poy eukotriene b4 receptor wrens) IE I PPR small inducible cytokine ubfamily A (Cys-Cys), 2 | or fon] oe mall inducible cytokine ubfamily A (Cys-Cys), small inducible cytokine levee PO
Accession
Polynucleotide/Protein Intensity (D273 [ID1g[ IDI [ a I ) small inducible cytokine AEN NN I subfamily B (Cys-X-Cys), member 6 (granulocyte =n mall inducible cytokine subfamily B (Cys-X-Cys),
Er | ie Loon ee mall inducible cytokine A3 (homologous to mouse Mip-
Sid I EI omplement component Clq cadherin 11, type 2, OB- adherin 3, type 1, P-cadherin ro IPR PF cadherin, EGF LAG seven- pass G-type receptor 2, lamingo (Drosophila) omolog 1.67 0.42 | 041 | 1.21 H39187 cadherin 13, H-cadherin
Sia ranR mE electin L (lymphocyte
ET [eo Jose] [ome vascular cell adhesion il PE YE intercellular adhesion al IEP FP fy
FCA cc i ie
Accession
Unstimulated Number
Polynucleotide/Protein Intensity [02 [D3
Fk Fc lal lil disintegrin and a
EA EP disintegrin-like and metalloprotease with hrombospondin type 1 motif, 3 2.11 0.32 | 0.63 | 0.47 | 0.35 | AA398492 disintegrin-like and metalloprotease with hrombospondin type 1 motif, 1.62 0.39 | 0.42 | 1.02 | 0.62 | AI375048 -cell receptor interacting
CC [ iphtheria toxin receptor (heparin-binding epidermal growth faclor-like growth actor) 1.62 0.49 | 0.85 | 0.62 | 0.15 | R4564C vasoactive intestinal peptide c fragment of IgG, low affinity IIIb, receptor for c fragment of IgG, low affinity IIb, receptor for
Fc fragment of IgE, high
Se EE 0
Accession
Polynucleotide/Protein Intensity (D2 [D3 [ID19| IDI a NN FF leukocyte immunoglobulin- sag J FF py leukocyte immunoglobulin- like receptor, subfamily B (with TM and ITIM domains), member 3 14.21 1.10 | 0.07 | AI815229 leukocyte immunoglobulin- like receptor, subfamily B (with TM and ITIM domains), member 4 2.31 0.75 | 0.43 0.40 | AA076350 leukocyte immunoglobulin- wi J PR fo py peroxisome proliferative
Soa FI PF protein tyrosine phosphatase, eceptor type, f polypeptide (PTPRF), interacting protein (liprin), a1 2.19 0.43 0.46 | N49751 protein tyrosine phosphatase, sil PO Po I py protein tyrosine phosphatase, protein tyrosine phosphatase, sna J PO FOP protein tyrosine phosphatase, il PF pp protein tyrosine phosphatase, protein tyrosine phosphatase, re | Jon[olus [ifm
: Accession
Unstimulated Number
Polynucleotide/Protein Intensity EHEC EDN
AP kinase 8 interacting 0.66 | 2.10 | 1.49 | W61116
MAP kinase 8 interacting
SP PF
IMAP kinase kinase kinase
Fl OY
SAA lO li
AP kinase kinase kinase
Sl Fo ed NO il Rl ad ial
Sl Ol a il i Ni
MAP kinase-activated protein
Sl OR Kc OR id
SO OC A Me id ic
SB WO cc a Ol cl egulator of G-protein i png oP egulator of G-protein pg po Fo py oy py BE protein-coupled receptor
BO nl PPO I 4
Accession
Polynucleotide/Protein Intensity (23 pig DI] orphan seven-transmembrane
Sodom PIP apoptosis antagonizing srl I PF pp caspase 1, apoptosis-related ysteine protease (interleukin 1, beta, convertase) 2.83 0.44 0.33 | 0.35 T95052 programmed cell death 8 or fy
[00108] Table 23: Pro-inflammatory polynucleotides up-regulated by peptide treatment of A549 cells. The cationic peptides at concentrations of 50 ug/ml were shown to increase the expression of certain pro-inflammatory polynucleotides (data is a subset of Table 21). Peptide was incubated with the human A549 epithelial cells for 4 h and the RNA was isolated, converted into labeled cDNA probes and hybridized to
Human cDNA arrays ID#PRHUO3-S3. The intensity of polynucleotides in unstimulated cells is shown in the second column. The “Ratio Peptide: Unstimulated” columns refers to the intensity of polynucleotide expression in peptide-simulated cells divided by the intensity of unstimulated cells.
Accession unction Intensity
IL-11 Ra; Receptor for pro- BLA ELAN — inflammatory cytokine, inflammation 0.55 2.39 | 0.98 4.85 1.82 | AA454657
IL-17 R; Receptor for IL-17, an inducer of cytokine production in epithelial cells 0.54 2.05 | 1.97 1.52 1.86 |AW029299
Accession unction Intensity |] mall inducible cytokine Bld subfamily A, member 21; a chemokine 3.88 2.41 Al922341
CD31; Leukocyte and cell to
CCR6; Receptor for integrin, alpha 2 (CD49B, alpha 2 subunit of VLA-2 eceptor; Adhesion to integrin, alpha 3 (antigen
D49C, alpha 3 subunit of
LA-3 receptor); Leukocyte integrin, beta 4; Leukocyte or
C-type lectin-like receptor- kil [PY PR py
[00109] Table 24: Pro-inflammatory polynucleotides down-regulated by peptide treatment of A549 cells. The cationic peptides at concentrations of 50 ug/ml were shown to decrease the expression of certain pro-inflammatory polynucleotides (data is a subset of Table 22). Peptide was incubated with the human A549 epithelial cells for 4 h and the RNA was isolated, converted into labeled cDNA probes and hybridized to Human cDNA arrays ID#PRHUQ03-S3. The intensity of polynucleatides in unstimulated cells is shown in the second column. The “Ratio Peptide: .
Unstimulated” columns refers to the intensity of polynucleotide expression in peptide- simulated cells divided by the intensity of unstimulated cells.
Polynucleotide/Protein; Function| Intensity oll-Tike receptor (TLR) 1; lida in Fp Pp
LR 2; Response to gram positive
LR 5; May augment other TLR er a oafun] | eee
LR 7: Putative host defence
NF receptor-associated factor 2:
NF receptor-associated factor 3; oii I PR PP po
NF receptor superfamily, member me wy Jon [an] Joe
NF R superfamily, member 17; weil I I I Pp
RAF and TNF receptor- small inducible cytokine subfamily pani [JP po small inducible cytokine subfamily prvi J Fp oy small inducible cytokine subfamily prc 90 FP small inducible cytokine subfamily
B, member 6 (granulocyte hemotactic protein); Chemokine 3.57 0.11 0.28 | 0.38 | AI889554 mall inducible cytokine subfamily ir Pp mall inducible cytokine A3 mo IY J
Unstim Accession
SR oe a 1L-12 receptor, beta 2; Interleukin HE I NS
Siig poy I electin L (lymphocyte adhesion ascular cell adhesion molecule 1; intercellular adhesion molecule 3; integrin, alpha 1; Leukocyte
Em ve Jean] Joe
[00110] Table 25: Anti-inflammatory polynucleotides up-regulated by peptide treatment of A549 cells. The cationic peptides at concentrations of 50 ug/ml were shown to increase the expression of certain anti-inflammatory polynucleotides (data is a subset of Table 21). Peptide was incubated with the human A549 epithelial cells for 4 h and the RNA was isolated, converted into labeled cDNA probes and hybridized to
Human cDNA arrays ID#PRHUO03-S3. The intensity of polynucleotides in unstimulated cells is shown in the second column. The “Ratio Peptide: Unstimulated” columns refers to the intensity of polynucleotide expression in peptide-simulated cells divided by the intensity of unstimulated cells.
Polynucleotide/Protein; Unstim Accession pr [re
IL-1 R antagonist homolog 1; hilid ual rg po po po is
L-10 R beta; Receptor for
Polynucleotide/Protein; Unstim | Ratio Peptide: Unstimulated | Accession
Function Intensity | 02 [ ID3 JIDIS|ID 1] Number
NF R, member 5; Apoptosis (CD40L) 33.71 2.98 0.02 H98636
NF R, member 11b; Apoptosis | 100 1529 | 450 [078] | AA194983
IK cytokine, down-regulator of
HLA 11; Inhibits antigen presentation 0.50 3.11 2.01 1.74 | 3.29 | R39227
GFB inducible early growth esponse 2; anti-inflammatory cytokine 2.38 2.08 | 0.87 Al473938
D2; Adhesion molecule, binds
LFAp3 1.00 2.62 0.87 1.15 | 0.88 | AA927710
[00111] Table 26: Anti-inflammatory polynucleotides down-regulated by peptide treatment of A549 cells. The cationic peptides at concentrations of 50 pg/ml were shown to increase the expression of certain anti-inflammatory polynucleotides (data is a subset of Table 21). Peptide was incubated with the human A549 epithelial cells for 4 h and the RNA was isolated, converted into labeled cDNA probes and hybridized to Human cDNA arrays ID#PRHUO3-S3. The intensity of polynucleotides in unstimulated cells is shown in the second column. The “Ratio Peptide:
Unstimulated” columns refers to the intensity of polynucleotide expression in peptide- simulated cells divided by the intensity of unstimulated cells.
Polynucleotide/Protein; Unstim Ratio Peptide: Unstimulated | Accession
Function Intensity | 102 [ID3 IDIS]ID | Number
[00112] Table 27: Polynucleotides up-regulated by SEQ ID NO: 6, in primary human macrophages. The peptide SEQ ID NO: 6 at a concentration of 50 ug/ml! was : shown to increase the expression of many polynucleotides. Peptide was incubated with the human macrophages for 4 h and the RNA was isolated, converted into labeled cDNA probes and hybridized to Human Operon arrays (PRHU04). The intensity of polynucleotides in unstimulated cells is shown in the second column. The “Ratio peptide treated : Control” columns refer to the intensity of polynucleotide expression in peptide-simulated cells divided by the intensity of unstimulated cells.
Gene (Accession Number) Control: Ratio peptide
Unstimulated treated:control cells
Ic FO WL
Ic NJ WL chromosome condensation 1-like eww ow
TERF1 (TRF1)-interacting nuclear
LINE retrotransposable element 1 1-acylglycerol-3-phosphate O-
Vacuolar proton-ATPase, subunit D; V-
potassium voltage-gated channel KQT- histone fold proteinCHRAC17
I LCA LJ pancreatic zymogen granule membrane hypothetical protein FLJ20495
E2F transcription factor 5, p130-binding hypothetical protein FLJ20070 glycoprotein IX (X52997) eukaryotic translation initiation factor
I I NL guanine nucleotide binding protein, gamma transducing activity polypeptide 1 (U41492) 0.80 3.3 glypican 1 (X54232) mucosal vascular addressin cell adhesion i LL translational inhibitor protein p14.5 hypothetical protein FLI20689 protein kinase, CAMP-dependent,
POU domain, class 4, transcription : POU domain, class 2, associating factor ——— matrix metalloproteinase 23A cyclin-dependent kinase inhibitor 1B
Ih WL bone morphogenetic protein 1 (NM_006129) 1.10 :
bone morphogenetic protein receptor, type IB (U89326) 0.50 2.1 interferon regulatory factor 2 (NM 002199) 1.46 2.0 protease, serine 21 (AB03133D
[00113] Table 28: Polynucleotides down-regulated by SEQ ID NO: 6, in primary human macrophages. The peptide SEQ ID NO: 6 at a concentration of 50 ug/ml was shown to increase the expression of many polynucleotides. Peptide was incubated with the human macrophages for 4 h and the RNA was isolated, converted into labeled cDNA probes and hybridized to Human Operon arrays (PRHUOQ4). The intensity of polynucleotides in unstimulated cells is shown in the second column. The “Ratio of Peptide: Control” columns refer to the intensity of polynucleotide expression in peptide-simulated cells divided by the intensity of unstimulated cells.
Gene (Accession Number) Control: Ratio peptide
Unstimulated | treated:control cells
Unknown (ALU49263) I CA I XS integrin-linked kinase (U40282)
RTAAO84Z protein (ABOZ0649)
Unknown (ABO37838)
Granulin (AF055008) 8s | 01a glutathione peroxidase 3 (NM_002084)
KIAA0152 gene product (D63486) 09 | 017
TGFB1-induced anti-apoptotic factor 1 (D86970) disintegrin protease (Y 13323) proteasome subunit beta type 7 (D38048) cofactor required for Spl transcriptional activation subunit 3 (AB033042) 0.23
TNF receptor superfamily, member 14 : (U81232) 0.26 proteasome 26S subunit non-ATPase 8 (D38047) 0.28 : proteasome subunit beta type, 4 (D26600)
TNF receptor superfamily member 1B (M32315) 1.7 0.29 cytochrome c oxidase subunit Vic
S100 calcium-binding protein A4 proteasome 26S subunit non-ATPase, 10
MAP Kinase Kinase kinase 2 (NM_006609) | 08 | 032 matrix metalloprotease 14 (Z4848) | 10 | 0.32
MAP kinase-activated protein kinase 2 proteasome 26S subunit, ATPase, 3 interferon alpha-inducible protein CatepnDM633®) | 46 | 036
TGF, bewainduced, 77349) | 18 | 037
TNF receptor superfamily, member 10b nuclear receptor binding protein protease inhibitor 1 alpha-1-antitrypsin proteasome subunit alpha type, 7 oo
LPS-induced TNF-alpha factor proteasome 26S subunit non-ATPase 13
MAP kinase kinase kinase kinase 2 peroxisome proliferative activated receptor defender against cell death 1 (D15057)
TNF superfamily member 10 (U37518) cathepsin H (X16832) protease inhibitor 12 (Z81326) 06 | 048 proteasome subunit alpha type, 4 (D00763) proteasome 26S subunit ATPase, 1 (L02426) 1.8 0.49 proteasome 26S subunit ATPase, 2 (D11094) 2.1
Caspase 7 (U67319) 2a oe matrix metalloproteinase 7 (Z11887)
[00114] Table 29: Polynucleotides up-regulated by SEQ ID NO: 1, in HBE cells. The peptide SEQ ID NO: 1 at a concentration of 50 pg/ml was shown to increase the expression of many polynucleotides. Peptide was incubated with the human HBE epithelial cells for 4 h and the RNA was isolated, converted into labeled cDNA probes and hybridized to Human Operon arrays (PRHUO04). The intensity of polynucleotides in unstimulated cells is shown in the second column. The “Ratio
Peptide: Control” columns refer to the intensity of polynucleotide expression in peptide-simulated cells divided by the intensity of unstimulated cells.
Accession Gene Control: Ratio peptide
Number Unstimulated | treated:control cells
AJ000730 solute carrier family | 001 | 282.0 725884 chloride channel 1 oor | 256.2 protein tyrosine phosphatase
M93426 ~ receptor-type,zeta 248.7 olfactory receptor, family 1,
X65857 subfamily D,member 2 0.01 228.7
M55654 TATA box binding protein BEE . AK001411 hypothetical protein
Accession Gene Control: Ratio peptide
Number Unstimulated | treated:control == diphosphooligosaccharide-protein m— tumor necrosis factor,alpha- ci Gc EL WC
SEC24 related gene family, glutamate receptor, ionotropic adenosine monophosphate
IE OC FF unknown | 0.28
Accession Gene Control: Ratio peptide
Number Unstimulated | treated:control = = 5,10-methenyltetrahydrofolate
Pal PY 0 Cc I NL
EC Oc UN a I hepatitis A virus cellular receptor il IV AP
I IL NL
Fl oc CL I cl CC NL LB
NADH dehydrogenase
Krueppel-related zinc finger
Accession Gene Control: Ratio peptide
Number Unstimulated | treated:control - = cc NL NL
TRAF family member-associated acetyl-Coenzyme A ]
UDP-N-acetyl-alpha-D- galactosamine:polypeptide N- mL iT Ec en I
Accession Gene Control: Ratio peptide ~ Number Unstimulated | treated:control cells a disintegrin-Tike and a disintegrin and metalloprotease
[00115] Table 30: Polynucleotides down-regulated by Peptide (50 pg/ml), SEQ : ID NO: 1, in HBE cells. The peptide SEQ ID NO: 1 at a concentration of 50 pg/ml was shown to decrease the expression of many polynucleotides. Peptide was incubated with the human A549 epithelial cells for 4 h and the RNA was isolated, converted into labeled cDNA probes and hybridized to Human Operon arrays (PRHUO4). The intensity of polynucleotides in unstimulated cells is shown in the third column. The “Ratio Peptide: Control” columns refer to the intensity of polynucleotide expression in peptide-simulated cells divided by the intensity of unstimulated cells.
Accession Gene Control: Ratio SEQ ID
Number Unstimulated | NO:1- treated:
Cells control
BH EA
Accession Gene Control: Ratio SEQ iD
Number Unstimulated | NO:1- treated:
Cells control polymerase (RNA) II ras-related C3 botulinum toxin
I J WL a cL IL
Human mRNA for ornithine
HLA-G histocompatibility antigen,
ATP synthase, H+ transporting oe
Homo sapiens TTF-I interacting
Accession Gene Control: Ratio SEQ ID
Number Unstimulated | NO:1- treated: ll I
Oa NO CLA anti-oxidant protein 2 (non- selenium glutathione peroxidase, acidic calctum-independent
D14662 phospholipas 0.19
IE I FL ILA
6-pyruvoyl-tetrahydropterin synthase/dimerization cofactor of
L41559 hepatocyte nuclear factor 1 alpha 9.1 0.20
RN
268 proteasome-associated padl tumor protein, translationally- a purine-rich element binding om | a protein disulfide isomerase-related ae
Accession Gene Control: Ratio SEQ ID
Cells control oe endothelial differentiation-related immediate early response 3 methylene tetrahydrofolate transcriptional intermediary factor solute carrier family 22 member 1- tyrosine 3- monooxy genase/tryptophan 5- - ubiquitin-conjugating enzyme lysosomal-associated membrane
I cc SI
~ [ Accession Gene Control: Ratio SEQ ID
Number Unstimulated | NO:1- treated: fe anti-Mullerian hormone receptor,
Homo sapiens ribosomal protein hypothetical protein glucose phosphate isomerase interferon induced transmembrane cold shock domain protein 6.3 0.26
Accession Gene Control: Ratio SEQ ID
Cells control gonadotropin inducible transcriptn complement component 5 receptor
LL NL cc TO FL LC ec OT FL a OT FO protective protein for beta- 0 cdc NF cc NL NLA
Accession Gene Control: Ratio SEQ ID
Number Unstimulated | NO: 1- treated:
Cells control
CT wee
[00116] Table 31: Up-regulation of Polynucleotide expression in A549 cells induced by Formula A Peptides. The peptides at a concentration of 50 ug/ml were shown to increase the expression of many polynucleotides. Peptide was incubated with the human A549 epithelial cells for 4 h and the RNA was isolated, converted into labeled cDNA probes and hybridized to Human Operon arrays (PRHU04). The intensity of polynucleotides in control, unstimulated cells are shown in the second and third columns for labeling of cDNA with the dyes Cy3 and Cy5 respectively. The “ID#: Control” columns refer to the intensity of polynucleotide expression in peptide- simulated cells divided by the intensity of unstimulated cells.
WO (3/048383 PCT/CA02/01830
Ss £ < ~ 0 oN wos |e — c 0 w= at on |o6 [oo 0 : [an] °o — — — — .. © > £5 a 2 “ ~ NE pe a = < a) <t ™ Nz ™m = 8 . © ® L = 0 oN = = =z wn a ~ r~ < wv ae TN (SN oe 2 3 “w B ~ 5 wy Ae i 0 a = <r wn jon fi r~ = 8 . © © E wn 2 © x No |= — a = on <r o~ o Oo Iv | O \O - ° (3) .w © } v5 2 0 |= 3 “ pt © (=) =~] «® ~~ — — wn — ~N = 5 1] 2S uh <r > on ON ~~ <tr
ES A = 8 N Q = RNS = g Q fe) Oo |o o o oo |e o
[5]
L] ° To) To)
ES == = 21 2 g QO o |e o oS o
[3] ! } .S [ wv I) E 9 |o = ' ! © 21% 552 BIE —|8 ¢ S15 IE %
S15 = ES 2 als >| 3 |3 (3 |S = = Ele FE |= © = Eg |€ |e (8 2
S 2 |= J |= (0 ¥ie Elo |Z 2 |g E £ |° cS ig cs |e S aS [30] 8 gv 5 8 IS = S R= a. 3 = Q Qa. = EE Jo —~ £ |0 N gE 2 ] °0 vn 5 |” c aN |e =) = oS 2 o O° =] ~ on < 0 : gd El © S 3 El | IRE| R g 3 pA NSIS] K 8 S leo © Eo) < on) x |< >< D oD | |< =
< °
SE Soo © - |e 0 = a £ ~ |e~ ~ ~ |r~ O Na) —- 3 . © ok SI: - o |e [7 |~ S
EE Agr a § << |< ~~ eT (VI bot [oe 8 .. © © £ “| NA <M oy = : a sg NSN a Oo | ~ fo 1%) . - ~ £ NW: Se < 5 S a £ ~ {en ~ =I Lg wy = ws 1%) . o
SC NN o Ne [2 oy 0 2 2 £ eT [a] w NTR [Ro A No ~ = — & . wv CZ on |n = — [ov [nn jo o ~ a £ ~~ | - NN [|e ~ r~
J— 15] —
S un a | <r Oo NN 00 = — |N N Nn oN = s © Oo |o o oc lo lo |o o (5) — e = - hog 0 IN [N10 00
EES A AN IN j= [N < 5g © o o Oo lo Io lo =) [¥] |/M < {0 m 2 le IB = . 8 . [9] |= . ‘aS lo Q = 4 > |E NIE TIE 82a lE|8 |g © © cE Q le = |e © | |= = |g =
S EI S212 28 = lg|¥|g|2 lg © = £ ££ Ble 8 28|l2 vs |e lE |S 2 ica © w
S | x |s |= Q jv (X |Oo = == — vo © (a © =] © 5B |d o (> Ss Lele |E |& & la © = ©T 3 |Z E © 0 a i= i |3 |= 3 © a | = 28 |= = cE 3 |& |< o
Ss — oo ~~ ~t
LS w 3 |x EO ~ ~ 2 £ bell Fy har A “J MR = Q =
Pu g E << [Mm 0 NB |= hn 2 = : 3 oo wn NT QO A <e ce Z CO A a nn © Mm NY RY << |< jun) = |X |< |< < <
Ss © -_ 5 |= ™~ ~ EEE SHEERS AJ ~M . a g O wn wn VaR [YOR [Vo wn Te) “w o . os £ \ on 7) 0 |\O |= ™~ <r a og | ISN] © A it | ™m oJ = [=] - -
S oe ° O ~~ a g [= — ~ NL SN [oN] o~ ~ .. © ~ Ew o ™~ aN en |r < ~ 2 |= eA ~ ~ je je< ™M t~ aE “vw © on © I lo | © r~ LN on ~ a 5 on ol <r hn | STN wv CF o » © ~r [oN] \O = ~ [nN NO ol oS) a S N ~N — — g un w on © [fn | 00 00 b=E ~™m - i Ai DA << ~N g Q o o o lo © ’ o o
Oo
A }
SC eo | un re) INES) <x 00 - Pn — ha NNN ~N ~N £ Q |c =) f=) SS lo lo o o
[5]
QQ 1
Q - = I= [= fos ol —- aa [e) g [=f = N pe = 3 ~My ~~ - o ‘= fo 3 © 2 c QL oe T= Q : oc @ -— [04 E [«] ~~ Q oo <S oD = [2] = x |e 8 alk 8 20 Cl I © 22 5 © - [9] — = I [3 [53 = 0 an Z © E I) BO o — a oO I = (= > 0 = Je) Oo [o}
ES 0 oF 8&8 ¢ jc aE |EBIE g &|5 2 5 - a. =) E 20 3 > « BR [] on
CN) @ 4 S = eS 5 00 ~~ r~ ~™ \O =] » Ve) Ve) oo ™ wv 7 Lis MM — o In un < 2 2 Elo wn oN oo | |~ — 8 5 I S S| SEB = g < Z |i tn us| wv | jo N < < < x << (xX fan] <
= © : —- = N= = oy 1°] oo ~ ~ I a E |v |» wn << I~ ~ <r <r ~ |= ~~ 9 : . © > Em |m o Tle ol; © 2 + |T a £ | |< SN Toh — uw o CNN -_— OQ [¥} .. © © Eo |= r~ 0 00 he. ~ 00 a 5 Im |v a = NN [ae] on J = NA 1% © co [I~ ~N ~ Coe foo — x d 5 wv ~ < ) ! _ ) ] , 82 § |© |N <r — |= — Ne) Oo wn : bat “w B® — o
Ee | ~ s on : oN a ££ =~ a « © joo wv ~~ x < _— 9 © . . ° i= (=) Lp 9 Qn N < ~ wv a & |» | Ne) aes Ww ~ ™ ~~ —_— Q
[5] —
Sn |v ~ < > [= = ™ Te) < |v = = (A (N ~ <= - — — |= § OO lo |o = oo o c o o |e
Q ra en |n |w ~ © [me on 00 on — f=
EE rl - - — AN N jn a <o co |o o o o o lo
Q
Yo) = 3 g => ° = ce |e (© < c |S ZT ~ [8 3 IS — |= = => a £ | | [8&8 & +o 5 © |= = |% 5 |8 [2d oc rT Id © LO OY = = lag ©
Q © |E In lo |lE EE B12 |e 88g = |= c |E|~ BF 8 lg le 5 o < 5 | 5 |@
X |x lop = [Bd 2 [XIE e E oO ®(g 2 (oo = |Tv £ jE |e & IN al ia 5 £ | ££ |& 218 <= a 3 |3 8 [2% Se a EE |5 8B |= E lo hv CS « o£ |= a = o° 2 3
SE oo |= Ne)
Ss 5 |a I ] NR N (h ~ nw L | lon un << {on ies o << I oo 2 E |= lo <r ~ |o 3 = ~ wo IS ] Qo IN — — jun D | on \O i . gS 2 [ee jo oo Ea [= aN — aN < |= < < |< < Z < = |Z
.e ° . [=] . —_ £ <t < on aN AN | — fe . a § <t ~r ~ <r < |< < |x 3S ee S ~ . 8 E ~ uN ~ 00 0 | < 5] .. 8 © L N=) N wv — ~~ Joo on =) g IN N ~t <t J lo ~ & . E ~ £ ™ hd oy — NR T jn
Q WN a ~~ ~ ~ |< To IT)
[3] : .. ©
No £ r~ © 0 ™ Jo =~ 8 § ~N <r \o ™ BU [0 J |= 9 .. © pi = — ~ < < |e < (mm 2 5 ~ 0 mM <Q Mm (N — e un O oy oe) £ > oe: = ~ SN Q ~ g o oc o = o =) @
LJ
3 oC a e on ~~
E> Q ~ S [= ~ |=
S o o o lo oo & oP 3? 2 © lo 5 50 = oc = S =]
QB 5 € Cig =|- 8 0 [8 c |E | =
Eg 2p 2 £18 a8 2 5 (8 5 (2 |x = slo Bl CS BE vw|g ls 21218 o |B = la oO Z Bl 5 | 2» EE oo IE 0 2 2 HS) bs oo = o o o 7 [e) [3°] o [ = = hot 2 |= & | 9 8 |5 = 0 a |a a 3] = e |5 ~E @ p = 2 E 3 8 | 2 5 = 3 a
S Q. o
SS r— <r Oo
Sg 8 2 Sos sR w = \O wv |S 17} [= — o = 2 0 [00 $ E <i N S 3 S IB S I3
Q Z s oO <Q — oR = KR > . < <3 4 nn | TR [=
Zz < << = < |< jo J je)
sS ©
R - 0 |x ™~ = = ~ MM = on 3 3 =) S 0 [ap] [ag] on on [ag] [ag] [3 . . © :
SE ~ |= b ~N Q lll 8 5 < |v ~t No) oo PERRIN >] — .e [=] ® 5 SY = — =< i: a aN ~ Ise) oN Te)
Tt [=4 [>] .. © ~ k no ~N a S ™ = i 8 5 < | ve) < ~ on < i
[3] . ©
R= nN ™ n — — — a c 00 |™M on <r a} r~ Vo) [=] [= : [3 . © vos “|e oN 3 o ~~ “ c NN 5 : 2 5 5 ~N a < & — e wy 0 {e~ ~N on oN) <r — = NM AN — ~N — —
FS ® o lo oS oS o o f=
S : — © = mT oN <r r~ <t l= = RAD ™ < n “a NS g © o |e = =] o Lo | o |e
[3] [} 9] 2] - LM =~ D — 3) [=
Mo hE ST o £2 SS ££ 3 |= = 5le |S 7 £ o |[@ 3 a 2 = 12 = £13
E 28 |S 5 2&8 BIZ ~ | 8" 8 Bis
Ss EES 18 8 EE [© 2 I= Zs © £ ZF = 17] Q ‘ah esd o-— < by a. [=% 2 Q s a. £2 Qo |2 I= te 73 = 2 lo = 3 2 E jo 2 5 ee > a Do a |= on £ 2 — ony < @ = 9c = s
S un Te) ~ ~~ 2 3 o- [5 50 ¢| 3 ¥ 2 E ~ |= 3 < 0 S S |e @ © |o oa — © S 8 |©
S = [oN < [en] ~™M [a=] oS © . & Z = | vy 5s o 3 |X = |< PS < = < D |< oe °
S 5 ~ a ~ - — S SS . a =] ag) on (ag) ag} 2g) (20) on - 8 . © . o£ o — <1 — ~ 00 5) a = — ~ <r (ae) ~ (eo <r fo [=] (3) wv © ® © © ~N wn ~ ™
I] Vo) 0 wn ™ —- 5 2 § — ©
[5] . O° ~- k ° N ~ A o < a = on r~ 00 (V2) <r wy [=] [=
S
“ © © Ek ™ nn AN io) ~ a a a \O (=) ~r (oV] 0 on o~ [==] [=]
Q
. © “
SAE = DA : ~ “ «© N a Ee ~ <r a ~ < < IN
So [=] oO . . £ wn Ig) ~ m= < on a) = — —- ~ N — - — . S ®] o o o oS o ) o
Oo vo =m <x 0 ~ un v— oN fo = ~ ~N - Mm a] ™ ~N £ @) o fe) o o o lo) o @ [V9] «© [+0] = c = 2 wo I+ 8 EE |= < 5 o EE oo [8 a |+ cs © |o = Z O ja >» |la S
[3] oO — Cc LQ c 4 Prt re pal = I] > Pot [@] = -o m — c— Q a. o. © Q — £
S 6 BR Els SDD Lis iF = tle 9 5 = = 3 |@ < o> 818 9 |v & 8 = [3] [3] c= = |= O < = [5 LQ |e 3 [3] N= a © Q Is 9 (XM — ad a a, ££ 2 315 8% S$ <|E EE E = alo Q |g hY4 [@] > =
E ono |© hs = oa |< o [3] © es ~
Se 3 & A ™ 1] E — <r 1% [eo] [@, r~
Oo = NR) tn -— AN O — on 0 © Nl < b= wn < © . < Z {, — ~ m oo 00 wn ] < < x < [) x io]
SS © . —_ = < a a io EE EEA ~N : a £ 4 ~~ |e aN al aN |e « — Q ’ i: © on fe
SAE] < : : wy on © | iN 0 a £ 0 ho <r aN Nea [es O
A) . ° ww “a < lm o ™M 00 0 hat se El | $p| 2] = C= o
[5] . © ~ ~ £ > a © N = | ht a ae} = 3 ~ ~ < | <
Po
[5] .. © - © 5 - 0 RQ ed) AT Ln A wn a g = on <t o\] non in on — bs} : . © nb 0 on © wn \O Und LB on [an] g ~ ~ ~ on fo NE 1s oT [200 3]
L bet -_
S un ) wv {oo — ~ — It lo wn = - i AN oN DA Ap he - : g Q o co |o =) =) co lo lo o 8 ’ — em 00 ~ wn <t O [00 [mM fo = Ao < Oo XN i hs g Oo o So o f=) co (lo jo =) (3) on TN : LY © ~ le 2 2 = ® s |, 2 |e a .
I ‘D R= © [= QL be > oS a. — L 2 hd c |= | Lz |2 «| 50 5 21] |8 xg & - sje 5a 8 2l< 2 5(2|2|& E 8
Oo a |e c c j= BV Ie) od [~~ Q >> | [= Zz So oO |= © | (Oo = D2 oo ol = £ = [od — jo > C— c po = [5] |[& (= 2 [5 IE © E 25 © 8 ie la a 9 phony iba 1 = = -
E 2 |8 & Nn © is 2 |e > la |p 2 E
Q |= o — ! E oh SS
I] —_ <t © — on = ~ 00 3 © In Sls IB 2 <£ nf ~ — PA = Ne
[7] E — — — 0 \O
Q — I~ po —t \O o =. [eal ~~ [Z] = O o [ng aN I | <r < o — ~M = < |« - — Zz |< |Z = on =]
NN = c © a << — ]S a cS o = gg 2 =
Ar “v= =
ZS En — ~ — 2 2 538 8 = © 2 . a § | ~ oN ~ © o = = 2 >! a — ve = £ 5 a = ss Ex we © EE = 9 wu ow a £5 2] 2 4 g 2 5 E 3 8 § [m 2g] ~ — © © = 5 = 1] 2 85 & © § . smo - 8 g oo 2 — ¥ 3 5 [@)
A 4 A 2 BZ © E |n < S 00 mE = a ev on <r 00 s «© 2 = 3 _— Oo I EAT. —~ B= <Q = a 2 2 9 5 J
E oo N = . 3B EO 5 8 ~ leo 00 a ~ € 8 ££ § = t |< ‘ . . a 5 Oo = a <t t~ 00 < ou LY => ao ©
SE 2 AZ 2g
T 82 EE — tt ww © ¢ 2 « 2
JE ~~ on oo 3 = » £5 a < . on TT § 9 ~ 5 82 5 © — ~ —_ £3 8 z 2 © 2 2 a2 §& p= T 5 < @ w £ . °S 3 Zz 0 4 a & | ~ & > oo «»u E —_ 0 ve = = 3 bs) < 8s © © = v oo Oo £ E353 5 © = ce © | 8 =
Eg wn |v ~ LC eg — = 2
EJS S 2 2 2 EE
SS o oo @ = E 8 5] I SRS & TY,
S23 EG 3 : $ Fg 5 2 8 ~ » © 9 =
S eo ln en Ny T eo gg 9° TF 2 = n(n ™ ha ES gg = ou = [=] 2 LY LL 0 51 © @ © © YE 2 @ = 8 23 ££ 8 = 2 Ue « 2 ££ 9 & FZ 3 on | 2 = r= 4 © TT 2 wv Ea c |S 3 SU |g 3 & 2 98 g 0° = Js © 2 |S = Som S$ oa x
TIE = € |B RIE 2 Se £ z 2 a = £ |lE § © 58 © se 5 2 3% ¢ 3 oi? £ ale gj = wm ce un @Q gE 8 Fle lz s cS wv Z Zu = 5 | = gE SC 3g SS p ® 50 =
Lc por} So © @Q ° wn ° Bo 2 2 2 2 2 ¥ ZZ o = =
I: EB >on & £ ov lo S58 E>
LC 9 IB x= 2 YY 9 2 2 8 nn ~ a oo + 2 gg BB gg E NY <r 00 NR = ££ =z oS 3 |= AR va) °S TT wv 3B [1 [en] ~~ oy Neo] Ew Sg ° «< Z | =H) <t — 2 2 ou ££ 2 = ¢ < = a a gE 8 3 FE =3 2 0 = £ ©
EC w= XT = — £3 2 38 :
E53 2 o« 8 - oo £ LL 7 3 : 2S § 5 ££ a E : co : : 2 38 oT & Boa
& OP —_ - 5 SE AS Ld ng It < x |= ONIN . a E ho A J f= NI (V=) 2) ~ 5 lN (FoR [NI IV) = 3 . - © ; ; Oo : Nn vg a £ NZS To i 6 |N jw 0 |N - 9 wv ® ~t oo — - ££ IN : | | 1\Q : QI ~~ N FI Loli Ly I Lp a § |v [Tv |v em = < | [VaR oT hemi SN LOW (Ve - 3 $F I~ = - E OT ed a «Q ~ |® AN (I~ joo (je Oo a £8 [x jm |Z |n < a NJ [OV I [oN I [oN I (NI Fo =~ 3 4 2 < |o wv Yo) ~~ ~ - 5 | s IY IN oo |= ees 9 a S|] [2 |v |~ |X XQ |= Nn en (8 |e — © a E oO joo |J— joo << - & : g : : ; ~ w= nN IS a 5 ac BL BL S = oo 00 r~ |= |~ ho - 3 — eg un r~ 0 | o> ~ © 0 jon foo ln un loo - — So < i — | [N= (SQ = |®) oS co lo o oc lo oo lo lo lo |e [3 —
S mn [on |x 0 0 te on ~ No f~ : ce Ae |= [N — N = | — Sn 8 O | |o |o o o o |e o oc lo lo |o
[5] > = ’ £ Ele |Z = ce ¥ £ ‘DS
Q vo |v |2 g = <r ] Ss |=
I< 3 J a. 3 = I) ° c Oo [= = = c ht [= W 3 00 [| = 8 = [=] edt Fr a £ 3 |[& 12 [|e |8 5 5 z [© £2 lz |&|5 [= |& 2 lo [gx |E I? 8% oio | 2 | |x | |® sc | |e |& Sc a |k c = |e [oo SENET] o0 [o] — —- [an} [e] < [34] 4 a 2 | |x = ls 9 |& x |g 2 |x | = ec © le [.€ [€ | © (oO cs |3 7 | © (© |e 2
Sj (3 | [9 [0 2B leo Ss lg > |3 |< a | |» < © [8 |&a = 2 < [0 | |& = ec |X o = E 3 —_ S |Z = [94
WY, ~N 2 ES RY = |= — = | 9 Te} 0 wn O |N ~
S 3 8 |= |N 3 00 QR | o 2 vw LIF Y= =v ~ o [© © (No lo 2 IR 7) E t~ | |= oS O fo —_ 1S (aT [= = J Pe NE = Io . ¥ 3 |v» 9 |= EA A co — IT 2 [M2 [un
S —_ oO |e <r ~ Oo |@ Oo 0 IQ I 9 |e 2 Z [0 ®» 32 |Z IN ~ |X 2 mo |¥¢ < |< |< [Zz [= = oD |< < |< {€ X |< (< se 2B
Lo ve 0 |n SN NEE oy a E « < © < | NOC Nm 0) . - =} 2 = ae ~~ fo ol Pa i Te BO VET gl = £ 0) «| < 12 2 @ in RN |< |=
Q 3 on BE 51 so 8 = & \0 o |o ENE I NE a a £ N=) a | < JN [0 NT [8 [2m [2 fen 2 ° _- = BS
IE oy — | Nn |e [© | [= t= Jon jo [9 |o ce To) aN No JN [To RNR INCU Foo [oN TR FOS FS CN I FN I TN 2 3 — J = on [aN I 8 0 [a] — ~ B ~ < lo Testi MINGIz =] ve) LU < |< © |v |» =m hn Ye a 3 . -J
I=) = E r ~~ |m o lov ja |r 0 |= = |= c Oo O° 0 (oS [VoRE (Vo NN [VSS (VOR [Vo FoR [Yo 2 [an BE 5]
LJ
2° FS CSUR Fo NO Ll [= NUN [SS a ES £2 N RN AREER RERKN EIS g © o oo oc lo ole lo lo lo lo lo lo
[3] . ° 0 lm ho fs js |= Joo
ER 2 FRI ZRRRERE MRR © oS I= [= oc lo Io lo io lo ole lo
[3] [y] 2 |E £12 |5 2 ¢ = IE z 28 Es g = |3 § |% £10 212 5205/5185 |g 5 12 8 | Zid Slo 28 818 lo |B |S g |= 9 |g 2 o [2 & |= 8 2
Lo |= = LE |€ oo [8B I c |e c |3 0 a 8 = = 18 jon Ix | Ix |X |= [2 |S
E |S w= [© c BB = | © |g nN [| loc i2 le £ lm 3 |e © 8 | [© |m [3 |3 |< [3 |«
EE |= = - OO | 1 < © | a «a [0 |€ |x ©» o£ |E «|S Iv] a | <a M 4 < = of g 5 = B 1 = 3 som — — 5 2 1 2 12 Nn IR mE Rl INQ I= = £ ~~ wn [oN BI [A oO on ’
Q J IY | VR a ae Bl [= fo
Oo 3 2 pt Ng o |! S |= 5 | [=
Sz 2 a |Z ~~ RERELDRBEOR < BS = |< Ala le jz a |< |< alc |D
<8 - = No No Eh Se Yn a & Noe jn hn STEERS ~ | oT (NI fe NE TON . = S g ? % . EE - nN RS > |N aN pn I hE a c aN nn | | via SNe | | |e a 3s aN be [3]
Ww © - = N Mm Mm | x [= NN Mm a E IN] < [oo wv oo nen I a WR [Vo [0 1) — 9 © - 5 — Nn =e a | SN «0 NN c SI [SSE ER LN Mm ~ al ~ aN |e a so — 1] - © - 5 Qe Ne x |™M Mm nN QI NN a £ < |v |N <r a |oo Mm ~ NT |» - 3 a4 © —- E Qe vm A oy [oe og joo | Ts c Tol (VaR AS SA <t |< |e aT (ao I aa Bl [a2 2 3 — 9 — eS un 0 [~~ [ZT {Ny on lo ~ [wo ~~ f= = - ANY [NN NM <Q |= — NNN
Q oo lo lo io oc (Oo oc lo Co lo leo |e [®] -— © eo aa J Sn [= NF Oo (wn on 0 IT [> |= - Ne | No Mm | N xT [= mM 5 @)] o lo lo jo <o lo o o jlo lo |e ’ (3) > 9 |S RS 2 Iz g 3 »n (WN S |N Is} 2 < oO = oi = — —
E12 c £15 | QB ce |alg « |= S |& |S 3 \O .— Ih) .— =] [5 Q ° £ [© a jo (oo |= | 9 (9 ls 5 |o [2 © [© [> an 7 |g (E88 |v J | |» = |€ JE IE [720 (= Pol |X ji fe 9} hl (© QL | I] ~ (00 [=]
CIN ale je | IN alo | 8 |e |o ce [2 |& 5 | 3 13 {'® [| < 5 S lo s [«€ 15 2 = > X < |3 El < |o 0 i= ray
Si pV 2 ne - NN
I. o ~ FoR a wv Oo
Le 9 a RIS p=, — a J («J pt w £2 N= (00 D |= 0 Isr 00 |X |X = — I~ a |Z oS |m <+ 2 o° Qe 3 . g = © |= [© ln (= [= SIF NI [= [= 4 Z AN NE I a ¥ 1M a |S ~ [@ |@ |= < | |<€ |X < |< < |X DC |< |Z 4
NC © - £ ~ NEE EE Al A : ~oNe ~N wv a E oo aa TI (VT fo NR EN py Ns [em ~ ws - 3 . & © o <r <r © - = Js 2 L S 2S | © — 1 [Sy ) ) . a § ha aVINN RLS [NO Po = at TI i A aa} - 3 os Ir)
LE i Dt S |= Mn f= \n 0 ~ E oN pS PEN NO | ~ ~ = 3 ¥ 2 - Oo vo [NY © Sy [00 |= N wn a £ < < jn [NN w << |N 00 ol = 3
AP — - kL : un <n : —- N ™~ oC a £ = aN ~ |= S ~ r~ o ~ - 9 4 © -_ & © Qo (n(n <. Mm ™M N — ao 1] (ag) [a2 TI [a TI [ao NN [4.0 (a2) on jen en on on = — eS wn 0 AN fe fe oN IIA I BC RN Nn = = < | N < <= [=e N AN
Q oS oS lo Ss = Cc lo |o <> to)
Oo —
Eg = 00 ~ | |= |= oN ~ [00 |e ~ ~ = < = NN [pn N NINN — AN
Ss Q o oo jo jo = o [lo | o o
[3] = Pe) 2 = “ % 2 |g ~ 5 N E S 2 |2 8 3) 2 12 |8 o |B |< E Ee 818 id = © oO. =f = e R= QQ. = | ry 5 Ec x [3 |o0 e = 2 |g —~ |9Q ©
Bs — ~ 3} oo Oo c Q £4 — = oO = 2 [8 |= jo [8 |2 |E ol BIS (88 = |a &
SZ le 8 wv lo £2 5 2 |= E = {9 © «© = y— o Q - 1 — ~~ by = = s [9] [3] 3 10 ec |= wn SS QL [i wn La [oR
So |S [2 @ £ |S | << 3s js |e pe = [8 |= 8 (& (38 e E 0 (© jo) 5 = a | en wv |= E 3 © | oO a {> on) Q [=I IS = = ¥ < A . x
Ss IB EN ~ R13 © » LL o ~ 2 lo (= Ne) = l= | =) 4 E N - 5 |Z lo 132) 8 [NI F-4 = < Z v4 ~ |= |[O |2 a S Ma — 5s) < x [Zz |< [< = < |< |< N <
Y
A = <n a < TS a — wn = fond ~ 9 oO © 0 .E —- = aN OAT DE el ST DE TE 2 = g
A & nN nn mn jn | Ss 3 FT © O° . [=] oo = = £8 2 _-— a 2 s&s = § — Q = © 5 a
E © “ £E S 2 «= x . - 5 A SAE PE SE A A LT A . 7 ® a © £ ~ |< YN [NN w 3 >)
Q 2 ¥ 5 © Em - 0 2 2 c 2 38 = 8 = 0° cc © OO © 3 & Ss E O° 3 = £ Jim [wn Jeo |v ~ ~ oo 2 2 2 a § © iN NN IN] O £ ZTE = = 9 E 8 ZS vw g = x 3 < [>= Bd .e = E ~ o + 9 Y = © - & No ho [oj [Ny wn 5 2 8 gg => a E a NON [Ns Joo ~ = a § 8 3 = LQ 5 Oo -C ZF ~ 2 a 8 hw oo uc es = TT § gg £ = a 2 o 0 ¥ = 8 = w - = 2 mS — | jn Ss = e ££
Nd | A~7 lAs S| (en Pa = r=] a £ ARMS [od J Xo I pl ag} °T 3 2 = o - gE 5 © 2 °C = 0° £2 2 a = & a 9 TT = a 29 - 8 Oy No eo nn IN © 3 Zz © 4 a E NNN NN IN NN @ a x Ss €
S wn E — © wR 2 = 5 < 3 BD 0 =
LV oo O 3 gE E gg 5 © eS wn © |N jv [oo (In oO wn ge © © 8 I
E = =a = I I le: S ¢c — = 8 gE © Co lo lo jo |e oc |o ‘2 5 © 3 = 3 $ 2 EE o 8 vo 5 © 2 x ao L ££ 3H ow — EE EE = e en So iv | |v jv | Jo @ — =
ER SRRRBRRERERER ® 2 z BT 2
EO ooo lo lo jo jlo jo ES g 2 2 = = © 3 833 CE 2 9 2 23 = - — = E oo 8 . oO & = e = D > cc © 8 = 3 = 3 2 3 © 2 T° 8 «< < < = 154 & 2, = gg © hal [= Se QO la ia [eo] = w= © a > 3] 2 I |® 2 |F |S |x © z 2 a = 2 eo |= |g [3 [2 [2 (S ce 2 oc YU BZ
NO te 5 = SQ « 32 “- c = OQ |B |g Is |= |= e = 3 Z|C |E |= |S |®|3 cE wz £5 9 2 8 |= Lo |= = : Pl RU IEINRB] 385% 238s =] p = a Bw 2 2 T° = —_ Io) = 2 ££ « © ££ =} 3] 2 Z » = © « @ ” ft EE 20 2B & = 8 = > 5 co r~ AN \O \O Wig Oo wv T
Le ow ~ = 8 | O me TT eg ez nL on <t I~ [oN] v= = = 17} [aa] o ~~ lon [© © O © ©
SE TRIFERPRBRE| £35223 T $2 SBRLERLRE| 2 ozé 22 es Z wy |= joo [@ | S 1M ~ © ww . ZZ & x |< (KX |< |< |Z |= |< ST 2g = 3 —_ Ek 8 © 2 3 > - - : 25832 << EO = uv £ LL ZF 3 2 § EE 3 E . E 5 2 9° 3 ev BS gM]
QE ~ i: SI ST DAC ET En 0 | |m a 5 = — ACTIN CN SV I hon hemi NO CE aS NI _— 9 vat - = ~ o ~N TN LN I [TR
TE &| 8 SIEBER ENES ol ht : a § [aV] — —_ |" LE PCT MVE SO PN <n - & °F © jo «a ~ TIN ee Te TT SEIN a § on od a NER N=TN oN [ NT LOU [YoU [FoR AR HE EN _-
LA < o lo
IN wn I OT Sc LST (I AS Lo Cle © a § 3] lo |» [oo |v [of HN DT (VN
Ld
[3] & 2 ~N = << on <t
NR Go| 5 3s ~ 2% —y
O
& © vo) fe) A joo jn | jon jo |m lo = _ NP I = boc bc be — a 5 on on OA) |r (emt fet et |e f= {em 0 {00 [oo
Dy oJ —_—
Ee =n wy ~~ ~~ ~ |m (> joo o~ -— lay jes = = < c= ee < NN g QO oo o S oc lo jlo | o Cc lo & — e mo <t rs wn f= Ir oso lo (r~ Mm nn [N = <Q = N= YN er en fe —- |@ N © o <> CS oo lo lo le ie |o oO lo [3 [=T} -— ELE |e R= =. |E = gs I5 [Eg |B ~ c Tv © e 18 |= |e [=~ Q c 2 | = c |e |e |G | [2 18 |© c |2
SE Sle E|= £ (3 (2 (82 | |&|a |Z |e 2 |u o Sx 2 |2 2 oo fo 8 |5 lo [8 [2 < |2 |8 lo | © IE |g |g 18 YB 2 |B vic (8
E Io = | 8 |¥ |[¥ | 2 |¥|8 IZ |g N |< 5 «© a |8a ale |e |e (2 |& |= |e lz [=EN(e 4 = = |< [>] S13 “© lols |° j= J = - FANE 2 |o & & 8 ~ [00 \O 0
SC ou bars a A I EN =I 0 |X nw LQ on TT == 9 |8 =< 2 Mm NIK 2 E = pe sq [J [SVN (SA TE [= DG Pon [= PA Lod IN 43 oS = < [© hin [20 12 |< [<8 foo f=
S 3 LN I —_ OS |S lo |S S = [25 es Z > 00 COR NT A = I EA PR PR ® |= pd >< < |€ [€ (€ |< |Z |Z |< 2 1<C (<< a 5 — |" | a cM on ~ [00 a © a lo el ~~ RUE IE ~ . I) bt 9 - © . a = o | [T © 7) x 12 lo Noli Vo) s Mm Re a} ~~ 0 I= f~ wi |oo a H pu — — — — [3] oo °
NJ © —- — oy [= |= 2 eo = ~ <r Ne) < | i RR [oV] a =) ~— onl 5} = 3 ~ a k AD SE Lh ~N : Mm (x (nn ~ NN a § =o |e |e IN wv ~ oN |e ~N — [3
S 8 a |= o x 5 ~ ! . < wn A= wn NO
J ASA a <t n= © jn a S ~N — ~ — _- 0 o © —- & ~ wn i] YS Oo NOY BER (5) [= oe} oo [oe} r~ ~ |~ [Wo On a 3 - 2 -— gE wn [> Joo — 0 on rs | o |= = mM <Q |e NN = <Q |e |N aN g Q o lo |e o f=) oc lo (jo oc lo (5) . —
S = oO ln |e <r <r — {m= | Ne) es — NN wn - NYY = £ Oo oc lo lo o o co lo lo o [¥) oh) = £ |. o m LE = 3 zz 8% ES (8 | ; |E
NOR 3 | = ‘Ds |= |0o |E © 9 [5 j= co bast «< O lt = |= = 7 I] a |S ~ 4 4 a |C =~ 3 [@) Q |= |O « > = lo 9g (2 ec © |, o£ |= I= | = & (5 = 5 |= [5 3 DoJ J = SE BI A= = SE e Q 2012 NIE 22 ££ |2 © |c | 12 < 5 |S alg = |¥ |v |= 5 2 |g Sloe le F 2° a |= ce © [= lo 52 a |& |g | 2 2 |e = oo < - 8S |la » jo | | © ww [|= © | 3 1 |S = 0 6 le |= 2 ££ 9 |B = v A le) oO Q a |. Lo 5] [ST fa » = oO bet bd = bot ' Q o Part Q. a py g MZ a |= gE |= = — = £5 wn ho ol
Le 9 AR SI = 3 wn a wn LD wn |= |O \O ~ DN — 2 g So lo |= % = N= ~ iT ed [a2 J LY A TE ho) \O [oN ~ [= oS —_ NO : g = o © |e oo oN a N o [© < |< |< = p= < 8 |< x |<
-« S a on on © a = < NSS ell woz ~” oN IN a £ hi 2 = IN < |= Ne) <
I [5] 4 & © a & ~~ wn 0 I< NIN ™~ ™ |Q a S [Ve 0 wn {en < IN 0 On : — [5] a4 ©
INE ~™ wn Qo 1% Mm |™M I. Ln A a a g ~N ol eT a} 0 | (N] ot IN |e buat [5] —
RL a & 0) Q © [N noe < NN © a g a\] ~t len ~ iN Ne) > I 2 BR 3s)
J
(®] = I Oo —
R= “2 ll od \ Ney |= a £ or - 5 |™ NS Nel ON bt [5] & © - 5 00 0 “a [™M a A ™~ ~ ie a £ 7) Ww nn wn [= <t < |= |< bt [3 —
Ag) ~ oN 0 a |m on a | oo = ~N QS N NS —- = ®} = et o oS © o o oo ©
[5] — . 2) a |= < |e fo 0 ho ho £2 3 = IN NR: Q Es |= g Q (=) SS jo oc © fa) Co lo lo
[3] @ on
[72] ] Q > £ TS © 2 on 2 5 8 1B BE. E. El. [8
Q e |S ww ® [3 |6 E [3 | Ol. 8 (E|5 © 3 |S £E ~|ojx wig [8 EE © |g |g
Nn = =n fe c (8 & le i [SI = e |= =) << & 2] oc oe |S Q. i a, 2 loo CE oO |x |= % IE © |g © [¥€ |8
N [= Re] [) > c |= 5 [=] wn = = ce |e
I £ c = |3 [3 © |3 |e & ws |Z |< 4 > 8 9 v O Fo D > a g |¥ “5 |B E | |Z i oe o = \O [3 I [= NI [=] 4 by 5 ~ 00 NTE PC (oN =) 2 © | r~ A j~
QO 3 = o ~ 2 RP = Ss 18 < Z = F oN om ~ na |R < = = |< oD << ES < |< |<
< © aE Z| EEA be ey |e wn o (2 a §& DL (Vo) on Io lo Jo < |= To) em NY v — S s ° ~ . ~ 5 Of |= oT 2° Mm eT = ~ |» 0 |i |= hn woo © I~ oo [an] o — po [>] a4 © a & oN — | jee |e ~ 0 > eR a E a [on CNT = NI IV SO (Vo SEAS NN [eo |» - 8 -— E [®)) on [ap] a 5 0 |< © NE ER =) Toes = oj jes - . . " f=) . . [oN] . . foe) . . a & a jin NS |e (er oN aa TN PACT [Yo a)
S © ~~ No)
SE o 2 on ~ OS fm ) f= nn
E aN < os Nt SFI R (a) [=] — — oN - J -— = Ai A heal A eI Mm iN |e a E < |< < (|< |= < |= << |< |< - 3 —
Se wn — [oo + [on on 0 | m= 7) - A — |= — |= N < NY — | =
FS @) oc lo = J (=) =) o lo o |o o [3%] — e =m To) 0 |v nn |© nN 0 |(— {Oo [=m = on —- RE hl A BA <Q | AN = g @ cS oS Io lo lo oS |o co lo |e [*] ©
Q — = = [Up]
Ss 2. |, 28 Nie | — |e |3 2 le |e la
Q [~~]
Eis 21318 32 Ez [ESE 2iz|8 © 3 (2 |e &jo lg = lo |B lela = |e l2 (2 [2 |E 212 wit |S & 5 18 |E |@ © |g |& c |e 2 | oo | 8 | X |O °0 jx |x [© gle E212 9oi5 |g |g (> E [¥ = EE |= [E |&8
EE BU |3|« ££ [93a I5 ig 5 [3 |53 [oc = a |.= =} = [e) § 5 2 5 E o£ ht > ire) ro) >= od 5 9) - hs 9 < [oN] [SN]
Lg 9 NI 0 = fo » 0 (en) on oo Th on IN o © I iN 2 E = |» mm lo |7 leo ~ | S | I wo g 3 SIN SA VS IN 2 |= LS ER —_ & Zz x 2 a [© ho a O |= = lo | |o < |< nT EO FO x |< Z [D0 |<< [XX
<+ E Ml
S lr~ [nn To (Vo) ES |e won in < |en 2 3° . bt [%] “- © a So |™ wn Se REE ha NT . £ [nN (mM oN not a [Mm [f nL
Q I=) — - J - a 5 |= ™ © IM ~ Mm Mm |e nos £ lm (nN nm ~ aa ed oes a s - = © on a Eo | JRE Oo A NE I IN a § [NT MEI [OV IN < | Joo <r p— [3] v3
QS = o ~ — lo =] REE) cl a & |[~ Wn — | wn woe <n . 8 - QO os © - 8 | | nM Mm iM NN = - g [7 [mm (aa BI [ae [aT (ae! (a aT (a on {en e 3 i uv |= 0 = oR I — loo < > YN AN —- = [7 |N Mn
Qo o o o lo |e o Jo
Q
-— =m lo |v 0 |= On non — = ° Yn ~~ ~ = wn ~™ (NN
E Uo © o |e o |S c lo co lo o -— 1] j= = -— wg 8 2 FE S|: i z - | B a. ££ 5 Ln oS w £ |, i= © |g 5 & e le ¥ |g |g |& § _ |= : 2 lag loo 9 2 |53 29 Sola z2 12 lo 2 Et [9 ols lo € |g [8 2 £18 Zia lely 2 © |=
SRE EE © CIS [2 8 |[E |g |0 2 35 |=
XX [Tle PB {¥2 I= a SE 5s |2 2 |= & 2 io ec 0 J|lz2 2 |e j= © Ss & le |s | wall
Slr EE 21° is = iz wv [3 |3 jo © 5 2 2 E S | S$ Qo. I>] = 3 8 a 2 5 = 3 . (=% o 2 id Oo.
R
E wu |O r~ T | S ho eS 3 |v IN 2 | © I NS) ® |S nw LL [90 I~ SN 0 |. on |N jo <Q |T 2 OE [= | << (~ =I Pa a [im ™M [on @ j= SIN 3 |= =] i wn | |m Qo 8 = [<M Po Pere) — oO O oO — [4 [eo] < Z |X |A a |= [|= © [M1 fn |= < |< a |< < |Z 2 |< |< < |<
¥ © ~
SE EN N 5 “ho Non |e an E ole < ha a Ils] a a BE [SV IR . 2) _— 9
A) a = < [© o | —~ | o ov [© Iwo <3 ~ | a (2 NEN a NE EE GN
Q 3
J
I)
N 5 < |= — —~ 2 © [© © lo |o |N = NER Ie) a | ~ | o NN 2 3 0
Ar) ~ 5 |= “ NN — |= © joo I~ jn = en IN NS Oi OY [Mm | lw
Qe lan BEN 5) ~ ©
SE © rs ny S |= ~ loo nfs = < | I) NEN Moi am 2 o _ o © - = =a =] CO a |S So |e EL LN I Ae ec on ton [aN] al AN) [aN IE [aN] al IN iN {Nl a _- — . e un mn — O (a \O |e Ov lo Joon Im
Es = VM N |= r~ |™ NM Nm g © oo o oo co |e Oo jo jo |o
[3] . []
E =m 00 [r= N oN r~ loo 0 Mm feo |r = = OM = on ™ |v AEE NE NS ns! sg © co lo o o cS lo co lo lo jo
[3]
[0] Ty 2 0
L c Q 32 £ Moje =
Q —t
Sines 28 «B12 2 ww |81]8 © cic |®
L 2 {ee 9 |&8 « |[E | 2 co (2 2 |5 ws LE |& a l= €£ |2 0 2 = |o |o g I= |B |1€ & |= a 12 ¥ « |E l= 5 IE |E |E
SE lx |e 90/2 EI2I|E ZL [E15 8 |¥ |% |3
E89 ET 2a @|EI& 2 2 |0|z2 als (2 = |° |3 Iz @ 0 |® ja 2 CE -ER ~ 5} Q =} Oo |£ E Cc |x on =] = = Ge -— | 20 o0 a = = so fo oe) 00
Zz 2 N= o 2 lo A lo EEE
SS E ~ ls ~ NEN = [IX Nx [Bd |B 3 = - 8 = ~ [0 Je] Soe je
SZ ao 3 «oq 2 2 cll eT Ne 4 < |< oo) = = |» a |< |< |<
QL fo = <r —t «un = < Ss ° $ 6 = eo = a 5 © hn jon TT EE vw = g = < [3 [en = 3 3» T © —_ a 3 8a = £ oo 3 -— © . = 9 a © 5 = 9 cn = Q © —-— - uv 5 8 cs |Q o— = ES oo a Q 3 Ia <3 £ 9 «& x -Q en I [Ve = = = Q [a IEEw oO | Re’ 2] = 2 $s ZZ 2 £ ww _ a 8 oN g 5 O E T Ss © = Qo = 2 ¢ 32 § a EI 2 8 8 © © £ |o = SS ES 3 2 ¢g [= ¥ 5 [3 —_— oa 2 [9 3 CO 3 a kB © (X= 2 + = g a § aN es Q £ 35 = > 3 = 9 £ 3 5 = = Q& Em 2 2 oo § < a ££ [x ve E oo n o - ® - 2 = Oo = © (3) = = a §| N° rl TR % B - 2a Za 3 aN 5 : vo E c
S © T 8&2 = gs
Q& E SQ jo |w gE SS £ 2 a § aE A © 8.8 = o - = 3 £35’ zo N En
[3] 3 2 2 2% £3 a § © eo 9 © > gL vv 2 =- 9
Lan = <e ©“ 95 Zz LL qu = [SNE [SION a fA s © —
Qe 3S TT A g = - 3 nw Hn 9 2 © fla [ed —_— 3 NN =] << << Tv OT = c |= ge EE 5 2 8 2 ¢ |— — = vO T - 0 un 0 Mm |o ce © ££ 8
Ed a a 2 & 332 5 ow |=
S ¢ 2 E E o EE» ge ¢ 9g 2 gE Ve * 3 EE A- N , £2 Le Te 2 2 TS “ |m g 0 cS lo |o ES g £ 2 = EE = 2 o 2 2 - 8 = g EQ c 5 8 ¥ © . E S 2 © 8 = > = ec = ® = 5 vu jo c 9 = ,, YY cc ‘DS — 2 € 9 § 2 3 3 $ £2 22% os — | -— ~~ ¥} = |& |g |B « = 8 § & = g 2 215 3 |e cs 2 235 8 3 3
BERENS Ett: PP oo |[€ |S SS eZ Zo» ou £ « = = “15 1° |Z S g ® 5g O 2
J uu Qo Q a — Wz £ £ £5 > iv; TIC B= BE <= TET 2m 2 5 = & = § Z > 3 Ss 2
[72] e 5 wy <Q +t oo + & gg = [TIE Na [a 1a 2 r~ 0 © own yg E> 2 g Z |8 2 EB —~ Iq |= ¥ «w & 7 To < Oo 5 5 8 In |B 2° un = 8 a - : < S = 2 8 . = 8 < >< FF Fg —_ 5 8 © 2 3 : oO © = DD < ) - vu Q < = - © <S OL > gE SS pg Z 2 § 2 8 a E
= £ oy No ~N So < ™~ b= IN — | 00 ~ jen — o = I Ia! EY —_— — fem - = ny 1 :
Ss © a 5 < — Mm Q Qo | & — =] ie) Nm wv ~ | ~ wv a ss . = <9
EN S — Nd a = r~ A on ~ : oN (= = ~ I |S ~ wo IN ~ (=) I=) <r —
Pt [¥] © © Ne)
N= wn IN ~ oy |oQ <, ~ = on wn (YN oA no ~ Ne) a =) — a>)
NI en a = 8] : |N - <r N =] o © oA < {N <r WN a =) — >) & © re)
SQ £5 on Te ~ — lo Ne) ! ~Nuad . wy - . . . . a) c oJ IN <r aN (nn ~ ot a o —
OD
— [= wy oN wy [ap] — — [vo] [oN
Eg = rp |= IN NS 5) g @] — [<= o o | o <Q
SA) IN ~ [~ ~ ~ | wn = 2» on S| — — |™ — gE Q I= oS (lo S oc |e oS ° ° [2] - ° < . pe Q ~ | Eg c [€ = [X cE 8 5 (® @ on c |p & nw wn O00 ™N = 3S wo Q I'S £ @ oO [¥ T= © 21s 8 FF oo |o [3 2 cE |8 = 5 = 2 cE o |2 |Z o c |e | ou €|T x
LQ © |g ~ 2 0 S |» N
Oo £ Oo ¢ © = |© py Lv |X S c 0 & |S = = 9 Ww [€ |g 8 ES © = S015 2M S 18 = 9 |=
Lc 3) > [+03 [SIN | a oo “— Q 0 9] 3 > Q —_— 3+] c 2 =
So - <tr [Vol (Vol 0) 2 9 3 Sw» IN S$ ve) [=] ht w= ~N ~ |e Py ve $ E o = 8 2 32 S = 9 35 S18 = N= 3 — — < Z = = |O © |= =
Zz < |< = < |< Zz <
= °
S 8 % 5 o ve ° . & E ~ 0m SS — [5] 3 a
EI — ™~ jo0 0
Qa 5 ~ < (™ ~ 3 0 a 5 0 , a H a [a\) [oN - 9 ~ [=] ~ 5 Lg S ~” a 5 ™~ QIN <t ( , P=
S 5 © |v < a § 9 Tol ON IN - —— enn r~ Oem 3] s = “ NN 0 2 |) ~ Cc | ~
So od pel o o ln = . — [I 51 1 [] [7] — 00 = 2 © Po] :
Oo = QL \ o = 2] = |S] j= 9) — v ov Qo = 2 SZ Elz [28 wo CH fd o ' [] [= N 17} ol Q Q o = 5 = .— 5 3S @ lg |= 2 8 O00 § LIS 8le|s 8 8 & 8 5
Oo ¢ = od id 2 EE |¥1|5 © £ 2 &£ T
S [3] = = = e a 5 c 3 oO a $= = Ss ™ Q = = [Vo] es by ~ 00 jr~ 2 ‘a a on 0 |r~ ~<t @ [a}] wn [a I — $g E = — |S b=)
[3] = QO oo) o0
[3] ya < QO < i he I es pS < < |< Z oe ir) - £ 0 ~ ~N N a f=] \O \O \O \O =) — 3}
J a EE x — I So << S a £ ~ ~|n ~ ~ ~
LL] & .e r=)
Q for Te) fT A uw S bt . . . . = ~ TI IAG <r wn 2 3 ~
[5] © ©
NE wn wv S wn nn a £ Ve) < (un wi oN Ve) — (¥) oe ° 8 E r~ mn mM o ™ : ) ) ) > a £ ~ Tee) fo ae) ™m — [¥} e ©
N= N nr — AE o~ a S ~ «rs r~ ~ IN —
[5] — © 0 > fo on £2 = — |e ie wn
S Oo ol oo |© o o
Q
= ~N ” XO
Q Ss = S 15} oo — ! — : on
[72] Py [3] = o Q << <Q -— o — _ [5 I > LU wv IE |O °o 9 - @ 2 ®E 28 FQ «lz Ela g|8 8 3 2 5 Ss = 2 sc C2 Z| 22 BIE 53 9 < = 2 Oo IF =} [= [F) x |x ° 3 © cESSR HF EREERE 8 E = oc Lo = @© = = a oO = 5 = ZS = > 3 cs | [o,3 — \O [o's] wn
Lv in wn r~ ~ ve) wn Oo on ~~ 2 wn on a ¢ E = 3 |= | § x bt o wv | <Q << =)
So 3 = |= S So
Pe [4 o'] |= 4 a , < 2 |< < < <
TRC
-~ E — ™~ © |e : cs \O wy uy [Va a 3 : bt Q
S © ~ a = ~M ~ ~ wv NO a 5 O [aV} [aN] [aV] ~™ ~ bt [3 3 & = ~ o 0 a IN [= on < << < [r~ 2 pt >) oS ] E ~ S r ~ |n = un <r un <t on
Qe sg - 0
NI
~a 5 La] 2 — 0° og iN =} ~ No) ~ ~~ << 2 ¢ & © ro a OE \O r~ ~N — 00 :
Nd . . . . . foe's) a & on I] 5) ~t Se Pct = 8 —_— © Ie) t~ O Ie
ED RA S — ” NE g @) — ~ (Va) o mo o e [ag] — -— ~~ o0 — — = = Qo wn — on g Q — i) ~r oc ao
Oo
Ct [od — © 0 ov = ‘© EN BT © — £ E g € vw, 2 9 5 c 18 = 9 © LQ 5 Sd 2 ww | © xX o lo E& |3 a wn 2 = 8B a a 2 218 5 LL 3 & 3 | 5 8 |E
S T OO OO =~ |g 3 8 ln. TB 9 la 2 {cE ES SL = = Eg wu 9 Mg g OQ IT mm & lo o E 3 5 wn > TT 8 5 ZL aw Zz «= |8 on = =O A SSE [V) a ‘N ££ [o8 — Q hb] [3 aN e pe ~ a > [@)3
LS we 2 in 2 & E S te ~ = = 8 £ 2 S|] 2
S 3 S o <x <Q oo < Zz el fr, ~ m PRIS a < = < Zz |=
= ~ E © [© ~ TM ~ je |= © [- [Yo RN (Vo [Tp] [So [Va] wv jn | <T wT 2 3 - = & E ~N “ Nn a [o |Z = a € IN 5 wo |e an [2 ~f - 8
A
Q E T | I © |N oN (2 2 a E NBII] 3 < | NSN Vo 5) «©
ES) - 9 © 2
NE N Ig |e — |r — : a £ nen un oN [a VI [QV IE oo N= o am lee ©
NE 2 |n = —- |x ~ leo (2 SH c S im IN 0 |m 0 (| < |Z a 3 — -Q
R=)
SE |= Q n joy Toy |T 0 = < | a aed Re (IS eo loo
Q s&s -
LJ
Se wn o jun <r fo wn fe |e no £ > Nn ae none = |= 5s © oo oS oI ole jo = [=]
S
ES om 0 je on nv jun o |v vo © |in << EE DA =, Nn Se mM ~ oN sg S |o = - lo — lo |e oS lo 3] [= — [J 50 “© — |= =e 1A EP EA cle IE _ 4 ® © |g 0 £8 222 =z 22 2 ¢ = ec |@ oc I© © |= = | jo © lo lols & s |= 3] Tle =SlE|€ 82 [SIE BEE |8 © = |» ] So |2 Z1< EE alg 5 |¥ |X |g 3 2 |< o Cc [= als SX [7 ia ajc |c a Q
I~ 3 = =" 10 13 3 |3 jz & © |x
Q. 15 A © © iy & el oa a |O a =
E o 00 — loo [m © 9 R® Ia O OR |o i -| 0 | ~N 0 ~~ |= [60 rod ¢ E 0 [= r~ o I= S (vv [Yo no
S 3 0 | Ia) no SL un on™
Q oS |S —_ MN i == (= < Z EN — O |r RV [oa S$ < |< < xX 1a < |<€ |<€ vn IX
WO (33/048383 PCT/CA02/91830 - . - E 0 no - oS ov
A E ~ < |< ~ < |= = 3 .e ir) oe NOE “ SM a E N aes 3 vo 4 = 3 3 £ on < <x
Ee) - ol) . [= c ig) ~N ~™ 2
Q 3 - 3 oT
NE 0 oI ~ ~ |m c ~ INERT oS) ™ |e a so - 3 oS 8 E — < | NN dd — . . » . a [= pa <r <r oy NO = 8 5 hed <t <r a ok ht NEN ci a cs ~~ oN — <r on = 8 1) @ wn xT (NN £2 = — wy [— g Q o o oo oS
Tm © |v en ~ |e
E> 8 | RR ? SN g Q oS - | oc oS lo
S
— — lo) [= — — < = « 1 hu o c ce 628 8 8 |8 |§ | uw N 2 2 oS 5 |f [+)] = - o [3] oO -— vo ES [3 [5] [9 < < = = Pot
QQ 8 (Oo = = | lo je 7 © sS 8 «© 8 |Q
S 3 2 |®E S15 SEE Faz g © 2 3 £
O 5 5E E<|BE(E5 8 S| ES & 3 [2 e IS 8 © ([& © SI 2 ew E (3 “|e 2 8 |x 210 2 0 «© = [] —- Ke a = he — c <r n> © by Ng Vo} S NE ‘mn 2 rS — 1D ~ ~~ in & £ a ei a « {I~
S 35 S S I= = 5 |= -— -— iz = MS =~ © 0 ee Tm . -_— ° en & og |r ™~ ~ ~ ©o he No a 5 on en ~™M oN on [aa IE [an TE [40
S— 3} & © = E Noy 0 ~N oN wv [= |e = a en ~ < No) INE = [aN
Q 3 — 0 . 3 8 “ a = ™m |N — on ; Mm ne c nen ~f ve) 3 NO |m 8 s ® [&] © © aN Ok Sn oe) wn 0 Ne = a £ NN [aN] [ag] uw [a VI [oN BN [ag] —- 3
NI o : ~ o£ NS N : I LE A a § oa [= r~ =? mm in —
[5] <3
SE ©O |= — ~~ o Noo a E NER ag) < K no [en =I -—
Se un wn = oN oO — o s “|g © N a s 0 o |e a o o o
Se : r~ [oN] — <t wn TT
Ss >» SC in S| N = IN |= [*] [<0] —_ — 9} wn @ [3 n > ss 2 ! fond L [Io] < [od © Ss = (52 gs E 8 ~ |g © £ ¢ z |S £ £2 21els FI £2 Alu 2 |» FT XX x 213 & 2 182 3/2 &—~|2 B82 2 E ¢ = |& a ae |g gla & ‘3 WIE © 2 4 cs |= > 3 oS = ce. © o£ sO = © a Qo = g 4 oN —t 2 2 ARE bon © IS) 2 © joo wn wn SR O |= [Oo $ E — = o wn n= he © = wy tn <tr on oN —_ | |\O
Q a o 00 Q ~ [ [= a Z | r = | CO hs J << |< a) jo) << jo I ol fo 125 fa
= © . mE EE TM Ne - lo a £ on jen jen Mn jon jen ~ en - 8 8° ~ ls ~ ~ a8 IR — a - |= cl = Qo a E RY ~ ~ o a £ pall [< N ~N RA ~ | 17 <Q pt <9 w © aE Ne <I > ee eM £ won oe eB [To A aN a 3s p— & .e °
N E R= 0 © [9 Se a £ IN < ~ | < |X =o
SB on 0 a = : > |e Noy rs QM a § J IN wv |G Men |<F < fs oe _y g un mo nN 0 |on Joo on r~ = — IY noe SIs EE gE 0 cS lo oc |o oc lo |o oc |o <Q go | RN Nn ~ |v oO
A ne NIN eld) Nn o [$0] wy an [0] ol g 0 a I. eX = ~~ Ss |d 9 |g |g = =
TX sl€ ls E = |§ | z | [© = 2 : 2 2 22 38 RE =a ls £13 |3 |g « 3
S E8Ee|lF 3 EEE EER 8 R 3 81S afr len g 8 g 2 9° |e cs |Z 2 3 — 4 9 E Ped N QQ. 3 << o us) = a x a wn = ¥ be
Ss 9 ® “|B 31g 18 3 ¢ E © (3 ss! 8% | SR
Ss 3 S|] S |= He |= oS < Z a |x Mo pI NET I) = 5 < 0 < |< Zz |< |< < |»
Claims (24)
- 24-11-2003 CA0201830 « WHAT IS CLAIMED IS: IY A method of identifying a polynucleotide or pattern of polynucleotides regulated by one or more sepsis or inflammatory inducing agents and inhibited by a cationic peptide comprising contacting the polynucieotide or polynucleotides with one or more sepsis or inflammatory inducing agents, contacting the polynucleotide or polynucleotides witha cationic peptide either simultaneously or immediately thereafter, and determining a change in expression, wherein a change is indicative of a polynucleotide or pattern of polynucleotides that is regulated by a sepsis or inflammatory inducing agent and reduced by a cationic peptide. J
- 2. The method of claim 1, wherein the sepsis or inflamniatory inducing agent is LPS, LTA or CpG DNA, bacterial components or whole cells, or related agents. oo
- 3. The method of claim 1, wherein the determining a change in expression comprises determining the level of expression of the polynucleotide prior to and following contacting with the sepsis or inflammatory inducing agent.
- 4. A polynucleotide or polynucleotide pattern identified by the method of claim 1.
- 5. A polynucleotide of claim 4, wherein the polynucleotide encodes a polypeptide involved in an inflammatory or septic response. : - .
- 6. + Amethod of identifying an agent that blocks sepsis or inflammation comprising combining a polynucleotide of claim 5 with an agent, wherein expression of the polynucleotide in the presence of the agent is modulated as compared with expression in the absence of the agent and wherein the modulation of expression affects the inflammatory or septic response. :
- 7. The method of claim 6, wherein the effect to the inflammatory or septic response is inhibition of the inflammatory or septic response. —
- 8. An agent identified by the method of claim 6.
- 9. The agent of claim 8, wherein the agent is a peptide, peptidomimetic, chemical compound, nucleic acid molecule or 2 polypeptide.
- 10. The agent of claim 8, wherein the peptide is selected from SEQ ID NO:4-54. Empfangsaeit 24.Nov. 20:41 191 AMENDED SHEET
- 24-11-2003 CA0201830 . 11. A method of identifying a pattem of polynucleotide expression for inhibition of an inflammatory or septic response comprising: . ) contacting cells with LPS, LTA, CpG DNA and/or intact bacteria or bacterial components in the presence or absence of a cationic peptide; detecting a patter of polynucleotide expression for the cells in the presence and absence of the peptide, wherein the pattern in the presence of the peptide represents inhibition of an inflammatory or septic response.
- 12. A method of identifying a compound that inhibits an inflammatory or septic response, comprising contacting cells with one or more compounds suspected of inhibiting an - inflammatory or septic response and identifying a compound that provides a pattern of a o polynucleotide expression similar to a pattem obtained in thie method of claim 11 with a cationic peptide that inhibits an inflammatory or septic response.
- 13. A compound identified by the method of claim 12,
- 14. A method of identifying an agent that enhances innate immunity comprising: contacting a polynucleotide or polynucleotides that encode a polypeptide involved in innate immunity, with an agent of interest, wherein expression of the polynucleotide in the presence of the agent is modulated as compared with expression of the polynucleotide in the absence of the agent and wherein the modulated expression results in enhancement of innate | __ immunity. ’ :
- 15. The method of claim 14, wherein the agent does not stimulate a septic reaction.
- 16. The method of claim 14, wherein the agent inhibits the inflammatory or septic response.
- 17. The method of claim 14, wherein the agent blocks the inflammatory or septic response.
- 18. Tbe method as in claim 16 or 17, wherein the agent increases the expression of a polynucleotide encoding an anti-inflammatory protein. Eppfangszeit 24.Nov. 20:41 192 AMENDED SHEET
- 24-11-2003 CA0201830 . 19. The method of claim 18, wherein the anti-inflammatory protein is selected from a subset that includes IL-1 R antagonist homolog 1 (A1167887), IL-10 R beta (AA486393), IL- ~ 10Ralpha (000672), TNF Receptor member 1B (AAL 50416), TNF receptor member 5 (98636), TNF receptor member 110 (AA194983), IK cytokine down-regulator of HLA IL (R39227), TGFB inducible early growth response 2 (A1473938), CD2 (AA927710), glucocorticoid-related polynucleotides (AK000892), or 11-10 (M5762720.
- 20. The method of claim 18, wherein the agent inhibits the expression of TNF-alpha.
- 51. The method of claim 18, wherein the agent inhibits the expression of interleukins.
- 72. The method of claim 21, wherein the interleukin is IL-8.
- 53. The method of claim 16, wherein the agent is a peptide. I
- 24. The method of claim 93, wherein the peptide is selected from SEQ ID NO:4-54.95. An agent identified by the method of claim 14.26. An agent of claim 25, wherein the.agent is a peptide, peptidomimetic, chemical compound, or a nucleic acid molecule.27. A method of identifying a pattern of polynucleotide expression for identification of a ' compound that selectively enhances jnnate immunity comprising: detecting a pattern of polynucleotide expression for cells contacted In the presence and absence of a cationic peptide, wherein the pattern in the presence of the peptide represents stimulation of innate inimumnity; ’ detecting a pattern of polynucleotide expression for cells contacted in the presence of a test compound, wherein a pattern with the test compound that js similar to the pattern observed in the presence of the cationic peptide, is indicative of a compound that enhances28. A compound identified by the method of clairu 27.29. The method of claim 27, wherein the compound does not stimulate a septic reaction. Enpfangszeit 24.Nov. 20:41 193 AMENDED SHEET }24-11-2003 CA0201830 . 30. The method of claim 27, wherein the polynucleotide expression pattern includes expression of pro-inflammatory polynucleotides.31. The method of claim 30, wherein the pro-inflammatory polynucleotides include ring finger protein 10 (D8745 1), serine/threonine protein kinase MASK (AB040057), KIAA0912 protein (AB020719), KIAA0239 protein (D87076), RAF], GTPase activating protein 1 (M64788), FEM-1-like death receptor binding protein (AB007856), cathepsin S (M90696), hypothetical protein FLI20308 (AK000315), pim-1 oncogene (M54915), proteasome subunit beta type 5 (D29011), KIAA0239 protein (D87076), mucin 5 subtype B tracheobronchial -(AJ001403), cAMP response element-binding protein CREBP3, integrin alpha M (J 03925), - Rho-associated kinase 2 (NM_004850), PTDO17 protein (AL050361) unknown genes : (AK001143, AK034348, AL049250, AL16199, AL031983), retinoic acid receptor Co (X06614), G protein-coupled receptors (Z94155, X81892, U52219,:U22491, AF015257, U66579) chemokine (C-C motif) receptor 7 (L31584), tumor necrosis factor receptor superfamily member 17 (729575), interferon garama receptor 2 (U05875), cytokine receptor like factor 1 (AF059293), class 1 cytokine receptor (AF 053004), coagulation factor I (thrombin) receptor-like 2 (U9297 1), leukemia inhibitory factor receptor WM_002310), interferon gamma receptor 1 (AL050337) or any combination thereof.32. The method of claim 27, wherein the expression pattem includes expression of polynucleotides encoding chemokines. . ;33. The method of claim 27, wherein the expression pattem includes expression of cell ~~ == differentiation factors. .34. The method of claim 27, wherein the polynucleotide expression pattern includes expression of cell surface receptors.35. The method of claim 34, wherein the cell surface receptors include chemokine receptors or integrin receptors.36. A method of identifying an agent that is capable of selectively enhancing innate immunity conprising: i contacting a cell containing a polynucleotide or polynucleotides that encode a polypeptide involved in innate immunity, with an agent of interest, wherein expression of the : Eppfangszeit 24.Nov. 20:41 194 AMENDED SHEET24-11-2003 CA0201830 . polynucleotide or polynucleotides in the presence of the agent is modulated as compared with expression in the absence of the agent and wherein the modulated expression results in enhancement of innate immunity."37. The method of claim 36, wherein the pattern of expression is utilized in screening for compounds that enhance innate immunity. :38. A compound of claim 28, wherein the compound stimulates chemokine or chemokine ’ receptor expression. :39. A compound of claim 38, wherein the chemokine or chemokine receptor is CXCR4, CCRS5, CCR2, CCR6, MIP-1 alpha, IL-8, MCP-1, MCP-2, MCP-3, MCP-4, or MCP-5.40. A compound of claim 28, wherein the compound is a peptide, peptidomimetic, ) chemical compound, or a nucleic acid molecule. ;41. A method of identifying an agent that is capable of both suppressing or blocking septic or inflammatory responses and enhancing innate immunity comprising: contacting a cell containing i) a polynucleotide or polynucleotides that encode 2 polypeptide capable of suppressing inflammatory or septic responses and ii) a polynucleotide or polynucleotides that encode a polypeptide involved in immate brumwmity, with an agent of interest, wherein expression of in the presence of the agent is modulated: as compared with ..... expression of the polynucleotide or polynucleotides in the absence, of the agent and wherein the modulated expression results in suppression of inflammatory or septic responses and enhancement of innate immunity.42. A method for inferring a state of infection in & mammalian subject from a nucleic acid sample of the subject comprising identifying in the nucleic acid sample a polynucleotide - expression pattern exemplified by an mcrease in polynucleotide expression of at least 2 polynucleotides in Table 55 as compared to a pon-infected subject. ‘43. A method for infewing a state of infection’in a mammalian subject from a nucleic acid sample of the subject comprising identifying in the nucleic acid sample a polynucleotide expression pattern exemplified by a decrease in polynucleotide expression of at least 2 polynucleotides in Table 56 as compared to a non-infected subject. : . Enpfangszeit 24.Nov. 20:41 195 AMENDED SHEET24-11-2003 Co CA0201830 . 44, Amethod for inferring a state of infection in a mammalian subject from a nucleic acid sample of the subject comprising identifying in the nucleic acid sample a polynucleotide expression pattern exemplified by a polynucleotide expression of at least 2 polynucleotides in Table 57 as compared to 2 non-infected subject. : no © 45. The method of any of claims 42, 43 or 44, wherein the state of infectionisduetoa bacteria, virus, fungus or parasitic agent. : oo46. The method of any of claims 42, 43 or 44, wherein the state of infection is due 10 2 Gram positive or Gram negative bacteria. oo \47. A polynucleotide expression pattern of a subject having a state of infection identified by the method of claim 43. 3 a. Cee vn48. A cationic peptide that is an antagonist of CXCR-4. :49. A method of identifying a cationic peptide that is am antagonist of CXCR-4 comprising contacting T cells with SDF-1 in the presence of absence of a test peptide and measuring chemotaxis, wherein a decrease In chemotaxis in the presence of the test peptide is indicative of a peptide that is an antagonist of CXCR-4.50. An isolated cationic peptide comprising the general formula XXX IKP KAP XXX (SEQ TD NO: 4), wherein X; is one or two of R, Lor K, X; is one of C, Sor A, X3isoneof R or P, Xs isons of Aor V and Xsis one of Vor W. CL Ce51. The cationic peptide of claim 50, wherein the peptide is selected from the group consisting of: LLCRIVPVEPWCK (SEQ ID NO: 3), LRCPIAPVIPVCKK (SEQ ID NO: 6), KSRIVPAIPVSLL (SEQ ID NO: 7), KKSPIAPAIPWSR (SEQ ID NO: 8), RRARIVPAIPVARR (SEQ ID NO: 9) and LSRIAPATPWAKL (SEQ ID NO: 10).57. The peptide of claim 50, wherein the peptide has anti-inflammatory activity.53. The peptide of claim 50, wherein the peptide has anti-sepsis activity.54. Anisolated cationic peptide comprising the general formula X, LX; XK X Xo Xs XP XX (SEQ ID NO: 11), wherein X is one or wo of D, E, S,TorN, X2 is one or two of P, Gor D, Xzisone of G, AV, L,IorY,Xsisone of R, KorH and Xs js one of S, T, C,MorR. Eppfansszeit 24-Nov. 20:41 196 AMENDED SHEET24+11-20083 CA0201830 _ 55. The cationic peptide of claim 54, wherein the peptide is selected from the group + consisting of: DILPAKRGSAPGST (SEQ ID NO: 12), SELPGLKHPCVPGS (SEQ ID NO: 13), TTLGPVKRDSIPGE (SEQ ID NO: 14), SLPIKHDRLPATS (SEQ ID NO: 15), ° . ELPLKRGRVPVE (SEQ ID NO: 16) and NLPDLKKPRVPATS (SEQ ID NO: 17).56. The peptide of claim 54, wherein the peptide has anti-inflammatory activity. :57. The peptide of claim 34, wherein the peptide has anti-sepsis activity.58. An isolated cationic peptide comprising the general formula XXX Xs WX WX XK (SEQ ID NO: 18), wherein X is one to four chosen from A, P or R, Xj is one or two aromatic amino acids (F, Y and W), Xa is one of P or K, Xa is one, two or none chosen from } : we A, P,Y or Wand Xs is one to three chosen romRorP. ... Tans -59. The cationic peptide of claim 58, wherein the peptide is selected from the group consisting of: RPRYPWWPWWPYRPRXK (SEQ ID NO: 19), RRAWWKAWWARRK (SEQ ID NO: 20), RAPYWPWAWARPRK (SEQ ID NO: 21), RPAWKYWWPWPWPRRK (SEQ ID NO: 22), RAAFKWAWAWWRRK (SEQ ID NO: 23) and RRRWKWAWPRRK. (SEQ ID NO: 24).60. The peptide of claim 58, wherein the peptide has anti-inflammatory activity.61. The peptide of claim 58, wherein the peptide has anti-sepsis activity. : oe An isolated cationic peptide comprising the general formula . oT XXX XX: VX XR GX Xa Xa Xa Xa Xy (SEQ ID NO: 25) wherein X, is one or two of RorK, X, is a polar or charged amino acid (S, T,M,N,Q,D, E,K, Rand H), X;3 isC,S,M,DorA and XaisF, LL, V,MorR. '63. The cationic peptide of claim 62, wherein the peptide is selected from the group consisting of: RRMCIKVCVRGVCRRKCRK (SEQ ID NO: 26), KRSCFKVSMRGVSRRRCK (SEQ ID NO: 27), KKDAIKKVDIRGMDMRRAR (SEQID NO: 28), REMVKVDVRGIMIRKDRR (SEQ P NO: 29), KQCVKVAMRGMALRRCK (SEQ ID NO: 30) and REEARRVAIRORDIR (SEQ ID NO: 31). ;64. The peptide of claim 62, wherein the i has anti-inflammatory activity.65. The peptide of claim 62, wherein the ii has anti-sepsis activity. : Eapfangszeit 24.Nov. 20:41 197 : AMENDED SHEET24-11-2003 . | : CA0201830 . 66. Anisolated cationic peptide comprising the general formula X XXX Xa VX SUR GX XXX Xa Xi (SEQ ID NO: 32), wherein X, is one or two of R or K, X; is a polar or charged amino acid (S, T, M,N, Q, D, E,K, Rand H), X; is one of C, 8, .. M,DorA Xsis one of F, I, V,M or R and Xs isoneof AL, S,M,DorR.67. The cationic peptide of claim 66, wherein the peptide is selected from the group consisting of: RTCVKRVAMRGIRKRCR (SEQ ID NO: 33), KK OMMKRVDVRGISVKRKR (SEQ ID NO: 34), KESIKVIIRGMMVRMKK (SEQID NO: 35), RRDCRRVMVRGIDIKAK (SEQID NO: 36), KRTAIKKVSRRGMSVKARR . (SEQ ID NO: 37) and RHCIRRVSMRGIIMRRCK (SEQ ID NO: 38). . \68. The peptide of claim 66, wherein the peptide has anti-inflammatory activity.69. The peptide of claim 66, wherein the peptide has anti-sepsis activity. -70. Anisolated cationic peptide comprisingjthe general formula KX KX FX KMLMX,ALKKX 3 (SEQ ID NO: 39), wherein X; is a polar amino acid (C, S, T, M, N and Q); Xz is one of A, L, S or K and X3 is 1-17 amino acids chosen from G, A, V, : L,I PFS, T,Kand H. .71. The cationic peptide of claim 70, wherein the peptide is selected from the group consisting of: KCKLFKKMIMLALKKVLTTGLPALKLTK (SEQ ID NO: 40), KSKSFLKMLMKALKKVLTTGLPALIS (SEQ ID NO: 41), © KTKKFAKMLMMALKKVVSTAKPLAILS (SEQ ID NO: 42), SR i KMKSFARMLMLALKKVLKVLTTALTLKAGLPS (SEQ ID NO: 43), KNKAFAKMLMKALKKVTTAAKPLTG (SEQ ID NO: 44) and oo KQKLFAKMLMSALKKKTLVTTPLAGK (SEQ ID NO: 45). | © :72. The peptide of claim 70, wherein the peptide has anti-inflammatory activity. : 43. The peptide of claim 70, wherein the peptide has anti-sepsis activity. .24. An isolated cationic peptide comprising the general formula oo KWKXX) Xa XXX XoXo Xi Xa XoXo IFHT ALKPISS (SEQ ID NO: 46), wherein X, 15 a hydrophobic amino acid and X, is a hydrophilic amino acid. + So Empfangszeit 24.Nov. 20:41 198 AMENDED SHEET :24-11-2003 : CA0201830 [] : " . 75. The cationic peptide of claim 74, wherein the peptide is selected from the group consisting of: KWKSFLRTFKSPVRTIFHTALKPISS (SEQ ID NO: 47), oo : KWKSYAHTIMSPVRLIFHTALKPISS (SEQ ID NO: 48), KWKRGAHRFMKFLSTIFHTALKPISS (SEQ ID NO: 49), Co KWKKWAHSPRKVLTRIFHTALKPISS (SEQ ID NO: 50), KWKSLVMMFKKPARRIFHTALKPISS (SEQ ID NO: 51) and Co KWKHALMKAEMLWHMIFHTALKPISS (SEQ ID NO: 52).76. The peptide of claim 74, wherein the peptide has anti-inflammatory activity. :77. The peptide of claim 74, wherein the peptide has anti-sepsis activity.78. . Anisolated cationic peptide comprising the sequence. Co : KWKSFLRTFKSPVRTVFHTALKPISS (SEQ ID NO: 53).79. Anisolated cationic peptide coraprising the sequence KWKSYAHTIMSPVRLVFHTALKPISS (SEQ ID NO: 54). . 80. The method of claim 14, wherein the agent is a Zinc finger protein (AF061261); Cell cycle gene (S70622); IL-10 Receptor U00672); Transferase (AF038664); Homeobox protein . (AC004774); Forkhead protein (AF 042832); Unknown (AL096803); KIAA0284 Protein (AB006622); Hypothetical Protein (AL022393); Receptor (AF112461); Hypothetical Protein (AK002104); Protein (AL050261); Polypeptide (AF105424); SPR1 protein (AB031480); : i: Dehydrogenase (017793); Transferase (M63509); and Peroxisome factor (ABO13818). :81. The polynucleotide expression pattern of a subject having a state of infection identified by claim 42, wherein the genes upregulated are Accession number D87451 -ring finger protein 10; Accession number AL049975, Unknown; Accession number U39067, eukaryotic translation initiation factor 3 subunit 2; Accession number AK000942, Unknown; Accession nuraber AB040057, serine/threonine protein kinase MASK; Accession number AB020719, KIAA0912 protein; Accession number AB007856, FEM-1 -like dedth receptor binding protein; Accession number AL137376, Unknown; Accession number AL137730, Unknown; Accession number M90696, cathepsin S; Accession number AK001 143, Unknown; Accession number AF038406, NADH dehydrogenase; Accession number : AK000315, hypothetical protein FLJ20308; Accession number M54913, pim-1 oncogene; Accession number D29011, proteasome subunit beta type 5; Accession number AL034348, Enpfangszeit 24.Nov. 20:4] 199 oo AMENDED SHEET24-11-2003 CA0201830 «Unknown; Accession number D87076, KIAA0239 protein; Accession number AJ001403, tracheobronchial mucin 5 subtype B; Accession number J03925, integrin alpha M, Rho- associated kinase 2 (NM_004850), PTDO17 protein (AL050361) unknown genes(AK.001143, AK034348, AL049250, AL16199, AL031983), retinoic acid receptor (X06614), G protein-coupled receptors (Z94155, X81852, U52219, U22491, AF015257, U66579) chemokine (C-C motif) receptor 7 (L31584), tumor necrosis factor receptor superfamily member 17 (229575), interferon gamma receptor 2 (U05875), cytokine receptor- like factor 1 (AF059293), class I cytokine receptor (AF 053004), coagulation factor II (thrombin) receptor-like 2 (092971), leukemia inhibitory factor receptor (NM_002310), interferon gamma receptor 1 (AL050337), or any combination thercof. i} 82. The method of claim 32, wherein the chemokines include CXCR4, CXCR1, CXCR2, . : CCR2, CCR4, CCRS, CCR6, MIP-1 alpha, MDC, MIP-3 alpha, MCP-1, MCP-2, MCP-3, MCP-4, MCP-5, and RANTES.83. The method of claim 33, wherein the cell differentiation factors include TGFp inducible early growth response 2 (A1473938), zinc finger proteins (AF061261, U00115, X78924), and transcription factors (U31556, AL137681, X68560). -84. A compound of claim 38, wherein the compound modifies kinase activity.85. A compound of claim 84, wherein the kinase is selected from MAP kinase kinase 3 (D87116), MAP kinase kinase 6 (807920), MAP kinase kinase 5 (W69649), MAP kinase 7 (139192), MAP kinase 12 (AI936909), MAP kinase-activated protein kinase 3 (W68281), or MAP kinase kinase 1 (1.11284). Co86. An agent of claim 25, wherein the agent decreases proteasome subunit expression.87. An agent of claim 86, wherein the proteasome subunit includes polynucleotides with accession numbers D11094, 1.02426, D00763, AB009398, AF054185, M34079, M34079, or AI031177. :88. Anisolated cationic peptide that reduces polynucleotide expression of SDF-1 receptor. Empfangszeit 24.Nov. 20:41 200 AMENDED SHEET
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US33663201P | 2001-12-03 | 2001-12-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200404919B true ZA200404919B (en) | 2006-05-31 |
Family
ID=23316965
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200404919A ZA200404919B (en) | 2001-12-03 | 2004-06-22 | Effectors of innate immunity |
Country Status (12)
Country | Link |
---|---|
EP (1) | EP1470249A2 (en) |
JP (1) | JP2005536985A (en) |
KR (1) | KR20040077669A (en) |
CN (2) | CN100357324C (en) |
AU (1) | AU2002365675B2 (en) |
CA (1) | CA2468907A1 (en) |
HK (1) | HK1075677A1 (en) |
IL (1) | IL162300A0 (en) |
NZ (2) | NZ533721A (en) |
SG (1) | SG159382A1 (en) |
WO (1) | WO2003048383A2 (en) |
ZA (1) | ZA200404919B (en) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7687454B2 (en) | 2001-12-03 | 2010-03-30 | The University Of British Columbia | Effectors of innate immunity determination |
US7507787B2 (en) * | 2001-12-03 | 2009-03-24 | The University Of British Columbia | Effectors of innate immunity |
CN1901933A (en) * | 2003-09-12 | 2007-01-24 | 英属哥伦比亚大学 | Methods of stimulating innate immunity using cationic peptides |
WO2006005190A1 (en) * | 2004-07-14 | 2006-01-19 | Inimex Pharmaceuticals Inc. | Method of screening for protection from microbial infection |
US7638340B2 (en) | 2005-06-22 | 2009-12-29 | Seikagu Corporation | Method of eliminating reactivity of lipoarabinomannan and application of the same |
GB0517090D0 (en) * | 2005-08-19 | 2005-09-28 | Tcp Innovations Ltd | ApoE mimetic agents |
PL2236608T3 (en) * | 2005-10-04 | 2017-06-30 | Soligenix, Inc. | Novel peptides for treating and preventing immune-related disorders, including treating and preventing infection by modulating innate immunity |
AU2007288080B2 (en) | 2006-08-21 | 2013-07-04 | The University Of British Columbia | Small cationic antimicrobial peptides |
CA2665351A1 (en) * | 2006-10-04 | 2008-04-10 | Inimex Pharmaceuticals Inc. | Novel peptides for treating and preventing immune-related disorders, including treating and preventing infection by modulating innate immunity |
WO2009057695A1 (en) * | 2007-10-30 | 2009-05-07 | Olympus Corporation | Method for detection of adenoma or cancer by genetic analysis |
WO2010026489A1 (en) * | 2008-09-05 | 2010-03-11 | The University Of British Columbia | Innate immunity modulators |
US20100099614A1 (en) * | 2008-10-06 | 2010-04-22 | Hodges Robert S | Antimicrobial Peptides and Methods of Use |
JO3623B1 (en) | 2012-05-18 | 2020-08-27 | Amgen Inc | St2 antigen binding proteins |
AU2021400488A1 (en) | 2020-12-14 | 2023-06-22 | Regeneron Pharmaceuticals, Inc. | Methods of treating metabolic disorders and cardiovascular disease with inhibin subunit beta e (inhbe) inhibitors |
WO2023063994A1 (en) * | 2021-10-13 | 2023-04-20 | Phenomune, LLC | Testing methods for determination of t2r phenotype and applications thereof |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5877274A (en) * | 1995-06-02 | 1999-03-02 | University Of British Columbia | Antimicrobial cationic peptides |
DE19734161A1 (en) * | 1997-08-07 | 1999-04-01 | Jerini Biotools Gmbh | Antagonists of stroma cell-derived factor-1, for diagnosis and treatment of human immune deficiency virus (HIV) infection |
US6288212B1 (en) * | 1998-08-28 | 2001-09-11 | The University Of British Columbia | Anti-endotoxic, antimicrobial cationic peptides and methods of use therefor |
-
2002
- 2002-12-02 NZ NZ533721A patent/NZ533721A/en not_active IP Right Cessation
- 2002-12-02 EP EP20020804139 patent/EP1470249A2/en not_active Ceased
- 2002-12-02 SG SG200605957-0A patent/SG159382A1/en unknown
- 2002-12-02 CA CA002468907A patent/CA2468907A1/en not_active Abandoned
- 2002-12-02 NZ NZ563261A patent/NZ563261A/en unknown
- 2002-12-02 JP JP2003549560A patent/JP2005536985A/en active Pending
- 2002-12-02 CN CNB028273273A patent/CN100357324C/en not_active Expired - Lifetime
- 2002-12-02 KR KR10-2004-7008519A patent/KR20040077669A/en not_active Application Discontinuation
- 2002-12-02 AU AU2002365675A patent/AU2002365675B2/en not_active Expired
- 2002-12-02 WO PCT/CA2002/001830 patent/WO2003048383A2/en active IP Right Grant
- 2002-12-02 IL IL16230002A patent/IL162300A0/en unknown
- 2002-12-02 CN CNA2007101680286A patent/CN101215601A/en active Pending
-
2004
- 2004-06-22 ZA ZA200404919A patent/ZA200404919B/en unknown
-
2005
- 2005-09-05 HK HK05107785A patent/HK1075677A1/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
CN101215601A (en) | 2008-07-09 |
CN1615368A (en) | 2005-05-11 |
WO2003048383A3 (en) | 2004-08-05 |
NZ563261A (en) | 2008-08-29 |
KR20040077669A (en) | 2004-09-06 |
SG159382A1 (en) | 2010-03-30 |
AU2002365675B2 (en) | 2007-04-05 |
CA2468907A1 (en) | 2003-06-12 |
AU2002365675A1 (en) | 2003-06-17 |
CN100357324C (en) | 2007-12-26 |
WO2003048383A2 (en) | 2003-06-12 |
NZ533721A (en) | 2007-12-21 |
HK1075677A1 (en) | 2005-12-23 |
IL162300A0 (en) | 2005-11-20 |
EP1470249A2 (en) | 2004-10-27 |
JP2005536985A (en) | 2005-12-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI649423B (en) | Anti-inflammatory peptide and its constituents (2) | |
TWI647311B (en) | Anti-inflammatory peptide and its constituents (1) | |
ZA200404919B (en) | Effectors of innate immunity | |
Zhao et al. | Identification of novel functional differences in monocyte subsets using proteomic and transcriptomic methods | |
US20070134261A1 (en) | Effectors of innate immunity | |
US7507787B2 (en) | Effectors of innate immunity | |
Higuchi et al. | The Epstein-Barr virus latent membrane protein 1 putative Janus kinase 3 (JAK3) binding domain does not mediate JAK3 association or activation in B-lymphoma or lymphoblastoid cell lines | |
Chuang et al. | Epstein-barr virus (EBV) latent membrane protein-1 down-regulates tumor necrosis factor-α (TNF-α) receptor-1 and confers resistance to TNF-α-induced apoptosis in T cells: Implication for the progression to T-cell lymphoma in EBV-associated hemophagocytic syndrome | |
Spriggs | Shared resources between the neural and immune systems: semaphorins join the ranks | |
Severa et al. | A cell type-specific transcriptomic approach to map B cell and monocyte type I interferon-linked pathogenic signatures in Multiple Sclerosis | |
US7687454B2 (en) | Effectors of innate immunity determination | |
WO2015072750A1 (en) | Peptide having anti-inflammatory activity and composition comprising same | |
US20070190533A1 (en) | Effectors of innate immunity | |
ZA200602754B (en) | Effectors of innate immunity determination | |
EP2706113A1 (en) | Synthetic peptide capable of inducing expression of type-2 tnf receptor and use thereof | |
Casnici et al. | Smac BV6 Has Proapoptotic and Anti-Inflammatory Effects on Rheumatoid Arthritis Fibroblast-Like Synoviocytes Activated by TLR9 Ligand | |
AU2007201885A1 (en) | Effectors of innate immunity | |
Takahashi et al. | IL-10 induces activated phenotypes of monocytes observed in virally-suppressed HIV-1-infected individuals | |
Novoszel | The role of the AP-1 proteins c-Jun and JunB in the development and function of plasmacytoid dendritic cells | |
Al-Anouti | Expression and functional characterization of CK-1: A putative rainbow trout (Onchorynchus mykiss) CC chemokine. |